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Abstract 
Due to their anti-inflammatory and immunomodulatory properties, mesenchymal 
stromal cells (MSCs) are under intense investigation in many pre-clinical and 
clinical trials as a potential cellular therapy to be used in an array of clinical 
settings. The majority of the literature surrounding MSC phenotype and function 
is derived from studies focusing on bone marrow (BM) derived MSCs. Recently 
however, it has become apparent that MSCs can be isolated in a less invasive 
manner, from the majority of tissues in the human body. In light of this, many 
studies have been published promoting the use of alternative tissue sources for 
MSC isolation with no thorough standardised comparison of the phenotype or 
potential in vivo function of these MSCs. The advanced therapeutics department 
within the Scottish National Blood Transfusion Service (SNBTS) is involved in the 
development and optimisation of several cellular therapies including the use of 
MSCs within various clinical settings. SNBTS has access to fully consented human 
tissues rich in MSCs including; pancreatic islets, visceral adipose tissue, 
liposuction aspirate, bone marrow and umbilical cord. Therefore this study 
aimed to objectively compare the phenotype and potential in vivo function of 
MSCs isolated from the aforementioned tissues in a stringent, standardised 
manner in order to assess if MSCs isolated from one specific tissue source might 
be optimal for use within the clinic. The beneficial therapeutic effect of MSCs 
often depends on their ability to migrate to target tissues and interact with 
residing or migratory immune and non-immune cells, frequently within an 
inflammatory environment. Therefore this study focussed on how MSCs might 
migrate in vivo by assessing and comparing MSC chemokine receptor expression, 
whilst also assessing and comparing MSC chemokine secretion profiles to 
understand which immune cells MSCs might attract, and therefore potentially 
interact with, in vivo. This study found that chemokine receptor expression by 
MSCs isolated from islet, visceral adipose, adipose, bone marrow and umbilical 
cord tissues was very low, with CXCR4, CCR7 and ACKR3 expression being 
restricted to visceral adipose and bone marrow derived MSCs. Inflammatory 
chemokines were secreted at very high levels by MSCs isolated from all of the 
aforementioned tissues, which induced migration of target immune cells towards 
all MSCs tested in vitro and in vivo, importantly however, the tissue origin of 
MSCs dictated the quantities of immune cells attracted. This study highlighted 
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that the tissue origin of MSCs could affect MSC in vivo migratory capacity and 
their ability to chemoattract surrounding immune cells, thereby potentially 
influencing their clinical performance.  
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Chapter 1 Introduction 
 Overview 1.1
As this study focussed on human MSCs, their migration and interaction with 
immune cells under homeostatic and inflammatory conditions, the introduction 
of this thesis will provide a broad overview of the immune system and MSCs and 
will include; i) reviewing the roles of various immune cells in orchestrating the 
promotion of resolution after an inflammatory insult, ii) considering the 
migration of immune cells during homeostasis and after an inflammatory 
response by exploring the chemokine family, and lastly, iii) an in depth 
examination of MSCs, their interaction with immune cells and how MSCs are 
beneficial in different clinical settings.  
 The immune system 1.2
We are exposed to potentially deadly threats every day in life, including a 
plethora of microorganisms – bacteria, viruses, fungi, parasites- and general 
injury which often result in inflammation. Our first line of defence against 
pathogens is the skin which acts as a physical barrier to deter entry. However, 
there are breaks in this protective barrier for digestive, reproductive and 
respiratory openings where chemical barriers known as mucous membranes serve 
as protection. Should these physical barriers be compromised, the immune 
system acts as our internal protection, primed and ready to respond to 
neutralise any breach. 
The immune system is a network of molecules, cells, tissues and organs that 
work together to protect the host from foreign pathogens. Should a pathogen 
enter the tissues or circulation, it will encounter the innate immune system. The 
innate immune response is always immediately available to combat a wide range 
of pathogens within the first few hours of infection. Cells of the innate immune 
system are continuously circulating the body, via the blood and lymphatic 
systems, whilst also sampling from their environment within tissues. Should a 
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pathogen be encountered, the cells are equipped with rapid defences to 
eliminate danger whilst also recruiting additional effector cells to the infected 
site via secretion of inflammatory mediators. Antigen presenting cells such as 
dendritic cells (DCs) are among the cells recruited to the infected site. They are 
responsible for migrating to the lymph nodes to present antigen(s) (Ag(s)) to the 
adaptive immune system. If DCs have phagocytosed infectious material they will 
be in an activated state and will possess specific surface molecules (CD80/86) 
that can interact with, and influence, the activation state of the adaptive 
immune system. If DCs are non-activated, they will lack these molecules and 
induce tolerance of the adaptive immune system to the self-Ags which they 
bear. Adaptive immunity (also known as the acquired immunity)  takes days to 
develop and provides long lasting protection through the production of memory 
cells (1). It relies on lymphocytes known as T and B cells which have Ag-specific 
receptors generated through a series of somatic mutations, resulting in a 
stronger, faster and more efficient response, should an individual be infected by 
that same pathogen again. Taken together, the innate and adaptive immune 
responses act in concert to provide protection against pathogens, whilst limiting 
damage to the body. The immune system is central to our survival and health 
and will be discussed in more detail in forthcoming sections.  
 Innate immune system in inflammation 1.2.1
As mentioned, the innate immune system is the first line of defence, responding 
in minutes to hours due to germline encoded receptors that recognise common 
features of many pathogens. Initial stages of infection and/or inflammation are 
characterised by five cardinal signs: calor (increased heat), rubor (redness), 
tumor (swelling), dolor (pain) and function laesa (loss of function). Calor and 
rubor are caused by vasodilation which increases blood flow and thus encourages 
the influx of leukocytes to the affected area which in turn leads to tumor and 
dolor. The combination of all of the above can lead to function laesa. This 
classifiction system of inflammation encapsulates a very complex interplay of 
molecules known as the humoral immune system and various cell types of the 
innate immune system, which all work together to clear infection and promote 
resolution (2). 
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 The complement system 1.2.1.1
The complement system is a complex network of 30+ proteins that aid or 
“complement” the killing of bacteria and clearing of damaged cells. The 
complement proteins are synthesized in the liver and circulate as inactive 
precursors in the blood.  Depending on the stimulus, one of three complement 
pathways can be activated; the classical pathway (activated via immune 
complexes), the alternative pathway (activated via pathogen surfaces and 
lipopolysaccharide (LPS)) or the lectin pathway (activated via bacterial surfaces) 
(3). Activation of these pathways causes protease cleavage of specific proteins 
and results in amplification processes causing further protein cleavage. All the 
pathways converge at the formation of C3. C3 is cleaved to form the products 
C3a, C3b, C5a and the membrane attack complex C5b-9. The formation of these 
proteins results in a wide range of cellular activity, including chemotaxis, mast 
cell degranulation and macrophage activation, ultimately leading to the 
initiation and perpetuation of the inflammatory response. To prevent aberrant 
complement activation and unwarranted perpetuation of the inflammatory 
response and potential harm to host, several complement inhibitory proteins 
exist in the circulation which degrade specific components of the complement 
systems and inhibits the cellular activity promoted by the activation of 
complement (4).  
 Cells of the innate immune system 1.2.1.2
The innate immune leukocytes are products of multipotent hematopoietic stem 
cells (HSCT) which mature and expand within the bone marrow (BM) and migrate 
to the periphery to perform effector functions upon relevant external signals. 
Innate cells derive from a common myeloid progenitor (CMP) which gives rise to 
neutrophils, monocytes, macrophages, DCs, eosinophils, mast cells (MC) and 
basophils (5).  
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1.2.1.2.1 Neutrophils 
 
Neutrophils are short lived phagocytic granulocytes. Accounting for 40-70% of 
white blood cells in mammals, they are the most abundant white blood cells and 
are essential in innate immunity. Their importance in host defence is 
demonstrated through individuals with congenital neutrophil deficiencies who 
suffer from severe infections that are often fatal (6). Primarily, neutrophils are 
found in the bloodstream, however upon challenge, they are typically the first 
cell to be recruited into tissues following signals such as chemokine (CXC motif) 
ligand 8 (CXCL8), CXCL2, complement component 5a (C5a), and vascular 
endothelial growth factor (VEGF) – to name a few (7). At the site of insult, they 
have a plethora of mechanisms to clear infection such as phagocytosis, the 
release of bactericidal molecules and neutrophil extracellular traps (8). 
Additionally, neutrophils release a number of inflammatory cytokines and 
chemokines which amplify local inflammatory responses and promote further 
leukocyte infiltration. Therefore, neutrophils are equipped with the necessary 
effector functions vital in pathogen clearance, whilst also promoting the immune 
response. Conversely, there is increasing evidence that neutrophils are involved 
in the resolution of inflammation, wound healing and angiogenesis (9, 10).These 
opposing functions of neutrophils in inflammation and resolution have led to the 
notion that two distinct populations of neutrophils might exist and are recruited 
independently of one another. In mice, pro-inflammatory neutrophils are 
recruited by the pro-inflammatory chemokine CXCL2, whereas pro-angiogenic 
neutrophils - shown to be essential for the formation of blood vessels -are 
recruited via vascular endothelial growth factor A (VEGFA) and secrete matrix 
metallopeptidase 9 (MMP9) which facilitates tissue remodelling (11).  
Whether neutrophils exist as two distinct populations – anti-inflammatory or pro-
inflammatory – or if they are one multifunctional cell in different environments, 
responding to extracellular signals is currently debated in the literature and is 
reviewed elsewhere (7). From these studies, what is clear is that neutrophils are 
phagocytic granulocytes, capable of rapidly killing and clearing infection whilst 
also promoting angiogenesis and resolution of inflammation. 
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1.2.1.2.2 Eosinophils 
 
Eosinophils are multifactorial granulocytes involved in host defence against 
parasitic helminth infections and the pathology of allergic diseases (12). They 
develop in the bone marrow and exist in to the peripheral blood where they 
briefly circulate before exiting into peripheral tissues including the thymus, 
ovary, lower gastrointestinal tract spleen and uterus (12, 13). Numerous stimuli 
recruit eosinophils to the inflammatory foci where engagement of 
immunoglobulin (Ig), complement and cytokine receptors results in eosinophil 
activation and degranulation of cytoplasmic granules filled with a plethora of 
chemical mediators. The contents of these granules include various cytokines 
(Interlukin-2 (IL-2), IL-4, IL-5, IL-10, IL-12, IL-13, IL-16 and IL-18) and 
chemokines (CCL11 and CCL5) which when released, result in activation and 
exaggeration of the surrounding immune response via the upregulation of the 
vascular adhesion system and an increase in vascular permeability, allowing for 
entry of more immune cells, leading to the perpetuation of the inflammatory 
response (12). 
Despite being most popularly known for their involvement in allergy and end-
stage parasitic infections, eosinophils also play roles in homeostasis where they 
are involved in post-natal mammary gland development (14) . Other roles 
include Ag presentation to T cells (15), promoting T cell proliferation (16) and 
resolution of inflammation (17).  
1.2.1.2.3 Monocytes    
 
Monocytes are circulating white blood cells that typically represent 4% (mice) 
and 10% (humans) of nucleated cells in the blood. They are derived from a 
precursor population that resides within the bone marrow which, in mice, 
requires the chemokine receptor CCR2 for their exit into the bloodstream (18). 
In the circulation -for both humans and mice- there are different populations of 
monocytes which are termed classical, intermediate and non-classical 
monocytes. When comparing human to mice, these monocyte populations may 
not fully overlap (19), however their roles in immune defence appear to be 
similar. Non-classical monocytes are involved in promoting wound healing and 
angiogenesis, whereas classical monocytes accumulate at sites of inflammation 
21 
 
in response to chemokines (namely CCL2 and CCL7) and microbial factors (20).  
It is unknown whether intermediate monocytes play a biologically meaningful 
role or whether they represent intermediates in a continuous differentiation 
system from classical to non-classical monocytes. Nonetheless, they have been 
found in increased numbers in certain pathologies such as rheumatoid arthritis 
(21) and patients with asthma (22), suggesting that they play a role in shaping 
the immune response in these pathologies. Classical, intermediate and non-
classical monocytes are the precursors of monocyte –derived macrophages and 
DCs which differentiate when they reach peripheral tissues under specific signals 
(23).  
1.2.1.2.4 Macrophages  
 
Macrophage populations include 1) bone marrow derived circulating monocytes 
recruited to sites of tissue injury, 2) infiltrating macrophages which have 
differentiated from in situ monocytes and 3) yolk-sac derived tissue resident 
macrophages present within the spleen, lung, skin, brain, liver, pancreas and 
kidney (24). Macrophages can be differentially termed, depending on their tissue 
of residence, e.g. Kupffer cells in the liver, osteoclasts in bone and microglia in 
the brain. As they are hugely phagocytic, they clear cell debris, apoptotic cells 
and erythrocytes whilst also possessing the ability to release effector molecules 
that attract other immune cells upon tissue damage or infection (24). 
Macrophages are also equipped with a whole plethora of pattern recognition 
receptors (PRRs) which are vital receptors in innate immunity recognising 
pathogen-associated molecular patterns (PAMPS) or damage associated 
molecular patterns (DAMPS).The expression of these germ-line encoded 
receptors allows them to be primary responders to damage or pathogens (25). In 
responding to their surrounding environment, infiltrating macrophages can 
differentiate into a spectrum of cells with distinct phenotypes, popularly – but 
perhaps not correctly - referred to as M1 or M2 (26). M1 (or classically activated 
macrophages) are thought to be induced by microbial stimuli and/or interferons 
(IFN) and are regarded as pro-inflammatory. Conversely, M2 (or alternatively 
activated macrophages) are induced via IL-4 and IL-13 and are involved in 
resolution of inflammation (27). This terminology suggests that only these two 
phenotypes of macrophages exist, whereas it is likely that they represent two 
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extremes of a continuum of diverse functional states which respond to 
extracellular cues and therefore the M1/M2 paradigm is limited (26). Due to 
their ability to attract and instruct other immune cells, they play a major role in 
commencing clearance of pathogens but also contribute to pathogenesis of 
inflammatory and degenerative diseases (28, 29).  
1.2.1.2.5 Natural Killer cells 
 
Natural Killer (NK) cells, originally referred to as large granular lymphocytes are 
now categorised as innate like lymphocytes (ILC). They are known to 
differentiate and mature in the bone marrow, lymph nodes, spleen, tonsils and 
thymus and differ from B and T cells due to their lack of somatic rearranged 
immunoglobulin and T cell receptor (TCR) genes (respectively), thus termed 
innate- like lymphocytes (30). In humans, they can be identified and divided into 
subsets via expression levels of CD56. CD56dim NK cells constitute 90% of the total 
NK cell population and have high cytotoxic activity, whereas the remaining 10% 
of NK cells are CD56BRIGHT and are mostly involved in the production of cytokines 
(31). Due to their ability to be highly cytotoxic, they respond relatively rapidly 
(~3 days post infection) to viral infections and are pivotal in suppressing tumour 
formation. NK-cell cytotoxicity is a complex process, tightly regulated by a 
balance between inhibitory and activating signals. Killer immunoglobulin-like 
receptors (KIR) are composed of activating and inhibitory receptors that 
specifically recognise human leukocyte antigens (HLA) A, B and C and upon 
binding HLA, KIRs can detect virally infected cells, transformed cells and host 
cells. The majority of KIRs are inhibitory receptors meaning that the binding of 
self HLA results in inhibition of NK-cell activation and promotion of self-
tolerance (32). Conversely, tumour cells and virally infected cells classically 
downregulate HLA molecules in an attempt to avoid recognition by cytotoxic T 
lymphocytes (CTLs), however this leaves them a target to NK cells, where 
activation receptors are no longer suppressed, resulting in strong stimulatory 
signals, tipping the balance towards NK cell activation (33). Once fully 
activated, NK cell cytotoxicity is applied via two pathways. One pathway induces 
apoptosis in the target cell via NK cell secretion of perforin (disrupts cell 
membranes) and granzymes. Alternatively, caspase-dependent apoptosis can 
also be induced in target cells which express death receptors (e.g. Fas/CD95) 
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(34). Thus, the NK cell is vital in early innate responses to protect against viral 
infections, formation of tumours and promotion of self-tolerance.  
1.2.1.2.6 Dendritic cells 
 
Like macrophages and neutrophils, DCs are considered professional phagocytes. 
However, in contrast to macrophages and neutrophils, DCs present self and non-
self-Ags in the form of peptides on MHC class I (endogenous) and II (exogenous) 
and present it to CD8 and CD4 T cells, respectively, thus activating the adaptive 
immune response. Importantly, DCs can also cross present exogenous antigens on 
MHC I, allowing DCs to activate naïve CD8 T cells and permitting them to 
recognise and kill transformed or infected cells (35). It is this ability to prime 
and activate the adaptive immune system that has resulted in the DC being 
termed a professional Ag presenting cell (36). DCs are a heterogeneous 
population of cells derived from hematopoietic bone marrow progenitor cells 
and remain in an immature form until activated. Upon activation via PRRs and 
CD40L, the DC alters its Ag processing and presenting behaviours, ultimately 
resulting in the upregulation of co-stimulatory molecules CD80/86, and the 
chemokine CC receptor 7 (CCR7) (37, 38). Mouse models have illustrated that 
CCR7 upregulation is indispensable for the mobilisation of the dendritic cell 
through the lymphatics to the lymph node (39). Once they have arrived, they 
make their way to the T cell zone and depending on whether they express co-
stimulatory molecules or not, will dictate whether the T cell is activated or 
tolerance is induced, respectively (40).  Collectively, DCs are professional Ag 
presenting cells, branching the innate and adaptive immune system, promoting 
activation or inducing tolerance, paving the foundations for formation of 
immunological memory which is created by the somatic rearrangements of the 
immunoglobulin and T cell receptor genes of B and T cells in the adaptive 
immune system.  
 Adaptive immune system 1.2.2
Unlike the innate immune system where germline encoded receptors recognise 
molecular patterns of common pathogens, the adaptive immune system relies on 
clonal expansion of Ag specific effector cells, specifically selected for via 
complex processes of receptor gene rearrangements. The adaptive immune 
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system is only present in vertebrates and cartilaginous fish and takes roughly 5-7 
days to respond to Ags whilst also forming immunological memory towards said 
Ags. This allows subsequent encounters with the same pathogen to be cleared 
more efficiently and it is this process of immunological memory that is the basis 
for vaccination (41). The system is termed adaptive, or acquired, due to its 
ability to create a plethora of Ag specific receptors which are expressed on 
lymphocytes. This process is known as somatic hypermutaion and results in an 
irreversible change in the DNA of each cells progeny. It occurs via the re-
arrangement of V(D)J genes, and cells which are most specific for the Ag are 
positively selected for and subsequently clonally expand (42). T and B 
lymphocytes are the cells of the adaptive immune system capable of VDJ gene 
rearrangements and provide us with specific life-long immunity.  
 B cells  1.2.2.1
B-cells - termed so due to their discovery in the Bursa of Fabricius in birds – are 
Ag presenting cells capable of secreting cytokines and antibodies (43). They 
develop in the bone marrow from a common lymphoid progenitor (CLP) and 
undergo a complex selection process which ensures that they bear a unique B 
cell receptor which is highly specific but also remains non-reactive to self. 
Immature B cells that have not yet seen their Ag, leave the BM and circulate 
through the blood and lymph. B cells visit and reside within secondary lymphoid 
organs such as the spleen, lymph nodes (LNs), tonsils and Peyer's patches. Within 
the follicles of the lymph node, B cells can acquire Ag via a population of 
subcapsular macrophages which sample particulate Ag from the lymph (44). B 
cells then make their way towards the T cell zone to encounter their cognate T 
cell. Only when a cognate interaction occurs does the B cell clonally expand 
resulting in short-lived plasma cells, long lived plasma cells or memory cells 
(45).  
Plasma cells are responsible for secreting large amounts of antibodies which are 
recognised as the basis for humoral immunity. Although there are 5 different 
kinds of antibodies involved in different aspects of immunity (IgM, IgG, IgA, and 
IgE & IgD), one plasma cell will produce copious amounts of one type of antibody 
and unlike their precursor, they cannot switch class once differentiated. These 
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antibodies will circulate in the blood and lymph and bind Ags causing 
neutralisation, complement activation or tagging for phagocytosis by other 
immune cells that express Fc receptors (46). Fc receptor binding to antibodies 
triggers cytotoxic killing or phagocytosis of the material. Several different Fc 
receptors exist on different types of immune cells. Each Fc receptor binds a 
specific type of immunoglobulin and exerts a specific function for example IgG 
binding to FcϒRIIA which is present on macrophages, neutrophils, eosinophils 
and will result in phagocytosis and eosinophil degranulation. Equally, binding of 
IgA or IgM to Fcα/μR present on B cells and macrophages will result in 
endocytosis and induction of microbe killing (47).  
 T cells 1.2.2.2
Like B cells, T cells also develop from a CLP in the bone marrow. From here, 
they migrate to the thymus where they undergo further maturation through a 
series of complex selection processes which are distinguished by the expression 
of different cell surface molecules.  For successful development into a CD4, CD8 
or T regulatory (Treg) cell, T cells must migrate through different areas of the 
thymus under the guidance of chemokines and their receptors (Section 1.3) and 
interact with thymic stromal cells presenting self-peptides on the surface of 
major histocompatibility molecules (MHC). This process ensures that T cells 
successfully develop their T cell receptor alpha, and beta chains and only 
thymocytes which have weak affinity for self-peptide presented by MHC will 
survive (48, 49). The majority of thymocytes die during this process, the ones 
that survive develop into i) T helper cells (CD4) - involved in shaping, 
perpetuating and assisting the immune response ii) cytotoxic T cells (CD8 +ve) - 
involved in direct lysis and killing of cancer and virally infected cells and iii) 
Tregs - involved in maintaining immune tolerance to self and the prevention of 
autoimmune diseases (50).  
Naïve T cells (not yet seen their cognate Ag) circulate in the blood and lymph 
and reside within secondary lymphoid organs. In lymphoid organs, activated DCs 
present peptides to naïve T cells, if the TCR is specific for said peptide an 
immune synapse forms resulting in a downstream signalling cascade ultimately 
ending in the activation of the naive T cell. During this process CD4 T helper 
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cells can develop into an array of different helper cells depending on cues given 
from the surrounding environment as to what kind of immune response is 
required. These subsets, termed Th1, Th2, Th9, Th17, T follicular helper cells 
(Tfh) and induced T regulatory cells (iTregs), are important in the activation of 
the innate immune response, B cells, cytotoxic T cells and suppression of the 
immune response (iTregs) (50). Conversely, the activation of CD8 T cells is less 
ambiguous and results in a very efficient killing machine via the secretion of 
perforin, granzymes and interferons. Once activated, these cells clonally expand 
and the majority are short-lived, with only a small proportion of them become 
life-long memory cells. These memory cells- with the exception of T effector 
memory cells (Tem) - circulate between the secondary lymphoid organs sampling 
the lymph for their peptide in order to respond rapidly upon secondary 
activation (51).  
 Chemokines and chemokine receptors 1.3
In order for immune cells to elicit the aforementioned functions, it is essential 
that they migrate from where they develop, to where they reside and ultimately 
to sites of infection and inflammation. Additionally, immune cells must 
constantly move under homeostatic conditions, sampling their surrounding 
environment. Chemokines and their receptors are pivotal in immune cell 
trafficking during homeostasis and inflammation.  
 Chemokines 1.3.1
Chemokines are members of a large, ancient family of chemotactic cytokines 
consisting of approximately 50 highly conserved members. They range from 7-15 
kDa in size and stimulate recruitment of leukocytes and some non-hematopoietic 
cells. Chemokines are secondary pro-inflammatory mediators as their secretion 
is activated via primary pro-inflammatory mediators such as tumour necrosis 
factor-alpha (TNF-α), IL-1β and IFN-γ (interferon-gamma) (52). By binding to G-
Protein coupled receptors (GPCRs) (Section 1.3.2) on the surface of immune 
cells, chemokines are involved in several processes such as immune development 
and homeostasis, activation of primary and secondary host defence mechanisms 
and also the initiation of wound healing (53, 54). Depending on their structure, 
chemokines are split into different families, dictated by the positioning of the 
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first two of four invariant cysteine residues and intervening amino acid residues, 
denoted by the letter ‘X’ and thus termed CC, CXC, XC or CX3C chemokines 
(Figure 1-1) (55).  
 
Figure 1-1 Highly conserved structures of the four chemokine families 
The chemokine proteins are separated into specific families based on the arrangement of invariant 
cysteine residues stabilised by disulphide bonds near the amino terminus (NH2). XCL1 and XCL2 
have one cysteine residue near the amino terminus (A), CC chemokines have 2 cysteine residues 
(B), whereas CXC chemokines have 2 cysteine residues separated by a non-conserved amino acid 
residue “x” (C). The only known member of the CX3C chemokine family (Fraktalkine) has 3 non-
conserved amino acid residues separating the two amino terminus cysteine motifs (D). CX3CL1 
and CXCL16 both have a mucin stalk domain which consists of a membrane-spanning hydrophobic 
α-helix and a short cytoplasmic tail. This mucin stalk allows these chemokines to be bound on the 
surface of cells, although soluble forms of fraktalkine exist.    
 
 CC-Chemokines  1.3.1.1
CC chemokines -also known as the β- chemokines- have 27 members and are 
numbered in the order they were discovered from CCL1 – CCL28 (56). They can 
be broadly categorised into homeostatic or inflammatory chemokines with some 
exceptions. The inflammatory chemokines are generally lower CC numbers with 
CCL1 being implicated in lung mucosal inflammatory responses (57), CCL3 in a 
model of colitis (58) and CCL8 in allergic responses (58). Despite these 
chemokines being implicated in these diseases, it is difficult to associate one 
inflammatory chemokine with a specific pathology due to the infidelity of the 
chemokine system. Put simply, one inflammatory CC chemokine will bind several 
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different CC chemokine receptors resulting in a massive amount of apparent 
redundancy in the system (Figure 1-2Figure 1-2), however this redundancy allows 
for efficient fast clearing of infection. Conversely, the homeostatic CC 
chemokines are produced at much lower quantities and are constitutively 
expressed by certain cell types in specific locations and often only bind one 
receptor. CCL19 and CCL21 bind to CCR7 which is expressed on DCs and they are 
involved in lymphoid organ development, trafficking of DCs and T cells to the 
lymph nodes and maintenance of lymphoid tissue microarchitecture (59). 
Similarly, CCL25 binds to CCR9 and is constitutively expressed in the thymus and 
the small intestine. CCL25, along with CCL28 (binds CCR10) are involved in 
immune cell gut homing during homeostasis (60). As mentioned, some 
chemokines serve as both inflammatory and homeostatic chemokines. CCL2 
binds CCR2 and is a potent monocyte and memory T cell chemoattractant during 
inflammation (61). This chemokine and chemokine receptor pair are implicated 
in several inflammatory diseases such as atherosclerosis (62) and 
neurodegenerative disorders (63), however, they are also involved in the 
homeostatic egress of LY6Chi monocytes from the bone marrow in mice and 
therefore play a dual role in inflammation and homeostasis (64). 
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Figure 1-2 Chemokine and chemokine receptor family binding patterns – human. 
Chemokine receptors bind several different chemokines and chemokines bind several different 
receptors. CCRs (purple receptors) will only ever bind CCLs (red circles), CXCRs (orange 
receptors) will only ever bind CXCLs (green circles). Apart from the atypical chemokine receptors 
(red receptors), ligand binding, induces an intracellular signalling cascade causing a calcium flux 
which ultimately results in cytoskeletal rearrangements, cell survival, angiogenesis, integrin-
dependent adhesion, among others. The atypical chemokine receptors (red receptors) lack the 
signalling motif DRYLAIV and therefore are unable to signal like conventional chemokine receptors. 
Despite an ‘unconventional’ signalling pattern, ACKRs are able to internalise their ligand and in 
some cases (ACKR2, ACKR3 and ACKR4) degrade it before recycling the receptor back to the 
surface of the cell.
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 CXC Chemokines  1.3.1.2
CXC chemokines are so called due to an amino acid in between the first two 
cysteine residues. Also known as the α-chemokines, there have been 17 
described in mammals that can be divided into two different sub-classes 
dependent on the presence or absence of an amino acid motif – Glu-Leu-Arg. 
These groups consist of ELR-positive (CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, 
CXCL7 and CXCL8) or ELR-negative chemokines (CXCL4, CXCL9, CXCL10, CXCL11 
and CXCL17). As well as leukocyte chemoattraction, ELR-positive chemokines are 
involved in angiogenic processes, whereas ELR-negative chemokines are 
angiostatic (65). Like the CC chemokines, they can also be segregated into 
homeostatic or inflammatory chemokines. The most primordial chemokine, 
CXCL12, is a homeostatic chemokine that binds CXCR4. Particularly well 
described for its pivotal involvement during development and retention of 
hematopoietic stem cells within the bone marrow, it is essential throughout all 
stages of life, from embryogenesis to adulthood. Being a homeostatic 
chemokine, CXCL12 is constitutively expressed by the BM stromal compartment, 
however during inflammation CXCL12 can be secreted by most stromal cells, 
resulting in chemotaxis of lymphocytes towards the affected area, promotion of 
vascular formation (angiogenesis) and maintenance of tissue stem cells (66, 67). 
Unlike CXCL12, CXCL8 - formerly known as IL-8 - is considered an inflammatory 
chemokine which binds to CXCR1 and 2 and is involved in the chemoattraction of 
neutrophils and other granulocytes towards sites of inflammation, promoting 
phagocytosis. CXCL8 is also a strong promoter of angiogenesis, fibrosis and 
tumorigenesis. Unlike other chemokines, CXCL8 can be stored as a fully formed 
protein in endothelial cell vesicles called Weibel-Palade bodies, allowing for 
rapid release (68, 69).Together, CXC chemokines are essential for development 
and initiation of inflammatory processes whilst also possessing the ability to 
promote resolution.  
 CX3C and XC – Chemokines 1.3.1.3
Fractalkine, otherwise known as CX3CL1 or neurotactin (in mice), is the only 
chemokine in the CX3C chemokine receptor family. Structurally, it is quite 
distinct from the other chemokines as it possesses three amino acid residues and 
a mucin-like stalk domain. Although it exists in a soluble form, the mucin-like 
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stalk allows it to be embedded and presented on the surface of cells. It is the 
only member of its family and binds one receptor – CX3CR1 (70). Similar to 
fractalkine, XCL1 and XCL2 only bind one receptor (XCR) and exist in a small 
family of their own. Their function is not fully appreciated or understood (71).  
 Chemokine receptors 1.3.2
As mentioned, chemokines signal through chemokine receptors which are 
members of the seven-transmembrane (7TM), G-protein-coupled receptor 
(GPRC) superfamily. There are roughly 20 signalling receptors which upon ligand 
binding at the N-terminal (Figure 1-3) induce downstream signalling causing a 
calcium flux. This ultimately leads to cellular responses such as cytoskeletal 
rearrangements, chemotaxis, cell survival and angiogenesis (52, 72). 
Similar to the chemokines which they bind, chemokine receptors are numbered 
in the chronological order in which they were discovered. Despite each receptor 
subtype binding several different ligands, they only ever bind ligands from one 
chemokine subfamily and therefore are named based on the chemokines they 
bind (CC, CXC, CX3C, XC) followed by “R” for receptor (73). There are 10 known 
CC receptors, 8 known CXC receptors and the CX3C and XCR receptor families 
consist of one known member each. Leukocytes express different chemokine 
receptor profiles depending on their maturation and activation status. 
Chemokine receptors can define a specific leukocyte population, for example 
the expression level of CCR2 is often used to distinguish mouse monocyte 
populations (74). Additionally, the expression of CCR7 is arguably what defines a 
mature dendritic cell and its upregulation is indicative of a DC’s activation state 
(75).  The CC receptor family bind several ligands as does 3 out of 6 of the CXC 
receptor family. Fractalkine receptor (CX3CR1) binds one ligand CX3CL1 and XCR 
binds XCL1 and XCL2. The expression of particular chemokine receptors will 
dictate leukocyte migration to specific sites and govern entry of cells into 
specific tissues, for example, CCR7 +ve cells will migrate towards the lymph 
node, CCR10 +ve cells will migrate towards the skin, CCR9 +ve cells will migrate 
to the intestine and the expression of CXCR4 can result in migration towards the 
BM, lung and spleen (76-79).  
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Figure 1-3 Typical Structure of a Chemokine Receptor  
Each chemokine receptor has 7-transmembrane regions (7TM) connected by extramembranous 
loops. The ability of a chemokine receptor to signal relies on the presence of the DRYLAIV motif in 
the second intracellular loop (not present in atypical chemokine receptors). The ligand binding N 
terminus is extracellular, whereas the C-terminus, coupled to G-proteins is intracellular. Upon 
ligand binding, the G-proteins change conformation ultimately resulting in a physiological response.  
 
 Atypical Chemokine Receptors 1.3.2.1
Atypical chemokine receptors (ACKRs) are structurally homologous to GPRCs, 
however they lack the DRYLAIV motif and therefore are unable to couple to G-
proteins and fail to signal in a “classical” manner, thus termed atypical and 
segregated into their own family. Unlike conventional chemokine receptor ligand 
binding, biding of ACKRs to their ligands does not result in chemotaxis, however, 
they are able to internalise their ligands. There are 4 members of the ACKR 
family termed ACKR1-4, some of which are involved in well-defined processes, 
whilst the function of others is currently unclear. Perhaps the best understood 
atypical chemokine receptor is ACKR2 (formerly known as D6), known for its 
ability to internalise and degrade inflammatory chemokines, thus considered a 
scavenging receptor with pivotal roles in the regulation of inflammation (80, 81). 
Like ACKR2, ACKR3 and ACKR4 are also known for their ability to scavenge their 
ligands. However, unlike ACKR2, both ACKR3 and ACKR4 bind significantly fewer 
ligands with only two known ligands for ACKR3 (CXCL11 and CXCL12) and three 
for ACKR4 (CCL19, 21, 25). The high expression of ACKR4 on lymphatic 
endothelial cells has led to the belief that it is involved in finely tuning 
chemokine gradients in the lymph node by binding CCL19 and CCL21 and 
therefore controlling the availability of these ligands for CCR7 expressing cells 
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such as DCs (82). ACKR3 is involved in germ cell migration during embryogenesis 
through the formation of tissue chemokine gradients (CXCL12) and is expressed 
at high levels in tumour microenvironments, promoting angiogenesis (83, 84).  
Thus, atypical chemokine receptors finely tune the immune response by 
scavenging chemokines whilst also playing important roles in development and 
the regulation of cell migration.  
 Chemokines and Their Receptors in Migration of Leukocytes 1.3.2.2
Neither the innate, nor the adaptive immune responses would occur without 
immune cells migrating from the blood into the tissue. This processes is termed 
diapedesis (Figure 1-4) and relies on immobilised chemokines presented on the 
surface of the endothelium by glycosylamminoglycans (GAGs). The migration of a 
leukocyte into a tissue is a tightly regulated process involving several different 
steps which depend on the leukocyte expressing a combination of adhesion 
molecules and chemokine receptors. This combination of molecules serves as 
tissue specific “address codes” and governs leukocyte entry into specific tissues 
during homeostasis and inflammation (85). Put simply, leukocytes come in 
contact with the endothelium and begin rolling which is mediated by selectins 
on the endothelial surface and glycosylated sugar ligands on the leukocyte 
membrane. If the leukocyte expresses the appropriate chemokine receptor - 
which bind specific chemokines presented by GAGs on the endothelial surface – 
the leukocyte begins to tether. Hereafter, G-protein coupled signalling results in 
conformational changes within the leukocyte which results in integrin clustering 
and activation. Activated integrins bind to adhesion molecules on the 
endothelium, resulting in firm adhesion of the leukocyte to the endothelium. 
Thereafter leukocytes undergo diapedesis through endothelial tight junctions 
into specific tissues (86). Once within tissues, it is relatively unclear how 
chemokines coordinate chemotaxis of leukocytes. Perhaps the best understood 
example of how chemokines dictate the movement of leukocytes within tissues 
is the role of CCR7 and its ligands CCL19 and 21 and CXCR5 and its ligand CXCL13 
in the movement and retention of cells at specific sites within the LN (87, 88). 
Moreover, the evidence of chemokine gradients and their necessity in vivo is 
sparse, however, the first documented in vivo existence of a chemokine gradient 
has been described for CCL21 in the LN (89).  
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Figure 1-4 Recruitment of leukocytes into tissues – rolling, tethering, tight binding and 
diapedesis 
The process of leukocyte migration into tissues is a serious of adhesive steps that can be 
categorised into rolling (B), tethering (C), tight binding (D), and transendothelial migration (E). 
Factors released by immune cells and endothelium during insult lead to endothelial cell 
upregulation of adhesion molecules, known as selectins (A). Glycosylated ligands on the immune 
cell bind to endothelial expressed selectins, resulting in a cell rolling across the endothelial surface 
(B). Chemokines in the surrounding environment, presented on the endothelial surface via GAGs 
will bind to immune cells with the appropriate chemokine receptor. This chemokine/chemokine 
receptor binding results in integrin clustering and a conformational change in integrin molecules on 
the leukocyte, leading to tight binding and immobilisation of the leukocyte (C, D). The cytoskeleton 
of the leukocyte rearranges and the leukocyte passes through the gaps in the endothelial cells, 
aided by junctional adhesion molecules (E). Once within the tissue, chemokines direct cellular 
movement towards the desired location, perhaps assisted via chemokine gradients (F).  
 
 The Stromal Compartment  1.4
Stromal cells are responsible for the secretion of several mediators, as well as 
Ag presentation, that initiate and shape the hematopoietic immune response. 
The stromal compartment is the connective tissue of organs and consists of a 
complex mixture of phenotypically similar, and somewhat functionally distinct, 
cells such as MSCs, fibroblasts and pericytes.   
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 Mesenchymal Stromal Cells 1.4.1
MSCs are multipotent precursor cells that give rise to cells from the mesoderm 
lineage. First described by Alexander Friedenstein in the 1970’s as spindle 
shaped, clonogenic cells in monolayer cultures that can be isolated from the 
bone marrow, he termed them as colony-forming unit fibroblasts (90, 91). 
Friedenstein later described them as cells that can serve as feeder cells in the 
bone marrow for hematopoietic stem cells (HSCs) and this lead to a series of 
studies which resulted in Arnold Caplan terming them mesenchymal stem cells 
due to their origin and supposed ability to self-renew (92). In more recent years, 
it has become apparent that MSCs can be isolated from most tissues in the body, 
however, their self-renewal capabilities in vivo are debated (93). Thus, due to a 
lack of true stem cell activity, the International Society of Cellular Therapy 
(ISCT) suggested a nomenclature alteration from mesenchymal stem cells to 
mesenchymal stromal cells - the two terms are used interchangeably within the 
literature, however, they describe the same cell type and are denoted the 
acronym MSC (singular) or MSCs (plural)(94).  
 Definition of a Mesenchymal Stromal Cell 1.4.2
For a cell to be defined as a MSC, it must reach specific criteria stated by the 
ISCT. These criteria include; adherence to plastic when maintained in standard 
culture conditions, capacity to differentiate into adipocytes, chondrocytes and 
osteocytes along with the expression of the surface markers CD73, CD90, CD105 
whilst lacking hematopoietic markers such as CD45, CD34, CD14, CD19 and HLA-
DR (95). MSCs also express several other markers including variable levels of 
CD29, CD44, CD166, CD146 and CD271. Some of these markers might be useful in 
the isolation of a particular type of MSC for example CD271 in BM MSC isolation 
(96). The variability of these surface markers on MSCs could be due to culture 
conditions, passage number, tissue or species origin.  
 Tissue origin of MSCs impacts their phenotype and function 1.4.3
As mentioned previously, MSCs can be isolated from a large variety of tissues 
around the body including, dental pulp, Wharton’s jelly, skin, placenta, 
umbilical cord (UC), periodontal ligament, adipose (Ad), pancreas and from the 
islets within the pancreas (Is) - to name but a few. BM MSCs are considered the 
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gold standard MSC to which other MSCs are compared. More recently however, it 
has become apparent that other tissue sources may be more suitable for clinical 
use due to them being more easily accessible and isolated in higher quantities 
from tissues that would often be regarded as medical waste, thus being 
relatively low cost to acquire, with no burden on the donor (97). Subsequently, 
studies comparing MSC source, phenotype and function have led to the belief 
that MSCs from different sources are phenotypically similar (similar morphology 
and surface CD expression levels) but differ in their proliferation capacity, their 
ability to differentiate into certain lineages, their immunomodulatory capacity 
and their cytokine secretion profiles (98-103). Despite numerous studies on the 
comparison of MSCs isolated from different tissue sources, not all avenues have 
been fully explored. Studies comparing their immunomodulatory capacity have 
focussed mainly on their ability to suppress T cells (104). Additionally, studies 
comparing MSC migratory potential are minimal. Moreover, in depth studies on 
MSC migration and immunomodulation have largely focussed on BM MSCs. 
Understanding and comparing the migratory and immunomodulatory capacity of 
MSCs isolated from various tissue sources will be important for the progression of 
clinical studies with MSCs.  
 MSCs and the immune system 1.4.4
When MSCs were discovered to be weakly immunogenic - due to their lack of 
HLA Ags and co-stimulatory molecules (e.g. CD80/86) - whilst also possessing the 
ability to be immunosuppressive, immunomodulatory and regenerative in both 
humans and animal models, they became particularly interesting to 
immunologists (104, 105). Their location in the stromal compartment within 
epithelial niches in close proximity to vessel walls, results in MSCs being one of 
the first epithelial responders in mechanical and microbial breach. Once 
breached, they are in the perfect position to recruit immune cells, whilst also 
promoting resolution via blood vessel formation (106). It is therefore, perhaps, 
of no surprise that MSCs can interact with, immunosuppress and 
immunomodulate the humoral, the innate and the adaptive immune systems. 
Their ability to interact with the immune system and promote resolution is 
enhanced during inflammation, a process known as MSC licensing, i.e. in order 
for MSCs to function as anti-inflammatory and pro-resolving cells they must be 
surrounded by an inflammatory environment, which is popularly mimicked in 
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vitro by stimulating MSCs with cytokines such as IFN-γ, TNF-α and/or IL-1β. 
Licensing MSCs in this way highlights how MSCs might perform in a clinical 
setting, as they are predominantly used as anti-inflammatory and 
immunomodulatory mediators in inflammatory environments (107).  
 MSCs and the humoral immune system 1.4.5
The humoral immune system is composed of macromolecules, secreted 
antibodies, the complement system and antimicrobial peptides. MSCs have been 
reported to have an effect on, respond to and interact with several components 
of humoral immunity. Perhaps the most comprehensively explored avenue of 
humoral immunity and MSCs is the complement system (Section 1.2.1.1).  
Studies suggest that MSCs express complement receptors C3aR and C5aR, 
allowing chemotaxis of MSCs towards the complement components C3 and C5, 
which are abundantly expressed in inflamed tissue. The binding of C3 and C5 to 
their receptors on the surface of MSCs ultimately results in MSCs having 
increased resistance to oxidative stress – a favourable attribute in an inflamed 
environment, leading to prolonged survival of MSCs (108).  Moreover, MSCs 
secrete complement factor H (CFH) which is a complement inhibitor and exerts 
its function via inhibiting the formation of C5 and C3 convertases, whilst also 
accelerating their degradation (109). Taken together, MSCs are able to interact 
with the complement system to migrate towards sites of inflammation. Once 
within the inflamed site, MSCs are able to survive longer by binding complement 
factors whilst also secreting factors that inhibit complement formation and 
degrade it.  
Secreted antibodies from B cells are heavily involved in humoral immunity as 
described in (Section 1.2.2.1).  The antibodies IgM, IgA and IgG secreted by B 
cells are reduced in the presence of BM MSCs, the mechanisms behind this 
phenomenon are largely unknown, however it is suggested to be T cell mediated 
(110, 111).  
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 MSCs and the innate immune system 1.4.6
As mentioned in Section 1.2.1, the innate immune system plays a crucial and 
essential role in initiating and resolving inflammation. Additionally, the innate 
immune system has been implicated in transplant rejection and autoimmune 
disease (112). Thus the observations documenting the immunomodulatory and 
anti-inflammatory effect of MSCs on various components of the innate immune 
system are crucial for understanding MSCs potential in the clinic. 
 MSCs and monocytes and macrophages 1.4.6.1
 
As mentioned previously, monocytes and macrophages are vital in the early 
stages of inflammation where they help clear debris whilst also perpetuating the 
inflammatory-immune response. The monocyte/macrophage system is a complex 
mixture of cells consisting of bone marrow derived circulating monocytes 
recruited to sites of tissue injury, infiltrating macrophages which have 
differentiated from in situ monocytes and yolk-sac derived resident 
macrophages. Monocytes and macrophages are involved in the persistence and 
perpetuation of several inflammatory and autoimmune diseases such as 
atherosclerosis and Crohn’s disease (113-115). Several studies have 
demonstrated that MSCs have an immunomodulatory effect on monocytes and 
macrophages and therefore could prove an advantageous treatment option for 
monocyte/macrophage driven inflammatory diseases (116, 117). Although the 
precise molecular mechanisms remain unclear, it has been suggested that MSCs 
can promote the differentiation of the anti-inflammatory “M2” macrophages 
from monocytes via MSC indolamine 2,3-dioxygenase (IDO) activity (118). This 
leads to IL-10 production from macrophages, which in turn has an inhibitory 
effect on surrounding proliferating T cells (119). Additionally MSC exposure to 
the anti-inflammatory M2 macrophage prolongs MSC survival when compared to 
pro-inflammatory M1 exposure (120). Further, in a rat model of spinal cord 
injury BM MSC infusion was linked with elevated levels of M2 cytokines IL-4 and 
IL-13. The elevated levels of cytokines matched the observation of increased M2 
cell numbers and decreased M1 cell numbers. This was associated with less 
scarring, preserved axons and increased myelin sparing (121). Collectively, MSCs 
promote the development of M2 macrophages from monocytes, which in turn 
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provide MSCs with survival signals. These M2 macrophages secrete anti-
inflammatory cytokines which act on surrounding immune cells such as T cells to 
prevent their proliferation.  
 MSCs and neutrophils  1.4.6.2
 
Neutrophils are involved in early immune responses, releasing reactive oxygen 
species along with other inflammatory mediators to clear infection. Along with 
monocytes and macrophages, they too have an important role in recruiting 
plentiful immune cells to the site of inflammation. Literature surrounding the 
interaction of MSCs and neutrophils is sparse, however, it has been reported that 
MSCs modulate neutrophil function in several ways that lessens their 
inflammatory capacity. Through the secretion of IL-6, MSCs have been shown to 
downregulate the respiratory burst of neutrophils, along with a delay in 
spontaneous apoptosis in resting and activated neutrophils (122). This 
downregulation of the respiratory burst is thought to promote the longevity of 
the neutrophil and could be important in the reservation of immature 
neutrophils in specific sites such as the BM (123).  
 MSCs and dendritic cells 1.4.6.3
As professional Ag presenting cells, presenting Ag to T cells, B cells (124) and NK 
(125) cells, depending on their activation status, DCs are capable of activating 
the adaptive immune system or inducing tolerance. Activated DCs express co-
stimulatory molecules such as CD80/86 as well as a marked upregulation of MHC 
II which allows them to activate T cells. Conversely, a peptide loaded DC which 
is still immature, i.e. low levels of CD80/86 and MHC II will not provide a T cell 
with sufficient activation signals resulting in T cell anergy or apoptosis. MSCs 
have the ability to interfere with the maturation and activation state of DCs. 
GMCSF and IL-4 stimulated monocytes were inhibited from maturing into DCs via 
MSC secreted IL-6 and PGE2 (126, 127). In addition to this, DC’s ability to 
endocytose, upregulate co-stimulatory molecules and secrete IL-12 were 
impaired when co-cultured with MSCs (128). This repressed activation state of 
the DC had a knock on effect on the DCs ability to activate T cells.  
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  MSCs and NK cells  1.4.6.4
 
NK cells are well known for their ability to kill other cells without needing any 
prior stimulation. This results in them being relatively unregulated killing 
machines, perhaps accounting for their well-documented involvement in 
autoimmune diseases (129). As previously discussed (Section 1.2.1.2.5) NK cells 
kill those cells expressing low levels of MHC I, leaving the MSC as a target for NK 
cells. Administration of IFN-γ (MSC licensing) to MHC:NK co-cultures upregulates 
MHC I on MSCs and protects them from NK cell cytotoxicity (130). Additionally 
co-culture of MSCs and NK cells downregulates the expression of activation 
receptors on NK cells (131). Moreover via the secretion of TGF-β1 and PGE2, MSCs 
are able to repress proliferation and IFN-γ production of IL-2 or IL-15 activated 
NK cells (132). Together, the microenvironment surrounding the NK cells and 
MSCs may determine which cell has the upper hand. During inflammation, MSCs 
are able to regulate the activation state of NK cells whilst in the absence of IFN-
γ, NK cells could be capable of cytotoxic killing of MSCs.  
 MSCs and the adaptive immune system 1.4.7
 MSCs and T cells 1.4.7.1
 
Upon TCR engagement T Cells are activated to perform a variety of effector 
functions including cytokine production to shape the surrounding immune 
response and cytotoxic killing of virally infected and tumour cells. They are the 
primary mediators of many inflammatory and autoimmune diseases, therefore, 
the observation that MSCs can inhibit T cell proliferation resulted in sequential 
studies dissecting the immunomodulation of MSCs on T cell effector pathways 
(133).  MSCs ability to supress T cell proliferation occurs directly or indirectly. 
Direct suppression of proliferation occurs through cellular contact or soluble 
mediators, whereas indirect suppression of T cells occurs via MSCs effects on 
other immune cells such as DCs. BM MSCs are able to inhibit the proliferation of 
T cells via the engagement of programmed cell death protein 1 (PD-1) in vitro 
(134). Additionally, MSC production of soluble factors such as indoleamine 2 3-
dioxygenase (IDO) (secretion leads to T cell anergy) (135), prostaglandin E2 
(PGE2) (suppresses TCR signalling) (136), Hepatocyte Growth Factor (HGF) and IL-
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10 have been reported to inhibit T cell proliferation and promote Tregs (137). 
The anti-proliferative effect MSCs have on T cells is associated with the arrest of 
T cells in a state of quiescence, which can be reversed upon administration of IL-
2. Additionally, due to the MSC mediated downregulation of co-stimulatory 
molecules on DCs, MSCs are able to promote T cell anergy indirectly via other 
immune cells. MSCs are also able to skew the type of T helper cell response 
along with downregulating CD8 T cell cytotoxicity (138). Co-culturing human 
MSCs with Th1 cells resulted in reduced IFN-γ secretion whereas IL-4 production 
from Th2 cells was increased. Moreover, the number of Tregs was increased 
(139). Similar observations were noted in a mouse model of inflammatory bowel 
disease, where the administration of xenogenic, allogenic or autologous Ad MSCs 
ameliorated disease (140). This was associated with a downregulation of IFN-γ 
alongside an upregulation of FOXP3 Tregs. Thus, MSCs can modulate the 
intensity of the immune response by inhibiting Ag specific T cell proliferation 
whilst also promoting Tregs.  
 MSCs and B Cells  1.4.7.2
 
B cells have been implemented in several autoimmune diseases such as Multiple 
Sclerosis (MS), systemic lupus erythematosus and rheumatoid arthritis (141, 
142). Their ability to form memory plasma cells and produce antibodies specific 
for self-Ag for a lifetime is what renders them key players in autoimmune 
diseases. The immunomodulatory effect of MSCs on B cells are contradictory, 
this could be due to a number of factors such as MSC isolation technique, 
passage number of MSCs and different experimental procedures. When co-
cultured with human BM MSCs and a B cell stimulus, purified B cells were 
arrested in the G0/G1 phase of the cell cycle and unable to proliferate. 
Additionally, soluble factors secreted from MSCs impaired IgM, IgA and IgG 
production. Moreover, B cell’s ability to migrate towards CXCL12, CXCL13 and 
CCL19/21 was diminished via the downregulation of the receptors CXCR4, CXCR5 
and CCR7 on the B cell (110). Interestingly, the ability of MSCs to 
immunomodulate B cells is thought to be dependent upon the presence of T cells 
(143).  
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 MSCs migratory capacity 1.4.8
Like hematopoietic cells, in order to carry out efficient effector functions, MSCs 
must migrate to sites of tissue injury. MSCs have been shown to possess the 
ability to home to sites of injury from the periphery. Human and rat MSCs have 
demonstrated the capability to migrate into sites of brain injury after cerebral 
ischemia (144, 145). Moreover, in a model of allograft rejection, MSCs delivered 
IV found their way towards sites of rejection (146). Others have observed MSC 
capability to migrate towards the lung in response to injury when injected IV 
(147). However, due to a large body of literature describing MSCs getting 
trapped in the lungs of mice when delivered systemically (148), it is hard to 
determine if the observation of MSCs in the lung is a result of specific homing to 
the injured lung or whether it is entrapment within the lung. The low 
engraftment rate of MSCs within target tissues could suggest that poor 
pulmonary passage is also occurring in humans (149, 150).  
The precise mechanisms that MSCs use to migrate from the periphery into tissues 
are unknown but it is likely that they use a combination of adhesion molecules 
and chemokine receptors to achieve this. In support of this, there is a large body 
of literature describing chemokine receptor expression on human MSCs, however 
the findings are somewhat contradictory.  
Expression levels of the homeostatic chemokine receptor CXCR4 is perhaps the 
most widely disputed within the literature. Some groups found no expression 
(151), some found very little (152) whilst others observed functional CXCR4 on 
MSCs (153). MSCs have also been reported to express other functional chemokine 
receptors such as CCR1, CCR7, CCR9, CXCR5 and CXCR6 (151, 154).  What is 
important to note is that all of these studies have only assessed BM MSC 
chemokine receptor expression. Interestingly, other studies have suggested that 
Ad MSCs express fewer adhesion molecules than BM MSCs and this allows for 
more rapid egress from the lung into sites of damage (155). This could suggest 
that MSCs isolated from different sources possess differential migratory capacity 
and therefore a particular tissue for MSC isolation might be favourable to 
enhance migration to specific anatomical locations.   
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 MSCs clinical use  1.4.9
As a result of the aforementioned observations of (BM) MSCs interactions with 
immune cells and migratory potential, MSCs are intensively studied as a cellular 
therapy in a wide range of inflammatory and autoimmune disorders. In the first 
instance, MSCs received attention due to their differentiation capabilities, thus 
interest grew in their potential application within the clinic for tissue degrading 
diseases such as rheumatoid arthritis and MS (156, 157). Secondly, their ability 
to immunosuppress and immunomodulate several components of the immune 
system, led to the concept of MSCs being used to suppress graft rejection, graft 
versus host disease (GVHD) and autoimmune disorders (158). Moreover, MSCs can 
be easily isolated from a variety of human tissue with little effort. To add to 
this, they can be easily and quickly expanded for mass production of a good 
manufacturing practice (GMP)-grade cell. Perhaps most importantly, MSCs have 
poor immunogenicity in vitro, in pre-clinical and in human studies (105, 159). 
This is due to their low expression of HLA molecules resulting in the possibility of 
MSCs being obtained from allogeneic donors. It is for these reasons that MSCs 
have gained much interest in numerous pre-clinical and clinical trials.  
Animal models of human disease are a tool in pre-clinical trials and have been 
indispensable in understanding the effect of MSCs within different disease 
models. Mouse models have been used to demonstrate the immunosuppressive 
capacity of MSCs in vivo. More specifically, mouse models have been used to 
understand the effects of MSCs in chronic obstructive pulmonary disease, Type 1 
Diabetes, experimental autoimmune arthritis, graft versus host disease and 
others.  
 MSCs in Graft Versus Host Disease and Solid Organ Transplantation 1.4.9.1
Graft versus host disease occurs after an allogeneic hematopoietic stem cell 
transplant (HSCT) which is a treatment for hematopoietic malignancies and 
immune deficiencies. It arises as a result of transplanted donor immune cells 
mounting a response to recipient tissues and/or organs, occurring in around 50% 
of transplants (160). Mouse models have allowed insight into the pathophysiology 
of the disease, allowing for better understanding of GVHD and improved success 
rate of HSCT. Mouse models of GVHD are created by the depletion of endogenous 
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hematopoietic cells in recipient mice via radiation or chemotherapy and then 
reconstituting the immune system with allogeneic bone marrow cells. The 
severity of GVHD in these animals is determined via the degree of MHC mismatch 
between donor and recipient, with the readout of disease severity being 
determined via weight loss, survival and histological examination of organs 
(161).  
Due to the properties of MSCs, they have therapeutic potential for the treatment 
and prevention of GVHD. A mouse model demonstrated that BM MSCS reduced 
the severity of GVHD, whilst also prolonging the survival of the HSCT recipients. 
These observations were coupled with the diminished infiltration of T cells into 
target organs and inhibition of the co-stimulatory molecules CD80/86 on DCs 
(162).  
In humans MSCs have been used in several clinical trials for patients with 
steroid-refractory GVHD (163). MSCs have shown to significantly lower the rate 
of acute GVHD and MSC infusions seem to be tolerated well in all patients (164-
166). 
Due to the success and safety of pre-clinical and clinical trials with MSCs in 
GVHD, MSCs are being investigated for use in solid organ transplantation (SOT). 
Interestingly, a mouse model of kidney allograft transplantation highlighted the 
importance of timing of MSC delivery. They demonstrated that a pre-transplant 
infusion of MSCs resulted in the localisation of MSCs within lymphoid organs and 
this promoted the expansion of Tregs. Conversely, an infusion of MSCs post-
transplant was associated with premature graft dysfunction coupled with 
neutrophils and complement deposition (167). This study suggests that infusing 
MSCs post-transplant does not allow the MSCs to be licensed (in an inflammatory 
environment) for long enough to exert their anti-inflammatory properties, an 
issue which has been associated with the failure of several pre-clinical and 
clinical trials (168).  
In humans, the use of MSCs in patients undergoing a renal transplant resulted in 
a lower case of acute graft rejection, reduced risk of opportunistic infection 
along with improved renal function at one year (169).  
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 MSCs in Diabetes Type1 1.4.9.2
Diabetes mellitus type 1 is an autoimmune disease that results from the 
destruction of the insulin producing pancreatic beta cells. Macrophages, 
dendritic cells, B cells and T cells have been shown to be involved in the 
pathogenesis of T1DM (170). In 2014, the number of people in the UK living with 
T1DM was 350,000, costing the NHS £1 billion per year, with this figure 
estimated to double by 2035 if current treatment options remain unchanged 
(171).  
There are several treatment options for individuals with T1DM including the most 
common method of daily insulin injections, along with other methods such as an 
insulin pump, an artificial pancreas and more invasive options such as whole 
pancreas transplantation and islet transplantation (172-174). The 
aforementioned options aim to restore blood glucose levels by replacing insulin 
production in some way. Insulin therapy was the first therapy discovered for 
T1DM however patients quality of life is still affected by frequent episodes of 
hyper and hypoglycaemia which can lead to undesirable side effects such as 
weakness, shortness of breath, fainting and in more severe cases coma and 
sometimes death. The only way to restore blood glucose levels and combat 
progression of diabetic complications is to replace β-cells. Whole pancreas and 
islet transplantation are two treatment options that can achieve this outcome, 
however, pancreas transplants are associated with early mortality and lifelong 
immunosuppressive drug use. Conversely, islet transplantation is a significantly 
less invasive surgery and presents as a much smaller immunogenic tissue (174). 
Moreover, investigation into protecting the islets from recipient immune system 
attack is underway. Current strategies include physically encapsulating the islets 
within a semi-permeable membrane consisting of polymer (175), along with 
infusing MSCs to act as an anti-inflammatory and regenerative cell to improve 
graft survival (176).  
A number of animal models exist to study the immunological pathogenesis and 
long term consequences of β-cell loss. The Non-Obese diabetic (NOD) mouse 
model is used as a model for spontaneous autoimmune disease which shares 
many similarities with T1DM. These mice have a mutation in exon 2 of the 
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) gene, which plays a vital 
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role in the suppression of T cells. Without a functional CTLA-4 gene, the β-cells 
are susceptible to autoimmune attack from T cells (177). Additionally, the 
administration of streptozotoan (STZ) which damages β-Cells results in the 
accumulation of immune cells and immune mediated destruction of β-cells. The 
STZ administration model is used to assess progressive loss of β-cells. Both of 
these models have been used to study the effect of MSC administration in T1D, 
and have shown that MSC administration can protect against disease (MSCs 
administered before onset), reverse disease (MSCs administered after onset) and 
can revert hyperglycaemic animals to normal blood glucose levels. These 
observations have been paired with a reduction of inflammatory CD4 T cells, a 
shift in cytokine production towards a Th2 mediated response and an induction 
of T regulatory cells (178). Due to the success of MSC infusion in T1D disease 
models, studies have focussed on understanding if the co-infusion of MSCs with 
islets is protective for the islets. Results show that MSCs can significantly 
improve islet survival (179), insulin secretion (180) and delay allograft rejection 
(181). 
 Thesis aims 1.5
Previous sections highlight how MSCs are of great interest for use as a cellular 
therapy to act as anti-inflammatory mediators in several diseases. As SNBTS 
provide an islet transplant service, our particular interest lies in the co-infusion 
of MSCs with pancreatic islets in order to improve graft function and longevity. 
However our interest is not limited to this and extends to understanding the 
potential roles of MSCs within any clinical setting. What is important to note 
from the previous sections is that the majority of our understanding of MSCs 
phenotype, function and performance within clinical trials comes from BM 
derived MSCs, with a relative lack of understanding of other MSC populations. 
Therefore we sought to understand if MSCs isolated from tissues that would be 
regarded as medical waste – islet (Is), visceral adipose surrounding the pancreas 
(Va), adipose (Ad), and umbilical cord MSCs (UC) – are comparable to BM derived 
MSCs. More importantly, this study aimed to elucidate if one population of MSC 
could be more beneficial than others in specific clinical settings. 
To understand this, we thought it would be appropriate to understand the 
chemokine receptor expression of all MSC types. This would help us gain insight 
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into whether one MSC would be more suited to migrating to specific target 
tissues if infused systemically. Equally, if MSCs were infused locally, low 
expression of chemokine receptors might be more desirable to ensure that MSCs 
do not migrate away from the graft site.  
In addition, it was important to address how MSCs isolated from various tissues 
might interact with their surrounding environment once infused into a patient. 
With several reports highlighting BM MSCs anti-inflammatory, immunomodulatory 
and pro-regenerative capacity in various clinical settings, understanding how 
MSCs isolated from various sources interact with surrounding immune cells is 
pivotal in elucidating their potential immunomodulatory and pro-regenerative 
capacity in vivo. In an attempt to examine this, we aimed to assay the 
chemokine secretion profiles of MSCs isolated from various sources and how this 
impacted their interaction with immune cells. The layout of this study and 
overall aims of each chapter are outlined below:  
1. The aim of Chapter 3 was to fully phenotype Is, Va, Ad, BM and UC 
derived MSCs at rest and under inflammatory stimulation (MSC licensing).  
2. The aim of Chapter 4 was to assess and compare the mRNA expression of 
all chemokines and their receptors by MSCs at rest and under 
inflammatory stimulation. 
3. The aim of Chapter 5 was to determine if the expression patterns of 
chemokines and their receptors would persist at a protein level at rest 
and under inflammatory stimulation. Moreover, through assessing the 
immune cell attraction profile of MSCs at rest and under inflammatory 
stimulation, the work in this chapter aimed to address whether the 
chemokines secreted by MSCs were functional.  
4. Chapter 6 - having observed immune cell attraction in an in vitro system, 
the work carried out in this chapter aimed to understand if this immune 
cell attraction profile persisted in vivo.  
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Chapter 2 Materials and Methods 
 
 General solutions and consumables 2.1
Solutions used in these studies, their composition and their concentration are 
detailed in Table 2-1. All Laboratory chemicals and plasticware were obtained 
from a variety of manufacturers and are detailed throughout this chapter.  
Table 2-1 List of solutions and their compositions 
Solution Composition Concentration 
1xs Dulbecco’s 
Phosphate-Buffered 
Saline 
Potassium Chloride (KCL) 
Potassium Phosphate Monobasic 
(KH2Po4) 
Sodium Chloride (NaCl) 
Sodium Phosphate Dibasic 
(Na2HPO4) 
2.7mM 
1.76mM 
 
137mM 
10mM 
Fluorescence-activated 
cell sorting (FACS) buffer 
DPBS 
FCS 
Sodium-Azide (NaN3) 
EDTA 
1% 
0.02% 
5mM 
0.01% 
Freezing down solution AB Pooled Plasma 
Dimethylsulphoxide (DMSO) 
90% (v/v) 
10% (v/v) 
 
 
 
 Cell culture methods 2.2
 Primary cell maintenance 2.2.1.1
All cells used during this study were primary cells, unless stated otherwise. Cells 
were handled in a sterile environment (Laminar flow hood with HEPA filtration) 
with sterile equipment at all times. Surfaces and equipment were sprayed with 
70% industrial methylated spirits prior to use. All centrifuge steps for cell culture 
were carried out at 200g for 7 minutes - unless stated otherwise, using a Biofuge 
primo centrifuge (Thermo Scientific). All cell cultures were incubated at 37oC / 
5%CO2 / 95% humidity. Mesenchymal stromal cells (MSCs) were seeded at a 
density of 3000 cells/cm2, unless stated otherwise.  
Islet (Is), visceral adipose (Va), adipose (Ad), bone marrow (BM) and umbilical 
cord (UC) MSCs were maintained in 0.26mL/cm2 (per tissue culture flask) 
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Dulbecco’s minimal essential medium (DMEM), high glucose, GlutaMAXTM 
Supplement (Life Technologies) plus 10% AB pooled plasma (provided by Scottish 
National Blood Transfusion Service), 4mM penicillin and streptomycin 
(Invitrogen) – this will be referred to as “MSC medium” for the remainder of this 
thesis.  
The cells were examined daily for growth using a phase-contrast microscope 
(Ziess) and maintained in culture until they reached 70-80% confluence. At this 
time, cells were washed twice with DPBS (sigma) and detached following a 
10min incubation at 37°C with 10mL of 1 x TryplE (Life Technologies), cells were 
then placed into a 15mL Flacon and spun down at 200g for 7 mins. Supernatant 
was discarded and the cell pellet was resususpended in the appropriate amount 
of MSC medium, counted as outlined in Section 2.2.3 and re-seeded at 3000 
cells/cm2. When cells were detached from flasks and re-seeded into new flasks 
as described above, this was termed as cell passaging and each time it was 
performed counted as one passage. Cells of lower passage were used when 
possible (Passage 1-3). This detachment method was used consistently 
throughout all experimental procedures.  
 Isolation of cells  2.2.2
Isolation of MSCs from various tissues was carried out by staff at the Scottish 
National Blood Transfusion Services (SNBTS). Single cell MSC cultures were 
transported from Edinburgh to Glasgow at Passage 1 (P1) for experimental 
purposes. Details on how MSCs were isolated are provided below.  
 Isolation of adipose and visceral adipose mesenchymal stromal cells 2.2.2.1
Human Adipose tissue isolated from liposuction and visceral adipose tissue 
(isolated from the adipose tissue surrounding the pancreas) were received from 
SNBTS and the protocols approved by Glasgow National Health Service Trust-East 
Ethics committee. Adipose tissue was manually disociated with scissors until the 
tissue was liquidised. The sample was then spun down at 300g for 10 mins. 
Supernatant was aspirated and the remaining adipose tissue was digested with 
1mg/ml of collagenase (Sigma Aldrich) + 2% Human Serum Ovalbumin (HSA) 
(Sigma Aldrich) in PBS for 1 hour. The sample was then spun down at 300g for 20 
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mins.  The supernatant was aspirated and the cell pellet was cultured in MSC 
culture medium. After 2 days, non-adherent cells were discarded, MSC medium 
was replaced and adherent cells were left to grow. From then on, cells were 
checked daily for growth and medium was changed every 2-3 days. When cells 
were 80% confluent they were passaged.  
 Isolation of islet mesenchymal stromal cells 2.2.2.2
Waste islet fractions were obtained from SNBTS Islet isolation lab - where the 
preparation of islets isolated from deceased donor’s pancreas occurs before islet 
transplantation.  
High purity islets (HPI) or low purity preparations were centrifuged and plated 
out in T125, T75 or T25 flasks at approximately 10 islets/cm2. All materials were 
treated as an explant. These materials were cultured at 37oC in 5% CO2 in MSC 
culture medium. At day 7 explant outgrowth was assessed and adherent MSC 
were observed migrating from the explanted materials. The medium was 
carefully changed and then further changed every 3-4 days. 
Once the cells had reached 80% confluency the adherent MSCs were passaged as 
described in Section 2.2.1.1. To remove any larger islets and cell debris the 
material was passed through a 100µM cell strainer. The cells were counted using 
a haemocytometer and classified as passage 1. These MSC were either 
cryopreserved at 1x106 cells per vial in 10% DMSO or plated out at 3000 
cells/cm2. 
 Isolation of umbilical cord mesenchymal stromal cells 2.2.2.3
The cord was dissected by stripping the epithelial tissue to expose the vessels 
and Wharton’s Jelly (WJ). Firstly, using a sterile bullclip the cord was clamped 
onto a dissection board. The cord was kept wet by the addition of PBS. The cord 
was cut by making a shallow circumferential incision into epithelium close to the 
clamp with a scalpel. Using dissection forceps, the epithelium was separated 
from the incision site around entire circumference of cord to expose underlying 
Wharton’s Jelly gelatinous tissue. Using forceps the loose epithelium was slowly 
pulled away, along the entire length of the cord, from the vessels and the 
Wharton’s Jelly (WJ) (Figure 2-1). This was performed for the length of the cord 
and the epithelium discarded. The vessels were separated by cutting down the 
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cord into the 3 vessels (2 arteries and 1 vein) with the associated WJ using 
forceps the WJ was carefully removed from the vessel walls and collected into a 
50mL conical tube containing PBS.  Once all WJ tissue was collected it was cut 
into small 1-2mm fragments using a scalpel. This tissue was then used as explant 
material into tissue culture flasks. Approximately 1mL of MSC culture medium 
per cm2 of tissue was added to a T75 flask. Cells were assessed for outgrowth 
from explanted material at day 5 and fed with fresh media on day 7. Flasks were 
assessed for outgrowth every few days and when cells were 80% confluent they 
were passaged as described in Section 2.2.1.1. Prior to re-seeding MSC into new 
tissue culture flasks, they were passed through a 100 micron filter, to remove 
large clumps, before re-plating. 
 
Figure 2-1 Schematic of the different compartments of the umbilical cord 
The diagram depicts the anatomy of the umbilical cord showing the 2 umbilical arteries and 
umbilical vein which are surrounded by an associated perivascular region. A gelatinous substance 
known as the Wharton’s Jelly - where UC MSCs in this study were isolated from – fills the centre of 
the cord, which is held together by the epithelial cord lining.  
 
 Isolation of bone marrow mesenchymal stromal cells 2.2.2.4
The bone marrow (BM) was received from patients undergoing hip revision 
surgery. The BM sample was weighed and dissected using a scalpel into 0.5-1g 
pieces. The BM fragments were digested with Collagenase II (Sigma) at a final 
concentration of 0.25mg/mL at 37oC in a 50mL centrifuge tube for 30-60mins. 
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Following digestion, the cells were centrifuged at 200g for 15mins. The 
supernatant was carefully discarded and the cell pellet retained. The pellet was 
re-suspended in Hanks Balanced Salt Solution (HBSS) (Thermo Fisher), passed 
through a 100µM cell strainer (Falcon) and cells were counted using a 
haemocytometer. Cells were then plated out in T75 flasks at 3000 cells/cm2 in 
MSC culture medium. Flasks were incubated at 37oC, 5% CO2. Cells were assessed 
for outgrowth daily and media changed every 3-4 days. Once at 80% confluence, 
the adherent MSC were passaged as described above and labelled P1. Cells were 
either cryopreserved or re-passaged by plating at a density of 3000cells/cm2. 
 Cell counting 2.2.3
Cells were counted using a Neubauer Haemocytometer (Hawksley). Dead cells 
were excluded using Trypan blue (Sigma). Trypan blue was diluted 1:10 in PBS. 
50µl of diluted Trypan blue was mixed with 50µl of cell suspension and incubated 
for 2-3 mins at room temperature (RT) before loading into the haemocytometer 
chamber. Live cells in the 4 large outer squares were counted, divided by 4 to 
obtain the average cell number, multiplied by 2 to account for the trypan blue 
dilution and then by 104 to give the number of cells per 1 mL of the cell 
suspension.  
 Freezing 2.2.4
Primary cells were frozen at early passage from all cell sources. Cells were 
washed in PBS, detached with TryplE as discussed in Section 2.2.1.1, spun down 
and resuspended at a density of approximately 1x106 cells/mL in freezing down 
solution (see Table 2-1). 1 mL aliquots were transferred to 2mL cryo-vials 
(Thermo-scientific) and stored in a freezing vessel (Nalgene), containing 
isopropanol. This was then placed at -80oC (cooling 1 ̊C per minute) and 
transferred to liquid nitrogen tanks within two days. 
 Thawing of primary cells from frozen  2.2.5
Cells were recovered from liquid nitrogen and rapidly thawed in a 37oC water 
bath. Once defrosted, the cells were transferred from a cryo-vial to a 15mL 
falcon tube. Warmed culture medium was slowly added drop by drop until cells 
were suspended in 7mL of MSC medium. The cells were then spun down at 200g 
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for 7 mins and the supernatant was discarded. The remaining pellet was then 
resuspended in the appropriate volume of MSC culture medium and transferred 
to tissue culture flask(s).   
 Stimulation of cells with inflammatory cytokines 2.2.6
When MSCs reached 80% confluency, culture medium was pipetted off and cells 
were washed twice with PBS. MSC culture medium was replaced and 
supplemented with 10ng/mL of Interferon-γ, Tumor Necrosis Factor-α and 
Interlukin-1β (Peprotech) in MSC culture medium. After 24 hours, the 
inflammatory culture medium was drawn off (and used for later experimentation 
where appropriate) and MSCs were ready for experimental procedures. 
 Differentiation Assays 2.2.7
MSCs were differentiated into adipocytes, chondrocytes and osteoclasts using 
the R&D Systems Stem Cell Kits. All Reagents and materials are listed in the 
manufacturer’s handbook (page 2). Constituents of the differentiation 
supplements are listed below in Table 2-2. 
Table 2-2 Differentiation supplements and their constituents 
Differentiation Supplement  Constituents 
Adipogenic Supplement  0.5mL of a 100X concentrated solution 
containing hydrocortisone, 
isobutylmethylxanthine and indomethacin in 
95% ethanol. 
Osteogenic Supplement  2.5mL of a 20X concentrated solution 
containing dexamathasone, ascorbate-
phosphate and β-glycerolphosphate. 
Chondrogenic Supplement 0.5mL of a 100X concentrated solution 
containing dexamethasone, 
ascorbatephosphate, proline. Pyruvate and 
recombinant TGF-β3 
 
 
 
 Adipogenesis and osteogenesis 2.2.7.1
For adipogenic and osteogenic differentiation, 13mm sterile coverslips (VWR) 
were inserted into the bottom of a 24 well plate. MSCs from different sources 
were plated at 2.1x104 (adipogenesis) or 4.2X103 (osteogenesis) on top of the 
coverslips within the 24 well plate. Cells were cultured in 0.5mL/well 90% α-
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MEM, 10% (v/v) FBS and 1% (v/v) 100X Penicillin-Streptomycin-Glutamine. For 
Adipogenesis, when MSCs reached 100% confluency, culture medium was 
replaced by 0.5mL/well of adipogenic differentiation medium (10μl/mL of 
Adipogenic Supplement (Table 2-2) added to α-MEM culture medium). For 
osteogenic differentiation, once cells were 50-70% confluent, culture medium 
was replaced with 50 μl/mL of osteogenic supplement (Table 2-2) added to α-
MEM culture medium. From then on, in both cases, fresh medium including 
supplement was replaced every 3-4 days for 14-21 days. Cells were then fixed 
and stained as stated in Section 2.4.1.1. 
 Chondrogenesis 2.2.7.2
For the differentiation of MSCs into chondrocytes, 2.5x105 MSCs were transferred 
into a 15mL conical tube in chondrogenic culture medium (99% D-mem/F12, 1%  
ITS supplement and 1% 100X Penicillin-streptomycin-Glutamine) and spun down 
at 200g for 5 mins at RT. Supernatant was poured off and MSCs were 
resuspended in chondrogenic culture medium and spun again at 200g for 5 mins. 
MSCs were left in the chondrogenic culture medium as a pellet and placed into 
the incubator with the 15mL conical tube lids slightly loosened for gas exchange. 
Chrondrogenic culture medium was replaced every 2-3 days with caution so as 
not to disturb the pellet and cultured for 21 days. After 21 days, the spherical 
mass of cells was removed and prepared for cryosectioning (Section 2.4.2) and 
further staining (Section 2.4.1.1) 
 Molecular Biology 2.3
 RNA  2.3.1
In an attempt to reduce degradation of RNA from environmental RNases, various 
measures were taken. All plastic and glassware was supplied RNase free or 
autoclaved. Additionally, sterile filtered tips were used, water was RNase/DNase 
free and bench tops and pipettes were sprayed with RNAzap before commencing 
work.  
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 Isolation of RNA from primary cells using silica-membrane 2.3.1.1
technology 
RNA was isolated from cells using the RNeasy mini Kit protocol (QIAGEN). Cells 
were pelleted and lysed according to manufacturer’s instructions using the 
appropriate amount of RLT buffer: 
≥1x106 cells 350μl RLT  
≥5x106 cells 600 μl RLT 
A micro kit was used for anything below 1x106 cells. The lysed cells were then 
homogenized using a QIAshredder spin column (QIAGEN). RNA was then 
extracted according to the Qiagen mini kit instructions. Unless specified 
otherwise, genomic DNA was digested as described in the protocol. RNA was 
eluted from the RNeasy spin column by adding 30μl of nuclease free water 
((QIAGEN). RNA was quantified by using a nanodrop (Nanodrop 1000 Thermo 
Scientific) and stored at -80⁰C in an eppendorf until needed. 
 cDNA 2.3.2
 cDNA synthesis - RT2 PCR™ Profiling Arrays 2.3.2.1
When preparing cDNA to be used on the RT2 PCR™ profiling arrays (RT2 Array), 
cDNA was synthesised using the RT2 First Strand Kit (QIAGEN) (Kit used for all 
PCR reactions in results Chapter 3). Instructions in the RT2 Array Handbook were 
followed for the synthesis of cDNA and in all cases, cDNA was synthesised to a 
final concentration of 400ng/µl (as advised by RT2 Array Handbook). The 
appropriate amount of RNA, RNase-free water and 2µl of Buffer GE were mixed 
and incubated at 42oC for 5 minutes and immediately placed on ice for at least 1 
minute to eliminate genomic DNA. The reverse transcription mix was prepared 
according to RT2 Array Handbook and incubated at 42oC for exactly 15 minutes, 
followed by 95oC for 5 minutes. 91µl of RNase-free water was added to each 
reaction and placed at -20 oC until required for gene expression studies. 
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 cDNA synthesis for routine qRTPCR 2.3.2.2
High capacity RNA to cDNA kit (Life Technologies) was used to synthesise cDNA 
for standard QRTPCR. In this case, for each experimental group, a minus reverse 
transcription control was included: 
–RT control: 20x enzyme mix was substituted with nuclease free water.  
cDNA was synthesised to a final concentration of 168ng/μl. 10µl of 2X Buffer Mix 
and 1.0µl RT enzyme mix and the appropriate amount of RNA and RNase-free 
water to bring the volume to 20µl, were mixed thoroughly and incubated at: 
37oC for 60 minutes  
95oC for 5 minutes 
4oC ‘forever’  
 Quantitative real-time PCR – QRT-PCR 2.3.3
 RT2 Profiler™ PCR Arrays  2.3.3.1
RT2 Arrays were used to assess the expression of chemokines and their receptors 
by MSCs and the results are presented in Chapter 3. RT2 Arrays Human 
Chemokines & receptors (Format E 384 well [4x96] HT option) were prepared 
and amplification carried out using a 7900HT (ABI) sequence detection system in 
accordance with manufacturer’s guidelines. The RT2 Array consists of 84 genes in 
quadruplicate, including 5 house-keeping genes, genomic DNA contamination 
controls and internal controls which monitor PCR and reverse transcription 
efficiency.  
Plate set-up was performed as recommended in the RT2 Array user’s manual. In 
short, 102μl of cDNA synthesis reaction was added to 650μl of RT2 SYBR Green 
Mastermix and 548 μl of RNase-free water. Volumes were scaled up 
appropriately depending on sample size. 10μl of the PCR mastermix was added 
to each well of the RT2 Array. Once loaded, the plate was sealed using an optical 
adhesive film. The plate was centrifuged at 1000g for 1 min at RT to remove 
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bubbles and run on an Applied Biosystems 7900HT cycler.  Cycling conditions 
were as follows: 1 cycle for 10 mins at 90oC followed by 40 cycles of 15s at 95oC/ 
1min at 60oC.  
 Standard qRT PCR 2.3.3.2
cDNA was prepared using the high capacity RNA to cDNA kit (Section 2.3.2.2). 
Prior to use, it was diluted 1 in 5 and then added to a mastermix consisting of 
PerfeCTa SYBR Green FastMix with ROX reference dye (VWR-international) 
custom made primers (IDT) and nuclease free water. Details of volumes per well 
are listed below: 
5μl SYBR Green 
3.85μl nuclease free H2O 
0.15μl pre-mixed primer pair (Section 2.3.3.3) 
The desired final volume was calculated and the above volumes adjusted 
accordingly to provide enough master mix for the reaction. Using a multi-
channel pipette, 9µl of the master mix was dispensed into each well of the 384 
well plate. Using a repeat dispenser pipette, 1μl of sample cDNA or –RT cDNA 
was dispensed into designated wells. For no-template control wells, cDNA was 
substituted with nuclease free water. The plate was then sealed using an optical 
adhesive film and then spun at 500g at 4oC to remove any air bubbles and run on 
an Applied Biosystem 7900HT thermal cycler. Cycling conditions were as 
described below: 
(95oC for 10 minutes) X1 cycle  
(95oC for 3 seconds then 60oC for 30 seconds) X40 cycles 
To confirm the specificity of the QPCR primers a dissociation curve was 
generated using the following cycling conditions at the end of the QPCR run: 
95oC 15 seconds 
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60oC 1 minute 
 Primer Design 2.3.3.3
To perform quantitative real-time PCR (QRTPCR), a pair of forward and reverse 
primers were designed to amplify each target gene. The design of these primers 
adhered to a set of strict criteria to ensure accurate amplification of a specific 
product.  
All primers were designed using Primer3 Input software version 4.0.0 
(http://primer3.ut.ee/). 
Criteria for QPCR primers: 
Primer size:    18 to 24 base pairs (bp) (20bp optimal) 
Melting temperature (Tm): 59.5oC to 61oC (60oC optimal) 
GC content:    40% to 65% (50% optimal) 
Max self-complementarity: 3 (<2 optimal) 
Max 3’ complementarity:   1  
Amplicon Size:    <150bp 
All primers were synthesised by Integrated DNA Technologies (IDT). The 
specificity of the primer sequences was first assessed using the free online 
bioinformatics resource, Basic Local Alignment Search Tool (BLAST) 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/). Primer specificity was 
then physically tested by running a PCR reaction with cDNA containing the 
transcript of interest. Specificity was confirmed if the primers amplified a single 
product of the appropriate size. Primers used throughout this study (Results 
Chapter 6) are detailed in Table 2-3. Where possible, to avoid amplification of 
any potential genomic DNA contamination, primers were designed so that they 
spanned exons. Exon spanning primers are marked with an asterisk.  
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Table 2-3 List of left and right primer sequences 
Gene Name Left Primer Right Primer 
IDO* GCAAGAACGGGACACTTTGC TGCCTTTCCAGCCAGACAAA 
CFH* GGAAGGGAGAATGGGTTGCT GATGTCCACAGGGCCTTTTCT 
CD274 GCCTCCACTCAATGCCTCAA CTGTCCCGTTCCAACACTGA 
HGF* TTGCCTGAAAGATATCCCGACAA CGGGTGTGAGGGTCAAGAG 
TGF-beta* AAGTGGACATCAACGGGTTCA GGGTGGCCATGAGAAGCA 
IL-10* TGCTGGAGGACTTTAAGGGTTAC CGCCTTGATGTCTGGGTCTT 
MMP9* GCCCCAGCGAGAGACTCTA ATTGGCCTTGGAAGATGAATGGA 
GMCSF ACTTCCTGTGCAACCCAGATT CCAGCAGTCAAAGGGGATGA 
TSG-6* AGCACGGTCTGGCAAATACA GCAGCACAGACATGAAATCCAAT 
B2M GCTCGCGCTACTCTCTCTTT TGAATCTTTGGAGTACGCTGGAT 
RPLP0* GGAAGGCTGTGGTGCTGAT CGGATATGAGGCAGCAGTTTCT 
 
 Standardisation of RT2 Profiler™ PCR Arrays 2.3.3.4
As all of the samples could not fit on one plate, inter-plate variability had to be 
controlled for. For this, one sample (induced pluripotent stem (IPSC) cells, 
differentiated into MSCs (IPSMSC)) was split over three different plates. cDNA 
synthesis, plate set up and plate reading were carried out on different days to 
replicate the typical experimental time course. The IPSMSC samples Ct values 
from all of the genes on each plate were compared to assess their correlation.  
The Pearson correlation coefficient was used to assess the relationships between 
each plate. The Pearson correlation runs from -1 (the two variables are in 
perfect opposites), through 0 (no correlation of the values at all) to 1 (indicates 
the two values are perfectly correlated).  
 Analysis of results (RT2 Profiler™ PCR Arrays) 2.3.3.5
Data analysis was performed using QIAGEN’s GeneGlobe data analysis centre 
(http://www.qiagen.com/gb/shop/genes-and-pathways/data-analysis-center-
overview-page/). The reference gene Beta-2 Microglobulin (B2M) was chosen for 
normalisation. Any gene with a CT value of >35 was determined as undetectable 
as advised by QIAGEN’s GeneGlobe data analysis centre. For each sample, the Ct 
values generated from duplicate wells were averaged and data were presented 
as 2 (-ΔCT) and calculated as below.  
ΔCT = Ct (sequence of interest) – Ct (reference sequence- B2M). 
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Each bar represents an n of 3 and is plotted as mean ± SEM. The appropriate 
statistical analysis was used and is stated in the figure legends.  
 Analysis of results – standard QRT-PRC  2.3.3.6
Data analysis was performed in a similar manner to the RT2 Profiler™ PCR Arrays. 
In this case, the reference gene used to calculate 2 (-ΔCT) was Ribosomal Protein 
Lateral Stalk P0 (RPLP0). For each sample, the Ct values generated from 
triplicate wells were averaged. Each bar represents an n of 3 and is plotted as 
mean ± SEM. The appropriate statistical analysis was used and is stated 
throughout the figure legends. 
 Protein Analysis 2.4
 Immunohistochemistry  2.4.1
 Immunohistochemistry for adipocytes, osteocytes and MSC ACKR4 2.4.1.1
expression  
MSCs that had undergone adipogenic and osteogenic differentiation were grown 
and treated as described in Section 2.2.7.1. MSCs being tested for ACKR4 
expression were grown on a 2-well NuncTM Lab-TekTM chamber slide system in 
1mL of MSC culture medium. When cells reached 80% confluency, MSC cluture 
medium was aspirated and MSCs were washed thoroughly with warmed PBS. The 
walls of the chamber slide were removed, leaving a flat microscope slide. A wax 
pen (Sigma) was used to create a hydrophobic barrier around MSCs for further 
staining. The following staining procedure was adopted for adipogenic, 
osteogenic and ACKR4 immunohistochemistry: 
Cells were washed twice with 1mL of PBS and cells were then fixed with 0.5mL 
of 4% paraformaldehyde in PBS for 20 mins at RT. Cells were washed three times 
with 0.5mL of 1% bovine serum albumin (BSA) (Thermo Fisher Scientific) in PBS 
for roughly 5 mins each wash. The cells were permeabilized and blocked with 
0.5mL of 0.3% Triton X-100 (Thermo Fisher Scientific), 1% BSA and 10% normal 
donkey serum (Sigma) in PBS for 45 mins. After blocking, cells were incubated 
with 300μl/well of the appropriate primary antibody (Table 2-4). Cells were left 
at 4oC overnight. Cells were washed three times with 0.5mL of 1% BSA in PBS for 
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5 mins each wash. Cells were then incubated with a diluted appropriate 
secondary antibody (Table 2-4) for 60 mins, in the dark, at RT. Cells were 
washed three times with 0.5mL of 1% BSA in PBS for 5 mins each wash. PBS was 
aspirated from the wells and replaced with 0.5mL distilled water. Coverslips 
were carefully removed with forceps and placed cell side down onto a drop of 
mounting medium (Vectashield + DAPI (Vector Labratories Inc) on a superfrost 
glass slide (Thermo Scientific). All slides were imaged with a Zeiss epifluorescent 
microscope using the appropriate fluorescent channels and magnifications. 
Images were prepared using Zen software. 
 Immunohistochemistry for chondrocytes 2.4.1.2
The pellet of cells was washed twice with 1 mL of PBS, then fixed with 0.3mL of 
4% paraformaldehyde in PBS for 20 mins at RT. The pellet was then washed 
twice with 1mL PBS for 5 mins. The pellet was carefully removed and placed into 
a cryomold. Cryosectioning was carried out as detailed in Section 2.4.2. Using a 
liquid barrier pen, a hydrophobic barrier was drawn around each section and 
cells were then blocked and permeabilised as described before. After blocking, 
sections were incubated with the Goat Anti-human Aggrecan (R&D) working 
solution overnight at 4oC in a container with adequate moisture. Sections were 
washed three times with PBS containing 1% BSA for 5 mins. Sections were then 
incubated in the dark for an hour with an appropriate secondary antibody (Table 
2-4 Antibodies used in immunohistochemistry).  Sections were washed three 
times with PBS containing 1% BSA for 5 mins. Sections were then washed once 
with distilled water. Excess water was removed and a drop of Vectashield + DAPI 
was added to each section before placing a coverslip on top of sections, being 
careful to avoid air bubbles. All slides were imaged using a Zeiss epifluorescent 
microscope using the appropriate fluorescent channels and specified 
magnifications. Images were prepared using Zen software.
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Table 2-4 Antibodies used in immunohistochemistry 
Experiment  Primary Secondary Company  
Differentiation 
Adipogenesis 10μg/mL 
Goat Anti-
mouse Fatty 
Acid Binding 
Protein 4 
(FABP4) 
Northern Lights 
557-conjugated 
Anti-goat. 
Dilution- 1:200 
Primary Ab: R&D Systems 
 
Secondary Ab: R&D 
Systems 
Osteogenesis 10μg/mL 
Mouse Anti-
human 
Osteocalcin  
Northern Lights 
557-conjugated 
donkey anti-
mouse 
Dilution- 1:200 
Primary Ab: R&D Systems 
 
Secondary Ab: R&D 
Systems 
Chondrogenesis 10μg/mL 
Goat Anti-
human 
Aggrecan 
Northern Lights 
557-conjugated 
Donkey Anti-goat 
Dilution- 1:200 
Primary Ab: R&D Systems 
 
Secondary Ab: R&D 
Systems 
Receptor Staining  
ACKR4 10μg/mL 
Mouse Anti-
human CCX-
CKR 
Northern Lights 
557-conjugated 
donkey anti-
mouse 
Dilution- 1:200 
Primary Ab: BioLegend 
 
Secondary Ab: R&D 
Systems 
 
 Cryosectioning  2.4.2
Cells were placed in a small cryomould, OCT compound (Tissue-Tek) was gently 
poured on top, avoiding any air bubbles, samples were then snap frozen in liquid 
nitrogen and placed in the -80oC freezer until sectioning. Frozen moulds were 
placed into the cryostat (Bright Instruments) at -25oC and sectioned 8μm thick 
onto superfrost glass slides.  
 
 Flow cytometry 2.4.3
 Flow cytometry staining 2.4.3.1
For every experiment, the same number of cells were added (~1x10^6 cells) to 
polystyrene tubes (BD Falcon) and washed with FACS buffer (Table 2-1). The 
Cells were then incubated at 4oC with 5μl FcR block, to reduce non-specific 
binding via Fc receptors. The cells were then washed twice with FACS buffer and 
incubated for 20 minutes with the appropriate antibody. The cells were washed 
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with FACS buffer again and data were acquired using the MACSQuant flow 
cytometer, LSR II (BD Sciences) or the FACSAria III (BD Sciences) and analysed 
using MACSQuantify version 2.6 or FlowJo version 10 software. All antibodies 
used for Flow Cytometry are listed in Table 2-5. 
 Mesenchymal stromal cell phenotyping  2.4.3.2
At Passage 3, MSCs were grown until they were 80% confluent, detached from 
the flasks as discussed previously and prepared for flow cytometry (as detailed 
in Section 2.4.3.1) using the “MSC phenotyping” panel of antibodies listed in 
Table 2-5 and run on the MACSQuant. 
 Mesenchymal stromal cell phenotyping in inflammation 2.4.3.3
Once MSC had reached 80% confluence at passage 2, MSCs -derived from one 
donor- were detached and re-seeded into two T75 flasks (Passage 3). When MSCs 
reached 80% confluency, culture medium was removed and cells were washed 
with warmed PBS. For each MSC donor, one T75 flask was stimulated with 
10ng/mL of TNF-α, IL-1β and IFN-ϒ in 20 mL of MSC medium for 24 hours, whilst 
the second T75 flask from each MSC donor remained in ‘homeostatic conditions’ 
through the addition of 20 mL of MSC medium alone for 24 hours. After 24 hours, 
MSC conditioned medium was removed and MSCs were detached and prepared 
for flow cytometry (as stated in Section 2.4.3.1) using the “MSC phenotyping in 
inflammation” panel of antibodies listed in Table 2-5. Samples were run on the 
MACSQuant.  
 Mesenchymal stromal cell surface chemokine receptor expression 2.4.3.4
MSCs were grown and treated as detailed in Section 2.4.3.3. MSCs were prepared 
for flow cytometry as described in Section 2.4.3.1 and MSCs were stained with 
each antibody listed in the “Chemokine receptor expression” section of Table 2-
5. Samples were run on the MACSQuant.  
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Table 2-5 List of antibodies used for flow cytometry 
 Antigen Flurochrome Clone Dilution  Company 
Phenotyping 
MSCs 
CD105 FITC 266 1:200 BD Biosciences 
CD90 Pe Vio770 DG3 1:200 Miltenyi 
CD73 PE AD2 1:200 Miltenti 
CD14 APC TÜK4 1:200 Miltenti 
CD45 VioBlue REA747 1:200 Miltenti 
Fixable 
Viability Dye  
eFluor 780  1:200 eBioscience 
MSC phenotyping 
in Inflammation  
HLA-DR  FITC Tu39 1:200 BD Biosciences 
HLA ABC PeVio770 REA230 1:200 Miltenyi 
CD146 VioBlue 541-10B2 1:200 Miltenyi 
CD166 PE 3A6 1:200 BD Biosciences 
CD271 APC ME20.4-1H4 1:200 Miltenyi 
CD73 Percp710  1:200  
Fixable 
Viability Dye  
eFluor 780  1:200 eBioscience 
Chemokine 
Receptor 
Expression 
CCR10 PE 6588-5 1:200 Biolegend 
CCR7 PE G043H7 1:200 Biolegend 
CXCR4 PE 12G5 1:200 Biolegend 
CXCR6 PE K041ES 1:200 Biolegend 
ACKR3 APC 358426 1:200 R&D Systems 
DRAQ7 APC CY7  1:200 Biostatus 
Transwell Panel CD16 PercPCy 5.5 3G8 1:200 Biolegend 
CD56 APC Cy 7 HCD56 1:200 Biolegend 
HLA-DR AF700 LN3 1:200 Biolegend 
CD1c  Biotin AD5-8E7 1:200 Miltenyi 
 SA 605  1:200 Biolegend 
Siglec 8  PE 7C9 1:200 Miltenyi 
CD4 FITC VIT4 1:200 Miltenyi 
CD 8  FITC BW135/80 1:200 Miltenyi 
CD14 VioBlue TÜK4 1:200 Miltenyi 
CD19 Pe Vio770 LT19 1:200 Miltenyi 
CD66b APC REA306 1:200 Miltenyi 
Fixable 
Viability Dye  
eFluor 506  1:200 eBioscience  
Adherent Panel 
(Transwell) 
CD16 PercPCy 5.5 3G8 1:200 Biolegend 
CD14 VioBlue TÜK4 1:200 Miltenyi 
CD4 PeVio770 REA623 1:200 Miltenyi 
CD8 FITC BW135/80 1:200 Miltenyi 
CD45 PE 5B1 1:200 Miltenyi 
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DRAQ7 APC Cy7  1:200 Biostatus 
NSG Mouse 
Model 
(Mouse 
Antibodies) 
CD11c APC NF18 1:200 Biolegend 
F480 PeCy7 BM8 1:200 eBioscience 
Siglec F PE E50-2440 1:200 BD Biosciences  
CD11b APC Cy7 M1/70 1:200 eBioscience 
Ly6c AF700 HK1.4 1:200 Biolegend 
Ly6g Pacific Blue 1A8 1:200 Biolegend 
CD105 
(HUMAN) 
FITC 266 1:200 BD Biosciences 
CD45 PercP A20 1:200 Biolegend 
Fixable 
Viability Dye 
eFluor 506  1:200 eBioscience 
OT-1 Mouse 
Model 
(Mouse 
Antibodies) 
CD4 APC GK1.5 1:200 eBioscience 
CD8 alpha PE 53-6.7 1:200 Biolegend 
B220 APC Cy7 RA3-6B2 1:200 Biolegend 
CD45 PercP A20 1:200 eBioscience 
CD105 FITC 266 1:200 BD Biosciences 
NK1.1 BV421 PK136 1:200 eBioscience 
 
 
 Cell counting using CountBrightTM Absolute Counting Beads for flow 2.4.3.5
cytometry  
When samples were acquired using the LSR II or the FACSAria III, CountBrightTM 
absolute counting beads were used to obtain accurate cell numbers in each 
sample. CountBrightTM absolute counting beads are a calibrated suspension of 
microshperes which are fluorescent in every channel (Excitation: UV to 635nm, 
Emission: 385-800nm). Beads were thoroughly vortexed and 50µl were added to 
each sample immediately before acquisition. How to calculate the number of 
cells in a sample is detailed in Figure 2-2 Identification of CountBright BeadsTM 
on the flow cytometer and subsequent cell counting analysis 
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Figure 2-2 Identification of CountBright BeadsTM on the flow cytometer and subsequent cell 
counting analysis 
CountBright beads are roughly 5-50 times brighter than the anticipated intensities of typically 
stained cells and fluoresce in every channel. For each experiment, the channels used to identify 
beads varied in order to isolate a clean, total bead population. Using the FSC and SSC parameters 
as an example, beads were easily identifiable (top left gate). Beads were gated to generate the 
number of bead events. This value, along with the assigned bead number of the lot (4.9x104/50μl), 
number of cell events and the volume of each sample was used to calculate the total number of 
cells in each sample.  
 
 Flow cytometry analysis  2.4.3.6
Irrespective of the flow cytometry software used for analysis, a similar approach 
was taken to identify live cells. When acquiring samples, FSC and SSC voltages 
were set to a suitable value to ensure all of the appropriate events were 
included for analysis. When analysing flow cytometry data, cells of interest were 
gated on using FSC and SSC, doublets were excluded using SSC-A and SSC-H or 
FSC-A and FSC-H, and live cells were selected based on lack of fluorescence of 
dead cell markers. This gating strategy was used prior to any further analysis for 
all flow cytometry experiments (Figure 2-3). 
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Figure 2-3 Initial steps in flow cytometry gating strategies 
Initial steps in flow cytometry gating strategies were consistent for each sample of every 
experiment in order to identify live cells. First steps included gating on cells of correct size and 
granularity (A), followed by doublet discrimination, to ensure cells were not clumped together (B). 
Cells negative for live/dead marker were indicative of intact, live cells (C) and were gated on for 
further analysis. In this example, granulocytes (green box), monocytes (orange box) and 
leukocytes (red box) are all live (D) and suitable for further analysis. 
 
 Fluorescent minus one controls 2.4.3.7
Fluorescence minus one (FMO) controls were used to accurately assess and gate 
on positive staining (Figure 2-4). In every antibody panel, an FMO was made for 
each fluorophore. The missing fluorophore in each FMO sample would be used to 
assess any spill-over of fluorescence from other channels, whilst also serving as a 
negative control, allowing clear visualisation of positive staining.  
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Figure 2-4 Using FMOs to accurately analyse flow cytometry data 
Fluorescence minus one controls are designed to identify spectral overlap into the channel of 
interest. The control is performed by adding all of the fluorochromes in your panel with the 
exception of one. When the data are displayed, the channel of interest – Pecy7 (A) and APC (C) 
will show you all spill-over from other channels. This allows one to draw a gate around true positive 
staining for Pecy7 (B) and APC (D) in fully stained samples.  
 
 Luminex 2.4.4
Conditioned media from the samples used for transcript work were collected for 
luminex analysis. The human personalised premixed magnetic multi-analyte kits 
were used in accordance with the manufacturer’s instructions (R&D systems). All 
reagents and standards were included in the kit and prepared as outlined in the 
guidelines. Briefly, samples were diluted 2 fold with calibrator diluent (75μl in 
75μl). 10 μl of the pre-coated microparticle cocktail was added to each well of 
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the 96 well microplates, followed by either 50μl sample or 50μl standard, sealed 
and placed on an orbital shaker (0.12mm orbit at 800 ± 50rpm) for 2 hours at RT. 
The plates were washed twice with 100 μl/well wash buffer and then incubated 
with 50 μl/well anti-biotin detector antibody for 1 hour at RT on the shaker 
(0.12mm orbit at 800 ± 50rpm). The plates were washed as before and 50 
μl/well of streptavidin-phycoerythrin was added and incubated for 30 mins at 
RT. Microparticles were resuspended in 100 μl/well of wash buffer and 
immediately read on the Bio-Rad analyser.  
 Analysis of results 2.4.4.1
The luminex analysis was acquired on a luminex 100 Bio-Rad instrument. Each 
microparticle bead region was designated as stated on the certificate of 
analysis. When beads are injected into the flow cell, a small number can 
aggregate and go through as doublets. To avoid this, the doublet discriminator 
channel measures the amount of light scatter from the particles that flow past 
the laser and specific gates were set between 8000 and 16,500 to ensure that 
only beads of the correct size were measured. Mean Fluorescence intensity (MFI) 
was acquired. Background protein levels from serum in medium were recorded 
and served as background controls (Chapter 5).  Each bar represents an n of 3 
and is plotted as mean ± SEM. Statistical tests included a One Way ANOVA in 
conjunction with a Tukey’s compare all comparisons test when comparing across 
MSCs from different sources. A Students T test was used when comparing 
stimulated vs unstimulated within one tissue source. Significance was marked 
where appropriate and detailed throughout the text in Chapter 5.  
 In Vitro Transwell Migration Assays 2.5
MSCs were seeded at 3000cells/cm2 and grown as a monolayer on the bottom of 
5μm-pore transwell plates (Fisher Scientific). When MSCs were 80% confluent the 
appropriate wells were stimulated with 10ng/mL of the cytokines detailed in 
Section 2.2.6 or left in MSC medium alone (600μl). Medium with inflammatory 
cytokines or medium alone was also added to control wells (no MSCs). After 24 
hours, all wells were washed twice with PBS, then 600μl of fresh MSC medium 
was added to all wells and left for a further 24 hours. 5μm-pore inserts were 
placed into the wells on top of the MSCs, ensuring there was no air bubbles 
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underneath them. Inserts were left to incubate with MSCs alone for 10 mins 
before the addition of leukocytes. Leukocytes were isolated as detailed in 
Section 2.5.1. 5.5x105 leukocytes in 100μl of MSC medium was placed on top of 
the insert. The transwell plate was put in the incubator at 37oC for 3 hours. 
After 3 hours, the inserts were carefully removed and discarded. The 
supernatant in the bottom wells was placed into appropriately labelled 15mL 
Falcon tubes. The wells were then thoroughly washed with PBS and placed into 
the same respective Falcon tubes. Adherent cells, attached to the bottom of the 
transwell were detached from the bottom of the wells with 1x TryplE as 
previously described and placed into different 15 mL falcon tubes. All cells were 
spun at 300g for 5 mins and transferred to FACS tubes for staining (Section 
2.4.3.1). Cells that were collected in the supernatant were labelled with the 
“transwell” panel detailed in Table 2-5 and run on the LSR II, and adherent cells 
were labelled with the “adherent” panel and run on the MACSQuant. 50μl of 
countbright beads (Section 2.4.3.5) were added to each sample immediately 
before flow cytometric analysis in order to gain accurate cell numbers. 
 Isolation of white blood cells from whole blood 2.5.1
Buffy coats were obtained from SNBTS under sample governance no. 6839/15, 
and used as a source of blood cells. To isolate leukocytes, 5-10mLs of buffy coat 
was added to a 50mL Falcon tube and spun at 300g for 20 mins. The top layer of 
plasma was pipetted off and discarded. To lyse the red blood cells (RBCs) 5mL of 
Red Blood Cell lysis buffer (RBClysB) (Miltenyi Biotech) was diluted with 45mL of 
double distilled H20 (ddH20). 45mLs of diluted RBClysB was added to the 
remaining layers of blood, vortexed and left at RT for 12 minutes, then spun at 
300g for 10 minutes. The supernatant was carefully poured off and any residue 
pipetted off. RBC lysis was repeated by adding 5mL RBClysB and incubated for 5 
minutes, followed by a 5 minute spin at 300g. The supernatant was discarded as 
before. White blood cells (WBCs) were washed with 10mL PBS and spun at 300g 
for 5 minutes (X2).  The supernatant was discarded and WBCs were resuspended 
in 10mLs of PBS for counting. Typically, 5mL of whole blood yielded 1.5-2.5x108 
WBCs.  
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 In Vivo procedures – murine air pouch model 2.6
 Animal welfare 2.6.1
All animals were housed within the Biological Central Research Facility and the 
Beatson Institute at the University of Glasgow. Animals were maintained in 
specific pathogen-free conditions within filter-top cages and given access to 
food and water ad libitum. All experiments received ethical approval and were 
performed under the auspices of a UK Home Office License.  
 Mice 2.6.2
 NOD Scid gamma (NSG) mice 2.6.2.1
Genotype of mouse: NOD.Og-Prkdcscid Il2rgtm1Wjl/SzJ gamma (NSG).  
This mouse has defects in both the innate and adaptive compartments of the 
immune system. Defects in antigen presentation, NK cell function and 
macrophage cytokine production, C5 complement and wound healing, coupled 
and IL2 receptor gamma chain deficiency which disables cytokine signalling 
resulting in a lack of mature T cells and B cells.  
Breeding pairs were obtained from Charles River Europe and the colony was 
maintained in house. 14-16 week old female mice were used for the air pouch 
model. Before experimental procedures were carried out, mice were given 7 
days to adjust and settle after being moved from the Beatson Institute to the 
Biological Research Facility. After experimental procedures, mice were 
sacrificed using a recognised Schedule 1 technique. All procedures on animals 
were carried out by Dr Kenny Pallas and Paul Burgoyne.  
 OT-1 Mice 2.6.2.2
Genoytpe of Mouse:  OT-1. 
The T cell receptor of these mice have been genetically modified to only 
recognise the ovalbumin peptide in the context of MHC-1 (CD8 T cell restricted). 
14 week old male C56BL/6 mice were bred and maintained in house. After 
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experimental procedures, mice were culled using a recognised scheduel 1 
technique.  
 Induction and maintenance of the air pouch model 2.6.2.3
One day prior to experimental procedures, the dorsal skins of mice were shaved 
in preparation for the generation of the air pouches. All procedures for NSG mice 
were performed in a laminar flow hood. All mice were put under general 
anaesthesia before and during the procedure. To ensure the air injected into the 
air pouch was sterile, the syringes were pre-prepared in a sterile laminar flow 
hood. 3mL of sterile air was injected subcutaneously into the intracapsular area 
of the mouse to create an air pouch. After 3 days, a top-up of 3 mL sterile air 
was injected into the air pouch. A third top up of 1mL sterile air was injected 2 
days later, followed by an injection of 5.5x105 pre-stimulated Islet MSCs (treated 
animals) in 1 mL of sterile PBS or sterile PBS alone (control animals) one day 
later. Cells or PBS controls were left in the air pouch for 24 hours before mice 
were sacrificed. Detailed timeline in Chapter 6 Figure 6-1. 
 Dissection and draining of the air pouch 2.6.2.4
Immediately after sacrifice, 1.5mL of PBS was injected into the hollow air 
pouches of the mice. In an attempt to obtain an optimal number of immune cells 
from the air pouch, mice were gently shaken to allow the PBS to mix throughout 
the air pouch.  
To separate the overlying soft tissues from the upper air pouch membrane 
(Figure 2-5), a small incision was made into the dorsal skin overlying the air 
pouch to reveal the apex of the upper membrane. The membrane was punctured 
with a needle and the pouch content was lavaged, transferred to an eppendorf 
tube and placed on ice (the contents of the lavage are referred to as “air pouch 
samples” throughout Chapter 6). Using blunt dissection with curved scissors, the 
upper membrane was separated from the overlying skin. The air pouch collapsed 
and the upper membrane was clipped off using scissors (the contents of this 
membrane are referred to as the “upper membrane” throughout Chapter 6). A 
thin sample of the lower membrane was also clipped off, avoiding blood vessels 
and the spinal cord (the contents of this membrane are referred to as the “lower 
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membrane” throughout Chapter 6). The upper and lower membranes were 
placed into 1mL of Hank’s balanced salt solution (Sigma-Aldrich) and put on ice.  
 
Figure 2-5 Simplistic diagram of a cross-section of the air pouch 
Sterile air was injected subcutaneously into the intracapsular area of the mouse creating a hollow 
pocket of air surrounded by a membrane. The membrane directly underlying the dorsal skin but 
overlying the hollow pocket of air was termed the upper membrane and the membrane underlying 
the hollow pocket of air and overlying the spinal cord was termed the lower membrane.  
 
 Digestion of the upper and lower membranes  2.6.2.5
To digest the upper and lower membranes of the air pouch, 35μl of liberase 
(Sigma) (stock conc = 2.5mg/ml) was added to each membrane sample and 
incubated at 37oC for 1 hour on a thermo-shaker incubator (800 rpm) (Thermo 
Shaker Incubator MS-100). Once membranes had fully digested into a single cell 
suspension, cells were passed through a 40μm sterile cell strainer (Corning) to 
remove any remaining debris. Cells were washed twice with 1mL of PBS and 
counted.  The remaining portion of the cells was prepared for flow cytometry as 
detailed in Section 2.6.2.6 and 2.6.2.7. 
 Staining for flow cytometry – NSG mice 2.6.2.6
Lavaged contents from the NSG air pouches were washed 2X with PBS. Cells 
were counted and an aliquot of 2x104 cells was put in an eppendorf tube for 
cyto-spin analysis (Section 2.6.2.8). Flow cytometry staining is detailed in 
Section 2.4.3.1, using the “NSG innate” antibody panel in Table 2-5 and samples 
were run on the Aria III.  
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 Staining for flow cytometry – OT-1 mice 2.6.2.7
Lavaged contents from the OT-1 air pouch were washed twice with PBS. Cells 
were counted and an aliquot of ~2x104 cells was placed in an eppendorf tube for 
cyto-spin analysis (Section 2.6.2.8). For flow cytometry analysis, the remaining 
samples were split over two polystyrene tubes in order to stain with two 
antibody panels- “OT-1 innate” and “OT-1 adaptive” panels (Table 2-5). The 
staining process is detailed in Section 2.4.3.1 and samples were run on the Aria 
III. 
 Cytospins 2.6.2.8
~20x104 cells were prepared in 100μl of PBS. Superfrost slides, filter paper, 
funnels and holders were prepared and assembled as detailed in Figure 2-6 
Preparation of slides for cytospins.. Each 100μl sample was loaded into an 
individual funnel which was anchored to an appropriately labelled slide and 
loaded into Shandon cytospin 2 and spun at 300rpm for 3 mins. Samples were 
left to dry overnight in preparation for histological staining.  
 
Figure 2-6 Preparation of slides for cytospins. 
Appropriately labelled super frost slides were loaded into the holder with filter card and a funnel on 
top. The holder was clipped together to hold everything in position and 20x104 cells in 100μl of PBS 
were loaded into the top of the funnel (red arrow). Picture modified from: http://bio-
protocol.org/e1303. 
 Histology 2.6.2.9
Slides that were prepared from cyto-spins were histologically assessed following 
Giemsa staining. Giemsa (Sigma) was diluted 1 in 10 with deionised water and 
poured into a glass staining jar. Slides were carefully placed into the jar 
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containing diluted Giemsa for 30 seconds. After 30 seconds, the staining jar and 
slides were transferred to a sink where tap water was added to the jar until the 
purple Giemsa ran colourless. Slides were left overnight to dry in a fume hood. 
Once dried, coverslips were placed on top of the slides using one drop of DPX 
mounting media (Sigma), making sure to avoid air bubbles. Slides were left to 
dry overnight and images were captured using a Zeiss epifluorescent microscope 
– bright field.  
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Chapter 3 Phenotyping MSCs 
 Introduction and aims 3.1
Mesenchymal Stromal Cells (MSCs) are broadly categorised as a cell type which is 
capable of differentiating into a variety of cells and 
immunosuppressing/immunomodulating the immune system. More recently 
however, it is becoming apparent that their phenotype and biological activity 
can differ depending on where MSCs are isolated from. Differences in surface 
marker expression (CD49d, CD54, CD34 and CD106) and proliferative capacity 
have been observed in bone marrow (BM) versus adipose (Ad) MSCs (182). 
Comparatively, variation in adipogenic differentiation potential has been linked 
to tissue specificity of MSCs, with umbilical cord (UC) MSCs showing little or no 
adipogenic differentiation compared to Ad and BM isolated MSCs (183). 
Moreover, MSC tissue source also has an effect on their immunomodulatory and 
immunosuppressive capacity, for example, Ad MSCs have been shown to have 
greater immunosuppressive capabilities than BM and UC derived MSCs (184) 
where their immunosuppressive capacity was measured by their ability to inhibit 
the activation and proliferation of T cells. Conversely, a separate study 
demonstrated that BM MSCs have greater immunosuppressive activity with 
regards to the activation of T cells than Ad MSCs (185).  
Discrepancies like the aforementioned are not uncommon within the MSC 
literature and are often due to a lack of standardised approaches in this field, 
resulting in differences in; isolation procedure, variations in culture medium and 
different passage number of MSCs (186-189). As a consequence of these 
variations between studies, it is becoming increasingly more challenging to 
compare results across the literature and therefore the International Society of 
Cellular Therapy (ISCT) has suggested minimal criteria to define a MSC. These 
criteria include adherence to plastic whilst maintained in standard culture 
conditions and surface expression of CD105, CD73, CD90 whilst lacking 
expression of CD45, CD14, CD34 or CD19 and HLA-DR. Finally, they must be able 
to differentiate into two out of three of adipocytes, chondrocytes and 
osteocytes (95).  
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Part of this study aimed to objectively compare cells isolated from different 
tissues using identical isolation methods and assays. Therefore, this chapter will 
focus on the phenotype of Islet (Is), Visceral adipose (attached to the pancreas 
at donation) (Va), (liposuction) adipose (Ad), BM and UC MSC morphology, 
surface molecule phenotype and differentiation potential using standardised 
assays. Additionally, as MSCs are generally used in an inflammatory setting, their 
morphology and surface phenotype was assessed after 24 hours of inflammatory 
stimulation – 10ng/mL of IFN-γ, TNF-α and IL-1β. Thus, this chapter aims to 
assess the cells isolated from Is, Va, Ad, BM and UC tissues for standard MSC 
functions and to understand the effects of tissue origin and inflammation on 
their phenotype.   
The study was begun by comparing Is, Va and Ad MSCs. BM and UC MSCs became 
available and were added to the data sets during the study. These latter two cell 
types are thus added to comparative data sets where available. For this results 
chapter - and the ones that follow - a colour code has been used for all data sets 
which is outlined in Figure 3-1
 
Figure 3-1 Schematic highlighting the colour scheme used in all figures throughout this 
study 
The above diagram illustrates the colour scheme throughout this thesis, linking a specific tissue 
source of MSC to a particular colour. When data are graphed, Is MSCs under homeostatic 
conditions will be graphed as a blue bar, and when they have been under inflammatory conditions, 
they will be graphed as a blue bar with black checks. This pattern is used for all tissue sources of 
MSCs with Va being graphed in green bars, Ad MSCs in red, BM MSCs in yellow and UC MSCs in 
orange.  
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Results 
 Physical morphology of MSCs 3.2
To ensure that MSCs isolated from the Is, Va, Ad, BM and UC possess and 
maintain the typical spindle-like morphology of MSCs through passage (P), cells 
were seeded at P0 and grown up to P8, and their morphology was monitored by 
phase contrast light microscopy. Within this study, a passage is defined as 
seeding MSCs at 3000 cells/cm3, letting them grow until they reach 80% 
confluence, detaching them and reseeding into new flasks - this would be 
classified as one passage. Upon seeding, cells isolated from all sources were left 
to attach for 5-7 days during which time small spherical cells transformed into 
plastic adherent small spindle-shaped cells. At P1, small spindle-shaped cells 
had enlarged slightly into fibroblast-like spindle-shaped cells. From here, their 
morphology remained consistent through passage (Figure 3-2). Cells from all 
sources were similar in size and shape. This demonstrates that in routine culture 
conditions and standard culture medium, cells isolated from all tissue sources 
exhibited an MSC-like morphology which was maintained through passage. This 
satisfies one of the ISCT criteria of MSCs being plastic-adherent, spindle-shaped 
cells in standard culture conditions.  
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Figure 3-2 MSCs isolated from all tissue sources exhibit an MSC spindle-like morphology, 
which is maintained through passage. 
MSCs were seeded at P0 and grown until P8. Their morphology was observed and monitored 
using a phase-light microscope. All MSCs were adherent to plastic and possessed the typical 
spindle-like morphology. Black arrow heads point to typical spindle shaped cells and thumbnail 
images show magnified, individual MSCs. Spidle-like morphology and adherence to plastic was not 
affected through prolonged passage (P1-8).  
 Surface Phenotype of MSCs 3.3
To establish that cells isolated from each tissue source express surface markers 
indicative of MSCs according to ISCT criteria, flow cytometry was used to assess 
their surface expression of MSC markers at P3. A cocktail of markers typically 
used to asses MSC phenotype was used and included; CD90, CD105, CD73, CD166, 
CD14 and CD45. Results show that all MSCs were negative for hematopoietic 
markers CD45 and CD14 (Figure 3-3 B.i, C.i, D.i, E.i & F.i) and positive for MSC 
markers CD90, CD105 (B.ii, C.ii, D.ii, E.ii &,F.ii), CD73 (B.iii, C.iii, D.iii, E.iii & 
F.iii) and CD166 (B.iii, C.iii & D.iii) (Figure 3-3 B-F).  
To assess whether the MSC tissue source had an effect on MSC marker 
expression, the percentage of live cells positive for each marker is graphed 
(Figure 3-3 G-L).  
The adhesion molecule CD90 (Thy-1) was positively expressed on a similar 
percentage of MSCs, irrespective of MSC tissue source (G). Similarly, CD105 
(Endoglin) a cell surface glycoprotein, was also expressed by the majority of 
MSCs, with very little variance in % positive cells when comparing across tissue 
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sources (H). Additionally, CD73, an enzyme that converts adenosine 
monophosphate to adenosine, was also expressed by a similar percentage of 
MSCs from all sources (I). Small variations in the % of positive cells were 
observed for the adhesion molecule CD166 in those MSCs tested (J) with Is MSCs 
having the highest % positive cells and Va MSCs having the lowest % positive cells 
(BM and UC MSCs not tested). 
As well as being positive for an array of markers, MSCs must be negative for 
others such as CD45 and CD14. The hematopoietic marker CD45 was consistently 
absent on all MSCs with only a very small percentage of cells showing positive 
staining (K). Similarly, CD14, the co-receptor for TLR4, was not expressed by 
MSCs and this was consistent among different MSC sources (L).  
These data indicate that MSCs isolated from Is, Va, Ad, BM and UC all express 
the relevant MSC markers meeting ISCT criteria. Importantly, the tissue source 
of MSC does not seem to affect the percentage of live cells expressing these 
markers. 
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Figure 3-3 Cells isolated from all tissues express MSC Markers 
MSCs isolated from Is, Va, Ad, BM and UC tissues were grown in culture until passage 3. MSCs 
were then stained with a cocktail of antibodies, to allow characterisation of MSCs by flow 
cytometry.  
Gating strategy: FSC and SSC were used to gate on cells of correct size and granularity (A.i), 
doublets were excluded (A.ii) and live cells were selected (A.iii) in all samples before assessing 
surface CD phenotype (B-F). All MSCs were negative for hematopoietic markers CD45 and CD14 
whilst being positive for MSC markers; CD90, CD105 and CD73 (B-F). Due to slightly different 
panel designs, Is, Va and Ad MSCs were also tested for their expression of another MSC marker - 
CD166- which they were all positive for (B.iii, C.iii & D.iii). The % of live MSCs which stained 
positive for each of the tested markers is graphed to compare expression between MSC tissue 
sources (G-L). Each bar represents an n of 3 and is graphed as mean ± SEM. ONE WAY ANOVA 
with Tukey’s post-test analysis was used for statistical assessment.  
 
 Differentiation of MSCs 3.4
To determine the ability of MSCs isolated from Is, Va and Ad to differentiate into 
two out of three of adipocytes, chondrocytes or osteocytes, cells were cultured 
with specific differentiation factors to push them down a particular 
differentiation pathway. After 2-3 weeks of differentiation, MSCs were stained 
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with antibodies specific for adipocytes (anti-FABP4), chondrocytes (anti-
aggrecan) or osteocytes (anti-osteocalcin) and fluorescence was assessed by an 
epifluorescent microscope (Figure 3-4 MSCs can successfully differentiate into 
adipocytes, chondrocytes and osteoblasts. Due to BM and UC MSCs not being 
available during the time course of this experiment, differentiation of these 
MSCs was not carried out.  
Within 21 days the majority of Is, Va and Ad MSCs were all able to differentiate 
into chondrocytes (Figure 3-4 A.i, B.i, C.i), where the majority of MSCs had 
transformed into aggrecan expressing cells. To ensure that undifferentiated 
MSCs were not aggrecan positive, MSCs were grown in the same conditions and 
culture medium, minus the differentiation cocktail, and stained with anti-
aggrecan (A.iv, B.iv & C.iv). The lack of fluorescence in the non-differentiated 
controls, isotype controls (A.ii, B.ii, C.ii) and no-primary antibody controls (A.iii, 
B.iii, C.iii) compared to differentiated samples suggests that positive staining 
was specific for differentiation induced aggrecan expression and that MSCs 
isolated from the Is, Va and Ad were fully capable of differentiating into 
chondrocytes.  
Is MSCs were able to differentiate into osteocytes (Figure 3-4 D.i). Being the 
only MSC tested for their ability to differentiate into osteocytes, the potential of 
other MSCs to differentiate into osteocytes cannot be commented on. The 
majority of MSCs isolated from Islets were able to differentiate into bone, which 
was confirmed by the large signal from the anti-osteocalcin antibody. The 
specificity of this antibody was confirmed using isotype controls (D.ii), no-
primary antibody (D.iii) and non-differentiated controls (D.iv).  
Similarly to chondrogenic differentiation, Is, Va and Ad MSCs were able to 
differentiate into adipocytes within 21 days (Figure 3-4 E.i, F.i and G.i). 
Positive staining for fatty acid binding protein 4 (FABP4), identified MSC 
adipogenic differentiation. Lack of signal in isotype controls (E.ii, F.ii, G.ii), no-
primary antibody controls (E.iii, F.iii, G.iii) and non-differentiated controls (E.iv, 
F.iv, G.iv) confirmed specificity of the anti-FABP4 antibody, highlighting that 
positive staining is indicative of successful differentiation.  
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The ability of Is, Va and Ad MSCs to differentiate into adipocytes, chondrocytes 
and - in the case of Is MSCs - osteocytes within 21 days was confirmed by specific 
positive staining of particular antibodies. Where tested, all differentiations were 
successful, thus satisfying ISCT criteria of MSC differentiation capabilities. The 
ISCT criteria suggests that MSCs must be able to differentiate into two out of 
three of adipocytes; chondrocytes and osteocytes which Is, Ad and Va MSCs are 
capable of. Moreover, all controls carried out during the experiment confirmed 
that the antibodies used were specific and that positive staining was indicative 
of full differentiation of MSCs.  
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Figure 3-4 MSCs can successfully differentiate into adipocytes, chondrocytes and 
osteoblasts 
 
Is, Va and Ad MSCs were differentiated into chondrocytes (A-C). 
Is (A), Va (B) and Ad (C) MSCs (P3) were seeded at 2.5x105 total, spun down in a 15 mL falcon 
tube and left culturing in spherical balls within the falcon in differentiation medium. Differentiation 
medium was changed every 2-3 days. Undifferentiated control samples (A.iv,B.iv,C.iv) were 
cultured in medium without differentiation factors. After 21 days of culture, spherical balls were 
removed, snap frozen and sectioned. All samples were stained with anti-aggrecan (GREEN), with 
the exception of isotype controls (A.ii, B.ii, C.ii) and no-primary controls (A.iii, B.iii, C.iii). Is MSCs 
differentiated into chondrocytes: n=2 (A). Va MSCs differentiated into chondrocytes: n=1 (B). Ad 
MSCs differentiated into chondrocytes: n=1 (C). 
Is MSCs were differentiated into osteocytes (D). 
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For osteogenesis, cells were seeded at 2.21x103 per cm2 and grown in 24 well plates. Once they 
had reached roughly 80% confluence, differentiation factors were added every 2-3 days for 14-21 
days. Undifferentiated control samples (D.iv) were maintained in medium without differentiation 
factors. After 14-21 days of differentiation, cover slips within the 24 well plates were removed and 
stained with anti-osteocalcin (RED), with the exception of isotype controls (D.ii) and no-primary 
controls (D.iii). Is MSCs differentiated into osteocytes: n=1 (D). 
Is, Va and Ad were differentiated into adipocytes (E-G).  
For adipogenesis, Is (E), Va (F) and Ad (G) MSCs were seeded at 1.11x104 per cm2 and grown in 
24 well plates. Once they had reached roughly 80% confluence, differentiation factors were added 
every 2-3 days for 14-21 days. Undifferentiated control samples (E.iv, F.iv, G.iv) were maintained 
in medium without differentiation factors. After 14-21 days of differentiation, cover slips within the 
24 well plates were removed and stained with anti-FABP4 (RED), with the exception of isotype 
controls (E.ii, F.ii, G.ii) and no-primary controls (E.iii, F.iii, G.iii). Is MSCs differentiated into 
adipocytes: n=1 (E). Va MSCs differentiated into adipocytes: n=2 (F). Ad MSCs differentiated into 
adipocytes: n=2 (G). 
In all cases, all samples were stained with specific fluorescent secondary antibodies. DAPI (blue) 
marks the cell nuclei. White arrow heads point to fully differentiated MSCs.  
 Phenotype of MSCs during Inflammation 3.5
In the clinic, MSCs are often infused into a pre-existing inflammatory 
environment (190, 191). Therefore, it is important to understand the effects of 
inflammation on the phenotype of MSCs isolated from various tissue sources. In 
order examine this, the effects of an inflammatory environment were assessed 
and mimicked by splitting MSCs isolated from one donor into 2 flasks, leaving 
one flask in “normal” conditions and stimulating the other with 10ng/ml of 
TNFα, IL-1β and IFN-ϒ for 24 hours. From there, surface phenotype of several 
MSC markers was assessed by flow cytometry (Figure 3-5 and Figure 3-6), as 
was the size and granularity of MSCs (Figure 3-7).  
Although true homeostasis in vitro is hard to define, MSCs which were 
maintained in normal culture medium are referred to as being in a homeostatic 
environment. Equally, when MSCs were stimulated with the inflammatory 
cytokine cocktail, this is referred to as an inflammatory environment - this 
terminology will be used throughout.  
 Surface Molecule Phenotype of MSCs in 3.6
Homeostatic Vs Inflammatory Conditions  
Representative dot plots illustrate the percentage of Is MSCs expressing the 
markers HLA ABC, HLA-DR, CD271, CD166, CD73 and CD146 during normal and 
inflammatory conditions (Figure 3-5 A-C). Positive staining was determined by 
92 
 
the use of Fluorescent minus one’s (FMO’s) and isotype controls. The percentage 
of Is, Va and Ad MSCs expressing these markers are graphed in Figure 3-5 D-I.  
During “normal” conditions, 4.90% (± 1.66%) of Is MSCs expressed HLA-DR, which 
slightly increased to 14.06% (± 5.76%) after 24 hours of stimulation. Like Is MSCs, 
Ad MSCs had a slight increase in the % of cells expressing HLA-DR when 
stimulated, going from 4.26% (± 1.39%) to 16.90% (± 4.66%). The % of Va MSCs 
expressing HLA-DR went from 7.77% (± 3.46) in normal conditions to 14.81% (± 
2.74%) when inflamed (Figure 3-5 D). 
Unlike the small % of HLA-DR expressing MSCs under homeostatic and 
inflammatory conditions, a large % of MSCs expressed HLA-ABC under both 
homeostatic and inflammatory conditions, with 81.28% (± 16.59%) of Is MSCs 
expressing HLA-ABC in homeostatic conditions, rising to 97.92% (± 0.82%) after 
inflammatory stimulation. The percentage of Ad MSCs expressing HLA-ABC rose 
from homeostatic (90.49% ± 4.90%) to inflammatory (98.97% ± 0.27%) conditions. 
By contrast, a smaller increase in percentage of Va MSCs becoming HLA-ABC 
positive was observed from 94.77% (±1.56%) in normal conditions to 96.716% (± 
2.04) under inflammatory stimulation (Figure 3-5 E). This upregulation of HLA-
ABC was more prominently reflected in the increase of mean fluorescence 
intensity (MFI) (Figure 3-6 A), where Is MSCs went from an MFI of 25.75 (± 11.22) 
to 47.17 (± 8.0), Va MSCs from 31.33 (± 6.60) to 51.58 (± 9.03) and Ad MSCs from 
22.63 (± 5.36) to 60.03 (± 13.15). No significant differences in the percentage of 
HLA-ABC expressing MSCs were observed going from homeostatic to 
inflammatory conditions or between MSC tissue sources.  
As previously mentioned, CD73 is a widely used marker for MSCs. The percentage 
of MSCs expressing CD73 was barely affected by tissue source or inflammatory 
stimulation. A marginal increase in the percentage of CD73 expressing Is MSCs 
was observed after inflammatory stimulation, from 91.43% to 98.54%, whereas 
the percentage increase in Ad MSCs expressing CD73 was slightly lower, going 
from 95.94% to 96.76%. The percentage of CD73 expressing Va MSCs was the 
same under homeostatic (96.90%) and inflammatory conditions (96.47%) (Figure 
3-5 F). The effects of inflammatory stimulation on CD73 was better reflected by 
the MFI (Figure 3-6 A), where all MSCs showed a reduction in MFI under 
inflammatory stimulation (Is=63.73 (± 21.81) to 57.25 (± 7.85), VA=65.55 (± 6.91) 
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to 56.38 (± 12.21) and Ad=64.24 (± 64.25) to 61.67 (±10.82)). No significant 
differences in the percentage of CD73 expressing MSCs or in CD73 MFI were 
observed comparing homeostatic to inflammatory conditions or between MSC 
tissue sources. 
Similarly, as mentioned before, CD166 is also a marker of MSCs. A uniform 
pattern of increase in the percentage of MSCs expressing CD166 was observed 
during inflammation in all MSCs tested, with Is MSCs increasing from 31.13% (± 
23.69) to 68.18% (± 18.41), Va MSCs from 66.55% (± 10.10%) to 78.82% (± 7.33) 
and Ad MSCs from 49.60% (± 10.52) to 74.13% (± 9.42) (Figure 3-5 G). 
CD271 is also a marker of MSCs (192) and is expressed at variable levels and 
sometimes not at all (193). Reflecting that, the percentage of MSCs positive 
under ‘homeostatic’ conditions varied from source to source as does the effects 
of inflammation on the percentage of CD271 expressing MSCs. Is MSCs displayed 
a small % of CD271 expressing cells with 10.03% (± 8.63%) under homeostatic 
conditions, dropping to 7.17% (±3.72%) under inflammatory conditions. Similarly, 
Va MSCs showed a decrease in the % of CD271 expressing MSCs under 
inflammatory stimulation, going from 33.50% (±15.77%) under homeostatic 
conditions to 20.72% (±14.56) under inflammatory stimulation, whereas the 
percentage of Ad MSCs expressing CD271 increased slightly going from 42.53% (± 
5.66%) to 51.08% (± 8.86%) (Figure 3-5 H). No significant differences in the 
percentage of CD271 expressing MSCs or in CD271 MFI were observed going from 
homeostatic to inflammatory conditions or between MSC tissue sources. 
CD146 is another marker commonly used to identify MSCs, however like many of 
the markers used, its expression is variable on MSCs (194, 195). All MSC sources 
showed a small percentage of CD146 expressing MSCs, which rose after 
inflammatory stimulation. 2.94% (±1.39%) of Is MSCs were positive for CD146 
under homeostatic conditions, whilst under inflammatory stimulation, this rose 
to 21.74% (± 8.53%) of Is MSCs being CD146 positive. Similarly Ad MSCs had a 
small percentage of CD146 expressing cells under homeostatic conditions (1.67% 
± 0.51%), which increased under inflammatory conditions to 12.81% (± 1.70%). Va 
MSCs showed the largest proportion of CD146 expressing cells under homeostatic 
conditions (6.24% ± 4.9%), which rose to 27.55% (± 7.57%) under inflammatory 
conditions (Figure 3-5 I).  
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Figure 3-5 The surface molecule phenotype of MSCs from the tissue sources tested 
following inflammatory stimulation 
MSCs isolated from the Is, Va, and Ad were seeded into 2 flasks at  P3. Once MSCs had reached 
80% confluence, one flask was stimulated with 10ng/mL of IFN-ϒ, TNFα and IL-1β (inflammatory 
conditions) and the other flask was left in MSC culture medium (homeostatic conditions) for 24 
hours. After 24 hours, cells were stained with an array of antibodies, including; HLA-ABC, HLA-DR, 
CD73, CD271, CD146 and CD166 and analysed by flow cytometry to examine the effects of 
inflammation on MSC surface marker phenotype. Representative dot plots show the expression of 
the aforementioned markers on unstimulated (A.i,B.i,C.i) vs stimulated (A.ii, B.ii, C.ii) Is MSCs. 
Positive staining was measured by the use of fluorescence minus ones and isotype controls and 
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gates were drawn appropriately. The data in the dot plots were graphed and presented as the 
percentage of MSCs positively expressing each marker under homeostatic and inflammatory 
conditions for Is, Va and Ad MSCs (D-I). Each bar represents an n of 3 and graphed as mean ± 
SEM. Student’s T test was used to assess statistical differences between unstimulated and 
stimulated MSCs from one source. To assess statistical differences between MSC sources, a ONE 
WAY ANOVA was used in conjunction with Tukey’s multiple comparison tests.  
 
Figure 3-6 MFI of selected markers fluctuates slightly under inflammatory stimulation 
Applying the same experimental set up as Figure 3-5, this is the same data, expressed as mean 
fluorescence intensity, allowing for more subtle changes in marker expression on MSCs to be 
observed. Each bar represents an n of 3 and graphed as mean ± SEM. Statistical analysis 
performed = ONE WAY ANOVA with Tukey’s multiple comparison post-test. A Student’s T test was 
used when comparing one tissue source of MSC- unstimulated vs stimulated. 
 
In summary, HLA-DR, CD271, CD166 and CD146 were slightly upregulated in all 
MSCs when maintained under inflammatory conditions, with the exception of 
CD271 on Is MSCs, where expression was extremely low/not detectable under 
both homeostatic and inflammatory conditions. HLA-ABC was markedly 
upregulated in all MSCs under inflammatory stimulation and CD73 was slightly 
downregulated in all MSCs under inflammatory stimulation, however expression 
levels of CD73 remained the highest of all markers tested. Importantly, there 
was no significant change in MSC surface molecule phenotype after 24 hours of 
stimulation. Moreover, there was no significant difference in the expression of 
these markers between MSC tissue source under homeostatic or inflammatory 
conditions.  
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 Size and granularity of MSCs in homeostatic vs 3.7
inflammatory conditions  
Using flow cytometry, the parameters forward scatter (FSC) and side scatter 
(SSC) were used to measure the size and granularity (respectively) of Is, Va, Ad, 
BM and UC MSCs under homeostatic and inflammatory conditions (Figure 3-7). 
The size of a cell is measured by the amount of laser light that can pass around 
the cell, whereas granularity is measured by the amount of light that bounces 
off particles within the cell. Thus the size and complexity of a cell can be 
measured using these parameters where a small FSC value is indicative of a 
small cell, and a large SSC value suggests a granular, complex cell.  
When MSCs were maintained under homeostatic conditions, Is MSCs had the 
lowest SSC, whereas BM MSCs had the highest. A significant difference was 
observed between Is MSCs compared to all other sources of MSCs (Is vs Va 
P<0.01, Is vs Ad P<0.01, Is vs BM P<0.001, Is vs UC P<0.01) under homeostatic 
conditions (Figure 3-7 A.i). Under inflammatory stimulation, the SSC increased 
in all MSCs, however a significant increase was only observed in Is MSCs 
(P=0.0015). When comparing the SSC of MSCs from all sources under 
inflammation, it mirrors the patterns observed during homeostatic conditions, 
i.e. Is MSCs exhibited the smallest SSC during inflammation, and BM MSCs 
exhibited the largest, however, the only significant difference observed between 
SSC of stimulated MSCs was between Is and BM (P<0.01). The same data are 
represented as histograms to clarify the graphed observations (Figure 3-7 A.ii-
A.iii).  
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Figure 3-7 Granularity of MSCs increases under inflammatory stimulation but size remains 
unchanged. 
Adopting the same experimental set up as Figure 3-5 and Figure 3-6 with the addition of UC and 
BM MSCs, flow cytometry was used to measure FSC and SSC to assess size and granularity of 
MSCs during homeostatic and inflammatory conditions. In all MSCs, side scatter increased after 
inflammatory challenge (A.i). Size of MSCs was unaffected by tissue source or inflammation (B.i). 
Each bar represents an n of 3, and plotted as the mean ± SEM. A Student’s T test was used when 
comparing one tissue source of MSC- unstim vs stim. When comparing all tissue sources of MSCs 
a ONE WAY ANOVA was used with Tukey’s multiple comparisons test.  
The graphed data were represented in histograms for clarity (A.ii, A.iii, B.ii, B.iii).   
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The size of MSCs did not vary significantly between tissue sources, nor was it 
affected by inflammatory stimulation (Figure 3-7 B.i). The graphed data are 
represented in histograms (Figure 3-7 B.ii-B.ii). 
These data show that tissue source of MSC does not have an effect on the size of 
MSCs, nor does inflammation. In contrast, tissue source appears to have some 
effect on the granularity of MSCs, with Is MSCs being significantly less granular 
than Va, Ad, UC and BM MSCs. When MSCs were maintained under an 
inflammatory environment, MSCs from all tissue sources became more granular, 
however, this increase in granularity was only significant in Is MSCs. When 
comparing the granularity of MSCs from all sources under inflammatory 
conditions, Is MSCs were the least granular and BM MSCs were the most, with this 
difference in granularity between Is and BM MSCs being significant.  
 Discussion and Conclusions  3.8
The aim of this chapter was to discover if cells isolated from the Is, Va, Ad, BM 
and UC meet the ISCT criteria for MSCs. In addition, this chapter also aimed to 
examine whether MSCs isolated from different human tissues had variations in 
their phenotype. Finally, as there is a large body of literature supporting the 
concept of MSC licensing - where MSCs need inflammatory stimulation in order to 
exert their anti-inflammatory and immunomodulatory capacity – the phenotype 
of MSCs was also assessed under inflammatory conditions (168). 
From their first description by Friedinstein in 1976, MSCs are now well 
established as being adherent, spindle-shaped cells (196). ISCT outlines that this 
morphology must be met in order to be defined as a MSC (95). Is, Va, Ad, UC and 
BM MSCs all satisfied this criteria from early (P1) through to later passage (P8).  
Importantly, this morphology was uniform among all MSCs, irrespective of the 
tissue they were originally isolated from. Akin to this, ISCT also states that MSCs 
must be able to differentiate into two of three cell types out of adipocytes, 
chondrocytes and osteoblasts, which Is, Ad and Va MSCs were all capable of. 
The third criteria that must be met in order to be classified as a MSC, is the 
expression of an array of markers including CD90, CD105, and CD73, whilst 
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lacking others such as CD14 and CD45 (95). Other markers are often used to 
identify MSCs such as CD166 and CD271, however the expression of these 
markers is not uniform and is known to fluctuate substantially for several 
reasons including passage number and tissue source of MSCs (194, 197).  
CD90 (also known as Thy-1), is a cell surface glycoprotein involved in cell/cell 
matrix interactions (198), inflammation and wound healing (199).  Whilst being a 
marker for hematopoietic stem cells (200), it is also a marker for MSCs and has a 
suggested function of attracting and immobilising monocytes and 
polymorphonuclear cells (PMN) on MSCs (201), as well as immunosuppressing 
lymphocytes (202). In contrast to Maleki et al, who reported the variability in 
percentage of CD90 expressing MSCs when isolated from Wharton’s Jelly 
(13.47%) and the hair follicle (50.85%) (197), MSCs isolated from Is, Va, Ad, BM 
and UC (Wharton’s Jelly) showed a similar percentage of CD90 expressing cells 
(>81%).  CD105 -otherwise known as Endoglin- is a cell surface glycoprotein 
expressed on lineages within the vascular system and endothelial cells as well as 
MSCs. It functions as an accessory receptor for members of the TGF-β 
superfamily (203) and is involved in blood vessel development, implicated in 
erythropoiesis and myelopoiesis (204), as well as representing a powerful marker 
for neovascularisation (205). Notably, culture medium has been shown to have 
an effect on expression levels of CD105, where serum free medium had reduced 
cellular CD105 expression compared to serum-supplemented medium. 
Importantly, serum-supplemented media contains growth factors such as TGF-β 
that could induce CD105 expression and subsequently downregulating its surface 
expression (206). Similarly, Ad MSCs have been reported to have varying 
expression levels of CD105 (207), however, here a consistent expression of 
CD105 was demonstrated, not only among Ad MSCs, but also among all other 
tissue sources of MSCs – Is, Va, BM and UC.  
CD73 (ecto-5’-nucleotidase) was also expressed evenly on >97% of all tissue 
source MSCs, To my knowledge, there have been no studies comparing the 
expression of CD73 on MSCs maintained under various conditions or comparing 
the expression of CD73 on MSCs isolated from different tissue sources. This could 
be due to the lack of literature surrounding its function on the surface of MSCs, 
with the exception of one study which suggests that it plays a role in MSC 
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migration (208). As a membrane bound glycoprotein, its function is to 
metabolise adenosine 5’-monophosphate (AMP) to adenosine. However, it is also 
known to play an important role in ion fluid transport, tissue injury and acts as 
an adhesion molecule for lymphocytes binding to the epithelium (209, 210). 
Moreover, CD73, and its product adenosine, have been implicated as an innate 
mechanism to inhibit excessive, harmful aspects of neutrophil activation and 
accumulation (211). In addition, CD73 is involved in tumour-associated immune 
suppression, where the production of adenosine has been shown to limit anti-
tumour T cell immunity (211, 212). If CD73 functions like the aforementioned on 
the surface of MSCs, this suggests an immunomodulatory role of the marker, 
which MSCs isolated from Is, Va, Ad, BM and UC MSCs could all mediate due to 
their uniform expression of CD73. Although MSC expression of CD90, CD105 and 
CD73 allows for rapid identification of MSCs, the expression of these markers is 
not limited to MSCs and therefore lack of expression of other markers such as 
CD14 and CD45 assures that MSC cultures are not confounded by other cells 
likely to be isolated along with MSCs. As CD90 and CD73 are found on 
hematopoietic stem cells and T cells respectively, ensuring that MSCs lack the 
pan-leukocyte marker, CD45, will account for any potential contamination of 
these cells within MSC culture. Additionally, CD14, the co-receptor for TLR4 
allows for identification of monocytes and macrophages which are the most 
likely hematopoietic cell types to be found in MSC culture (95). MSCs isolated 
from Is, Va, Ad, BM and UC show only small percentages of cells positive for 
CD45 (<3%) and CD14 (<1.16%).  
With the three MSC criteria stated by ISCT being satisfied for Is, Ad and Va MSCs 
and two out of three of the criteria being satisfied for UC and BM MSCs, it may 
be concluded that the cells isolated from these tissue sources can be regarded as 
MSCs. 
As MSCs are being evaluated as treatments for inflammatory conditions and 
diseases, understanding their phenotype during these conditions, and if tissue 
source of MSC has any affect, is important because it could suggest preferential 
tissue sources for MSC isolation for therapeutic use (213).  
Human leukocyte antigens (HLA) ABC and DR, are vital in regulating the immune 
system and encode the major histocompatibility complex in humans – MHC I and 
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MHC II, respectively. This system is designed to bind self and foreign antigens 
from within (MHC I) and out with the cell (MHC II) and present them on the cell 
surface in the form of peptides. MHC I is expressed on all nucleated cells within 
the body and interacts with cytotoxic T lymphocytes (CD8), whereas MHC II is 
normally expressed on antigen presenting cells and allows interactions with CD4 
T cells. With respect to transplant rejection, MHC molecules can themselves act 
as antigens in the recipient and thus aid in transplant rejection. MSCs are known 
to elicit a weak cellular and humoral allogeneic immune response, due to low 
expression of HLA antigens and co-stimulatory molecules (214, 215). For this 
reason, their use within transplant settings has been popular (216). In line with 
the literature, Is, Va, and Ad MSCs express HLA-ABC under homeostatic 
conditions which was upregulated under inflammatory conditions (217). In the 
current study, Is, Va and Ad MSCs markedly upregulated HLA-ABC expression 
under inflammatory stimulation, which was reflected in a substantial increase in 
MFI. Importantly, Ad MSCs showed the largest increase in MFI (increase of 37.4) 
from homeostatic to inflammatory conditions, whilst also displaying the highest 
HLA-ABC MFI (60.03) compared to Is (47.17) and Va (51.85) MSCs. Notably, the 
expression of HLA-DR on Is, Va and Ad MSCs was very low in homeostatic 
conditions but this was slightly upregulated under inflammatory conditions. This 
upregulation of HLA-DR on MSCs under inflammatory stimulation is well 
documented within the literature (218).  Little variation in HLA-DR expression on 
MSCs under inflammatory conditions was observed, with Ad MSCs being the 
highest expressers and Is and Va expressing similar levels. Despite the expression 
of HLA-ABC and HLA-DR (after stimulation) on MSCs being documented within the 
literature, to my knowledge, this is the first report of MSCs isolated from these 
locations, being compared and showing subtle variations in the expression levels 
of these markers.  
As well as HLA-ABC and HLA-DR being upregulated on MSCs under inflammatory 
stimulation, CD166 (ALCAM), which plays an important role in adhesion of 
epithelial cells to T cells via CD6, was also upregulated in Is, Ad and Va MSCs 
under inflammatory conditions (219). As mentioned, CD166 has variable levels of 
expression depending on where MSCs are isolated from (194, 197), therefore 
understanding if its expression varies between Is, Va and Ad MSCs under 
homeostatic and inflammatory conditions was of interest. During homeostatic 
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conditions, the expression of CD166 fluctuated largely within one tissue source, 
with Is MSCs showing the largest variability. Due to such large variabilities within 
one tissue source of MSC, no solid comparison or conclusion can be made from 
comparing the percentage of CD166 expressing MSCs across tissue sources. 
However, there is a trend of upregulation when Is, Va and Ad MSCs were 
maintained under an inflammatory environment, perhaps suggesting that under 
inflammatory conditions, MSCs are able to adhere to T cells more readily.  
Similar to CD166, CD146 (MCAM) is a marker of MSCs which varied in expression 
depending on MSC tissue origin (194). Its expression has been observed to 
fluctuate within one tissue source of MSC (BM) where an increase in age of BM 
donor was linked to a decreased expression (195). In line with the literature, Is, 
Va and Ad MSCs exhibited large variations in the proportion of CD146 expressing 
cells. This large variation was exaggerated when MSCs were maintained under 
inflammatory conditions, however the overall trend of MSC CD146 expression 
was to upregulate when stimulated.  
Consistency and pattern of CD271 expression was not similar to the other 
markers tested, as a uniform pattern of upregulation or downregulation was not 
observed when MSCs were inflamed. Despite being classified as a universal 
marker for MSCs, studies suggest that CD271 is useful for identifying a particular 
fraction of BM MSCs, where other studies have shown UC blood MSCs to have no 
expression, and MSCs from the Wharton’s jelly have varied CD271 expression (96, 
220, 221). In agreement with the literature, we found that Ad MSCs expressed 
CD271 (193). Importantly, CD271 expression was highest on Ad MSCs, and this 
was the only source of MSCs to upregulate their expression under inflammatory 
conditions. Is and Va MSCs downregulated CD271 expression when maintained 
under inflammatory conditions, and showed large variability in expression, 
suggesting that differences were due to donor variation. Studies have suggested 
that age affects CD271 expression, therefore the donor variation observed here, 
could be due to variance in patient age (193).  
As previously mentioned, CD73 is perhaps the most reliable and popular marker 
used in conjunction with other markers to identify MSCs. Interestingly, no 
difference in expression levels was observed between Is, Va and Ad MSCs under 
homeostatic and inflammatory conditions. There was a slight trend for all MSCs 
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to slightly downregulate CD73 expression. Due to the lack of knowledge 
surrounding its function on MSCs, why MSCs would do this is unknown. One study 
suggests that CD73 is involved in MSCs migration, therefore its downregulation 
could be a mechanism used by MSCs to minimise their migration and be retained 
within the inflammatory site (208).   
Overall, the expression of the commonly used markers CD90, CD105 and CD73 
remained consistent amongst Is, Va, Ad, UC and BM. CD14 and CD45 were absent 
in all MSC cultures. Expression levels of CD166 and CD146 varied within one 
tissue source of MSC, suggesting donor variability. The upregulation of CD166 on 
the surface of Is, Ad and Va MSCs under inflammatory conditions, could be a 
mechanism used by MSCs to adhere T cells to their surface via CD6 to ensure the 
immunomodulation of T cells in close proximity during inflammation (219, 222, 
223). In addition, CD146 is also an adhesion molecule thought to be involved in 
leukocyte transendothelial migration, therefore its upregulation on MSCs during 
inflammation could be a mechanism to allow leukocytes to gain access to the 
site of damage (224). Importantly, HLA-ABC and HLA-DR were upregulated under 
inflammatory conditions, with Ad MSCs showing the highest expression levels for 
both markers. As these molecules are involved in transplant rejection, these 
data have implications when considering which tissue source of MSC might be 
most suited in a transplant setting.  
As well as MSCs being used within transplants, they are also used within other 
inflammatory diseases (225), with one route of delivery being intravenous 
infusion into patients (226). One limitation of this route of delivery is the lack of 
targeted delivery of MSCs to the site of inflammation. Mouse models suggest that 
MSCs become trapped in the lung after infusion (148, 227), however their anti-
inflammatory capacity is not affected by this (228). As the literature suggested 
pre-stimulation of MSCs before patient infusion in order to upregulate anti-
inflammatory mediators secreted by MSCs (229), MSC phenotype during 
inflammation was assessed. One parameter which might affect the likelihood of 
MSC entrapment is their size, thus the size of MSCs from Is, Va, Ad, UC and BM 
was compared under homeostatic and inflammatory conditions where no 
differences were observed. One particular phenotype which was different from 
source to source, and which drastically changed under inflammation, was MSC 
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granularity. Granules are small vesicles within cells that contain a variety of 
molecules important in immunity for example histamine which is important in 
vasodilation, CXCL8, a chemokine stored pre-made in Wiebel-Palade bodies 
important for attracting immune cells, Von Willebrand factor which is important 
in blood clotting and angiopoietin-2, vital in angiogenesis allowing vascular 
remodelling (230, 231). Therefore granules hold many factors that contribute to 
inflammation, homeostasis and angiogenesis. With respect to the functions of 
the mediators within granules we can conclude that upon MSC de-granulation, 
MSCs isolated from the Is have the potential to be less inflammatory and less 
angiogenic under both homeostatic and inflammatory conditions when compared 
to Va, Ad, UC and BM MSCs. However, this assumption would have to be further 
tested in order to confirm this conclusion.  
All of the data in this chapter show that MSCs isolated from the Is, Va, Ad, BM 
and UC can confidently be considered MSCs. Additionally, markers that are 
typically used to identify MSCs that might also have the potential to play a role 
in MSCs immunomodulatory capacity, CD73, CD90 and CD105, were all expressed 
at similar levels on all MSCs. MSCs from all sources tested were of similar size 
and this did not change under inflammatory conditions. The expression of HLA-
ABC and HLA-DR on Is, Va and Ad MSCs was upregulated post inflammation, 
where Is MSCs showed the least expression of both markers. In addition to this, Is 
MSCs were the least granular out of Ad, BM, UC and Va MSCs. Thus, MSCs isolated 
from different anatomical locations do not show variation in markers involved in 
MSC identity, however molecules which may have an impact in a transplant 
setting such as HLA-ABC and HLA-DR, show subtle variation between MSC 
sources.  
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Chapter 4 Transcriptional profiling of MSC 
chemokine and chemokine receptor expression 
 Introduction and aims 4.1
Work described in the previous chapter led to the conclusion that MSCs isolated 
from the Islet (Is), visceral adipose surrounding the pancreas (Va), adipose (Ad), 
bone marrow (BM) and Wharton’s jelly within the umbilical cord (UC) satisfied 
the ISCT MSC classification criteria.  
Overall, the aim of this thesis was to assess the potential in vivo behaviour of Is, 
Va, Ad, BM and UC derived MSCs by assessing their response to an inflammatory 
environment and their interaction with immune cells. As chemokines and their 
receptors govern the in vivo migration and interaction of cells under 
homeostatic and inflammatory conditions, the transcriptional expression of 
chemokine and chemokine receptors by MSCs was assessed. Importantly, 
understanding if MSCs isolated from different tissues exhibit differences in their 
chemokine and chemokine receptor expression, could highlight a preferential 
MSC for use within specific diseases.  
In addition to MSCs being co-transplanted with e.g. organs, they are being 
investigated for use within a wide variety of clinical applications such as liver 
fibrosis and kidney repair (232, 233). For the majority of these applications, 
systemic infusion (intravenous or intra-arterial) of MSCs is the preferred route of 
delivery as it is less invasive than local administration (intracoronary injection or 
direct injection into the tissue of interest). Moreover, as they are infused into 
arteries or veins, this ensures that they are in close contact to oxygen and 
nutrient-rich blood vessels (234). However intravenous infusion (IV) is not 
unproblematic as IV delivered MSCs often results in MSCs getting trapped within 
the lung (148). Despite pulmonary passage being a challenge for targeted MSC 
infusion, MSCs have been observed in other tissues such as the gastrointestinal 
tract, kidney, liver, thymus and spleen following IV injection (148, 235). 
Whether these observations reflect specific migration of MSCs to these organs or 
whether the MSCs become entrapped is unknown. Evidence to support the 
specific migration of MSCs in vivo has been published, where MSCs have been 
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observed to specifically migrate towards tumour microenvironments, wound 
sites and islets (236-238). Despite the in vivo migration of MSCs not being fully 
understood, it is assumed that it is similar to leukocyte migration and therefore 
thought to involve the expression of specific chemokine receptors. MSCs isolated 
from the BM have been shown to bear functional CCR3, CCR4, CCR5 and CXCR4. 
Interestingly, Ad derived MSCs have been shown to express CXCR4 but at 
differential levels in comparison to BM derived MSCs, highlighting that MSCs 
isolated from different sources exhibit differential chemokine receptor 
expression, suggesting potential variations in MSC migratory potential, which 
could impact clinical outcome in various clinical settings (98, 182).  
Similarly, chemokine secretion by MSCs has been demonstrated to attract 
leukocytes and thus understanding which chemokines MSCs secrete will allow us 
to predict which type of leukocytes MSCs might attract towards them in an in 
vivo setting (239-241).  
Therefore, this chapter aimed to identify; i) which chemokines and chemokine 
receptors MSCs expressed at a transcriptional level, ii) whether MSC tissue 
source influences the expression of these molecules and iii) how inflammation 
alters MSC chemokine and chemokine receptor transcription.   
Due to the large number of samples within this study, initial investigations 
focussed on establishing a suitable assay. Several factors were considered, 
including; array sensitivity and accuracy, cost efficiency, reproducibility, high 
quality controls, appropriate targets and time effectiveness.  
After consideration, two arrays were of interest; the TaqMan Low Density Array 
(TLDA) (Applied Biosystems) and the RT2 profiler PCR Array (RT2 Array) (QIAGEN). 
Despite the TLDA being more time efficient and perhaps more sensitive than the 
RT2 array due to the design of the array and its probes, respectively, the 
inclusion of a built in panel of 5 housekeeping genes (HKG) and 3 internal 
controls on each plate, resulted in the RT2 Array being used in these studies. The 
internal controls on the RT2 array allowed for the assessment of PCR 
reproducibility on an intra and inter-plate basis, satisfying the requirements of 
the controls needed for a large study. Notably, a built-in genomic DNA 
contamination well on the RT2 array allowed for the detection of non-specific 
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DNA amplification, an important factor when dealing with human samples. 
Moreover, this control monitored the specificity of the primers within the assay, 
as primers that are not exon-spanning can result in the amplification of genomic 
DNA. 
Therefore, initial experiments focussed on the reliability and reproducibility of 
the RT2 arrays.  
Following that, the RT2 arrays were used to transcriptionally profile the 
expression of chemokines and their receptors by Is, Va, Ad, UC and BM MSCs. See 
Section 2.3 for specific methodology of the RT2 arrays.  
Results 
 Assessment and validation of RT2 Arrays for 4.2
transcriptional analysis of chemokine and chemokine 
receptor expression by MSCs 
Due to the large numbers of samples tested under both homeostatic and 
inflammatory conditions, it was expected to appreciate that not all samples 
could be collected, prepared and tested at one time. Therefore sample 
preparation would occur over several weeks, resulting in transcriptional analysis 
of MSC chemokine and chemokine receptor expression being carried out on 
different days. To ensure that this approach was feasible and accurate, a ruler 
sample (human skin fibroblast isolated induced pluripotent stem cells (IPSCs) 
differentiated into MSCs (IPMSC), provided by Dr Jo Mountford – University of 
Glasgow was spread over three RT2 arrays. A ruler sample is a sample which is an 
example of your cell type and allows for cross-array comparison. Using the ruler 
sample over three plates and running them on different days allowed us to 
detect possible discrepancies of cDNA conversion, cDNA storage and machine 
laser alignment on separate days.  
 IPMSCs satisfy the ISCT criteria to be classified as an MSC 4.2.1
In order for IPMSCs to serve as an accurate ruler sample on the RT2 arrays, 
experiments were carried out to ensure that they satisfied ISCT criteria of a MSC 
prior to transcriptional assessment.  
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As well as being spindle shaped (highlighted with black arrows) and adherent to 
plastic (Figure 4-1 IPMSCs can be classified as MSCsA), flow cytometry was used 
to assess IPMSCs surface marker expression of typical MSC markers (Figure 4-1 
B). 98.17% of IPMSCs expressed CD105 (B.iv), 98.06% expressed CD90 (B.iv) and 
94.88% expressed CD73 (B.v). Additionally only 3.73% of IPMSCs expressed CD14 
(B.v), 2.76% expressed CD45 (B.vi) and 1.82% expressed CD34 (A.vi). In order to 
satisfy all of ISCT’s criteria, IPMSCs were also assessed for their differentiation 
capabilities (Figure 4-1 C & D). IPMSCs demonstrated successful differentiation 
into adipocytes using anti-fatty acid binding protein 4 (FABP4) antibody (C.i) and 
chondrocytes using anti-aggrecan antibody (D.i). Specificity of the antibodies 
was demonstrated through the lack of fluorescence in isotype (C.ii, D.ii) and no 
primary controls (C.iii, D.iii).  
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Figure 4-1 IPMSCs can be classified as MSCs 
Morphologically, IPMSCs presented as spindle shaped cells(marked with black arrows) that 
adhered to plastic (A). Flow cytometry was used to assess the surface protein expression of MSC 
markers on IPMSCs (B). 96.54% of IPSCs expressed both CD105 and CD90 (B.iv) and 91.21% of 
IPSCs expressed CD73 (B.v). IPSCs were negative for CD14, CD45 and CD34 (B.v, B.vi). 
Fluorescence microscopy was used to assess the differentiation of IPMSCs into adipocytes (C.i) 
(detected by the specific binding of fatty acid binding protein 4 (FABP4) (RED)) and IPMSC 
differentiation into chondrocytes (D.i) (detected by the specific binding of aggrecan) (RED)). 
Specificity of both antibodies was demonstrated through the absence of fluorescence in isotype 
controls (C.ii & D.ii) and no primary controls (C.iii and D.iii). DAPI (blue) stains cell nuclei. IPMSC 
n=1.  
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Therefore, based on their spindle shaped morphology, surface marker expression 
and ability to differentiate into adipocytes and chondrocytes, IPMSCs could be 
classified as MSCs, which allowed them to serve as an accurate ruler sample on 
the RT2 arrays.  
 Standardisation of RT2 Arrays 4.2.2
 Experimental design and plate set-up 4.2.2.1
To assess the consistency and accuracy of the RT2 arrays, the experimental set 
up was designed to test for potential areas where inconsistencies might arise, 
such as cDNA synthesis on different days, freezing of cDNA vs immediate use of 
cDNA, and PCR efficiency on different days. To achieve this, RNA was extracted 
from one IPMSC sample, frozen and then converted into cDNA on three different 
days, resulting in 3 lots of cDNA from one sample of RNA. cDNA that was 
synthesised on day 1 was immediately put onto plate 1 and analysed. cDNA 
synthesised on day 2 was frozen for 1 day and run on plate 2. cDNA synthesised 
on day 3 was frozen for 2 days and run on plate 3 (Figure 4-2). Whilst the 
experimental set up was not precise enough to pin point exactly where 
discrepancies might be introduced, the design aimed to test the system for 
inherent discrepancies.  
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Figure 4-2 Experimental workflow outlining the timeline of events when testing the RT2 
arrays reproducibility. 
3 lots of cDNA were synthesised from RNA on Day 1, Day 2 and Day 3. cDNA synthesised on day 
1 was used immediately on an RT2 array.  cDNA synthesised on day 2 was frozen for one day and 
applied to the RT2 array the following day. cDNA synthesised on day 3 was frozen for 2 days and 
run on the RT2 arrays 48 hours later. This set up resulted in 3 plates being assayed over 5 days. 
 
The experimental set up is further outlined in Figure 4-3. Each plate consisted 
of 94 genes, with 4 wells per gene. Thus, the most accurate and cost efficient 
approach was to have 2 technical replicates per sample, per gene. Therefore 
IPMSC cDNA was applied to half of each of the three plates and either Is, Va or 
Ad cDNA on the other half (Figure 4-3 B).  
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Figure 4-3 Diagrammatic illustration of the preparation of cDNA and RT2 array set up. 
                         
To assess if cDNA synthesis on different days would result in varied, non-comparable results, three 
lots of cDNA were synthesised over three separate days (A). The IPMSC cDNA synthesised on 
day one was applied to one half of plate 1, with Va MSCs applied to the other half of plate 1 (B.i), 
IPMSC cDNA synthesised on day two was applied to one half of the plate 2, with Ad MSCs applied 
to the other half of plate 2 (B.ii) and IPMSC cDNA synthesised on day three was applied to one 
half of plate 3, with Is MSCs applied to the other half of plate 3 (B.iii). 
 
 Analysis of controls to assess intra- and inter-plate reproducibility 4.2.2.2
To measure the reproducibility of the plates on an intra- and inter- plate basis, 
three controls were assessed; 
1. Reverse transcription control (RTC) wells 
2. Positive PCR control (PPC) wells 
3. Comparison of the cycle threshold (CT) results from the IPMSC cDNA. 
RTC wells assessed the efficiency of the reverse transcription reaction in the 
cDNA synthesis step (Figure 4-4 A). A ΔCt (details on how ΔCt values were 
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calculated are in Section 2.3.3.5) value less than 5 signified successful reverse 
transcription (http://www.sabiosciences.com/pcrarraycontrols.php), therefore 
the reverse transcription step for the cDNA synthesis of plate 1 (ΔCt = 1.74), 
plate 2 (ΔCt = 1.13) and plate 3 (ΔCt=1.43) was successful. Importantly, similar 
RTC ΔCt values on each plate suggested that although cDNA was synthesised on 
different days for each plate, this has no effect on the reverse transcription 
reaction and each reaction performed to a comparable level (Figure 4-4 B).  
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Figure 4-4 Internal controls on the RT2 array suggested accurate reverse transcription over 
several days. 
A schematic of the RT2 array is included for reference and clarity (A). The schematic illustrates the 
setup of the genes in quadruplicate (indicated by the red box) and internal controls at the bottom of 
the plate (rows O + P). These internal controls include; 5 housekeeping genes (purple wells), 
Genomic DNA contamination control wells (red wells), RTC wells (indicated by the blue box) and 
PPC wells (green wells). The experimental set up was the same as in Figure 4-3 where IPMSC 
cDNA was applied to three plates in order to assess the reproducibility of the RT2 arrays. Due to 
patented technology in the control wells, information on their make-up and execution is limited, thus 
the schematics represent the control wells starting materials and methods of detection in a very 
simplistic manner. The reverse transcription control wells detected a template synthesised by an 
RNA template provided by the RT2 first strand kit (cDNA synthesis kit). If there were enzyme 
inhibitors, low incorporation of SYBR into the newly synthesised DS DNA from the internal RNA 
template will result in very high CT values (A). The RTC from all of the wells containing IPMSC 
cDNA on one plate (6 wells) is calculated and graphed as either plate 1 (1.74), plate 2 (1.13) or 
plate 3 (1.43) (B). For more details on RTC controls, visit: 
http://www.sabiosciences.com/pcrarraycontrols.php. 
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Positive PCR control wells (PPC) assessed the efficiency of the PCR reaction 
(Figure 4-5 A). The PCR efficiency for each sample was monitored by this 
internal control. A CT of 20±2 suggested that the PCR reaction was optimal 
(http://www.sabiosciences.com/pcrarraycontrols.php). Plate 1 (CT=21.16), 
Plate 2 (CT=21.81) and Plate 3 (CT=21.33) demonstrated successful PCR 
reproducibility for the IPMSC sample on an intra-plate basis (Figure 4-5 B). 
Notably, this value did not vary more than 0.34 of a Ct between plates, 
indicating that PCR reproducibility was also precise and successful on an inter-
plate basis.  
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Figure 4-5 Internal controls on the RT2 PCR profiler array suggested accurate PCR 
reproducibility over several days. 
Experimental set up and design was as shown in Figure 4-3. 
PPC wells are highlighted by the blue box at the bottom right hand side of the 384 well plate (A). 
They consisted of an artificial DNA sequence and the assay which detects it (Primer in blue) (A). If 
PCR inhibitors exist in your sample / in a well then PCR efficiency will be reduced and will result in 
low CT values or very high CT values – depending on which type and quantity of PCR inhibitors 
are present. Reverse transcription control value (ΔCt) was calculated by ΔCt = AVG CTRTC- AVG 
CTPPC. The PPC was calculated as the average CT value across the 6 wells. IPMSCs average CT 
values from plate 1 (21.16), plate 2 (21.81) and plate 3 (21.33) are plotted (B). For more details on 
PPC controls, visit: http://www.sabiosciences.com/pcrarraycontrols.php. 
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To further assess the inter-plate consistency of the RT2 arrays, the raw CT values 
from the IPMSC samples for each of the 84 genes were graphed to assess the 
correlation between each of the plates (Figure 4-6). Plate 1 vs plate 2 and plate 
1 vs plate 3 showed high levels of correlation, with an R2 value of 0.9493 (Figure 
4-6 A) and 0.9359 (Figure 4-6 B), respectively. Plate 2 vs plate 3 displayed the 
largest correlation with an R2 value of 0.9771 (Figure 4-6 C). 
Reproducibility of the results was further examined by statistically assessing the 
IPMSC CT values of 10 genes. The cycle threshold values (Ct) of 5 housekeeping 
genes and 5 genes with a Ct near that of undetectable (Ct>35) were graphed and 
analysed to ensure that there were no significant differences between them. A 
Ct of 35 or over was the recommended “undetectable” value on the RT2 arrays 
provided by QIAGEN.  
Ct values of the house keeping genes on all three plates were exceptionally close 
with an average standard deviation of 0.32 (Figure 4-6 D). As expected, the CT 
values of genes near the limit of no detection were slightly more spread, with an 
average standard deviation of 0.46 (Figure 4-6 E). No significant differences 
were calculated between the CT values of the house keeping genes, or the genes 
with high CT values.  
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Figure 4-6 Strong correlations of RT2 arrays suggested that inter-plate analysis was 
comparable. 
IPMSCs were used as a ruler sample to compare the reproducibility of the arrays. The IPMSC Ct 
values of all the genes present on the plate (94) were compared to each other across the three 
plates, and the correlation (R2) was calculated. Comparison of all plates illustrated a high 
correlation value of >0.93 (A-C). Housekeeping genes (D) and 5 genes with very little to no mRNA 
expression (E) (based on CT value), were graphed and analysed to determine if there were any 
significant differences between the CT values from each plate. No significant differences were 
observed when comparing the raw IPMSC CT values over three plates. 
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Taken together, successful RTCs, PPCs and high correlation of all Ct values on 
the three plates (R2 > 0.93) suggested that although cDNA synthesis, plate 
preparation and plate reading occurred on different days, the reproducibility of 
the array was suitably robust to allow intra- and inter-plate analysis. Moreover, 
no significant differences were observed between genes of high or low CT value, 
therefore concluding that the RT2 arrays were consistent over different PCR runs 
and were therefore suited for this large study. 
 Transcriptional analysis of chemokine and 4.3
chemokine receptor expression by Is, Va, Ad, UC and 
BM MSCs under homeostatic and inflammatory 
conditions.  
To understand how MSCs might migrate and interact with the immune system, it 
was important to elucidate their chemokine and chemokine receptor expression. 
To do this, transcriptional analysis of all the chemokines and their receptors, 
along with other molecules important in migration and interaction with the 
immune system were carried out. Is, Va, Ad, UC and BM MSCs were 
transcriptionally evaluated under homeostatic and inflammatory conditions to 
determine whether MSC tissue source and/or inflammatory conditions altered 
the MSC chemokine and chemokine receptor transcriptional profile.   
 Transcriptional analysis of CC chemokines under 4.3.1
homeostatic and inflammatory conditions.  
The results of the transcriptional analysis of the CCL chemokines (and all other 
genes) are graphed as 2(-ΔCT) (Figure 4-7). All transcriptional data throughout 
this chapter was normalised to the HKG beta-2 microglobulin (B2M). As this study 
did not have a reference sample (i.e. we did not want to visualise an 
upregulation or downregulation in specific genes relative to one specific MSC 
sample), the data is represented as 2(-ΔCT) as opposed to ΔΔCt. This 
representation of the data allows one to visualise the expression levels of 
specific genes normalised to B2M for each sample. Due to the nature of 
normalisation, genes that generated a CT of 35 or above resulted in 2(-ΔCT) less 
than or equivalent to ~ 0.0001. Genes with 2(-ΔCT) values similar to ~0.0001 are 
marked with a red box on the following graphs and are likely not transcribed by 
MSCs. 
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Figure 4-7 Inflammation and MSC tissue origin impacts CC chemokine transcript levels in 
MSCs. 
MSCs from all sources were grown to passage 3. MSCs isolated from each donor (n of 3 for each 
MSC tissue source) were split into two T75 flasks. Once MSCs reached 80% confluency, MSCs 
were either cultured under homeostatic conditions or treated with 10ng/mL IFN-gamma, TNF-alpha 
and IL-1beta in MSC medium for 24 hours. Quantitative reverse transcription PCR (qRT-PCR) was 
performed to evaluate CCL transcripts in Is, Va, Ad, BM and UC MSCs under homeostatic and 
inflammatory conditions. Bars represent mean ± SEM (n=3). Data are normalised to the HKG B2M 
and expressed as 2(-ΔCT). Appropriate statistical analysis was performed and includes Students 
paired T test between one MSC tissue source (Homeostatic vs Inflammatory Conditions) and One 
Way ANOVA with Tukey’s multiple comparisons post-test to compare all MSC sources. Significant 
differences are marked with the appropriate number of asterisks and P values are stated 
throughout the text.  
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Under homeostatic conditions, Is, Va, Ad, BM and UC MSCs transcribed very 
little, if any, CC chemokines with the exception of CCL2 which was transcribed 
by all tissue sources of MSCs at similar levels (Figure 4-7 B).  
A pattern of transcriptional upregulation after stimulation in all MSCs was 
observed in CCL1 (Figure 4-7 A), CCL2 (B), CCL3 (C), CCL5 (E), CCL7 (F), CCL13 
(I), CCL19 (O) and CCL20 (P). Noticeably, these chemokines were upregulated 
differentially, depending on MSC tissue source: 
Va and Ad MSCs exhibited the largest transcriptional upregulation of CCL1, 
whereas Is, BM and UC MSCs showed little upregulation (Figure 4-7 A). As 
mentioned, CCL2 was transcriptionally expressed under homeostatic conditions 
at fairly substantial levels in all MSCs with Va MSCs expressing the most. 
Inflammatory stimulation resulted in a substantial and significant upregulation of 
CCL2 transcripts by Is, Ad, BM and UC MSCs and a significant upregulation by Va 
MSCs (P=0.0129). UC MSCs had the highest levels of CCL2 transcripts, whereas Is 
MSCs have the lowest under inflammatory stimulation (Figure 4-7 B). CCL3, 
transcribed at similar levels to CCL1, showed a large spread between sources. 
Like CCL1, expression levels of CCL3 varied between sources under inflammation 
with Va, Ad and BM expressing the most transcripts and Is and UC MSCs 
expressing relatively little (Figure 4-7 C).  
CCL5 was the most transcribed CCL in BM, Ad and Is MSCs. Under homeostatic 
conditions, CCL5 was transcribed at low levels by BM MSCs only. Inflammatory 
stimulation resulted in all MSCs upregulating CCL5 transcription. BM MSCs 
produced the most CCL5 transcripts, an 11 fold upregulation compared to UC 
MSCs which transcribed the least CCL5 (Figure 4-7 E).  
Transcript levels of CCL7 were very low during homeostatic conditions. Under 
inflammatory stimulation CCL7 was significantly upregulated by Ad (P=0.0018) 
and UC MSCs (P=0.0142), however, overall transcription levels still remained 
relatively low. One Is MSC donor exhibited high CCL7 transcripts during 
inflammatory conditions, accounting for the large error bar (Figure 4-7 F).  
CCL19 was transcribed at low levels in all MSC sources during homeostatic 
conditions. Following inflammatory stimulation, all MSCs (with the exception of 
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UC MSCs) upregulated CCL19. Transcriptional levels of CCL19 varied between 
sources with Ad MSCs transcribing 107 fold more than Is MSCs (Figure 4-7 O).  
During homeostatic conditions, CCL20 was transcribed at similar levels to CCL19 
during inflammation. Inflammatory stimulation resulted in a substantial 
upregulation of CCL20 in BM MSCs, resulting in BM MSCs producing significantly 
higher CCL20 transcripts than UC MSCs (P≤0.05) (Figure 4-7 P).  
Other CCL chemokines do not show the same pattern of upregulation under 
inflammatory stimulation. CCL8 (Figure 4-7 G), CCL11(H), CCL14(J), CCL15(K), 
CCL16(L), CCL17(M), CCL18(N), CCL21(Q), CCL22(R), CCL23(S), CCL24(T), 
CCL25(U), CCL26(V), CCL27(W) and CCL28(X) showed variable patterns of 
upregulation or downregulation under inflammatory stimulation between MSC 
tissue sources. Transcripts of all of these chemokines, with the exception of 
CCL11, were very low (as marked with a red box).  
During homeostatic conditions, CCL11 was transcribed at low levels by Is and Ad 
MSCs and high levels by Va MSCs. BM and UC MSCs did not transcribe CCL11 
during homeostatic conditions. Inflammatory stimulation resulted in a pattern of 
CCL11 transcriptional upregulation by all MSC sources except Va MSCs, where 
CCL11 was downregulated. Tissue origin of MSCs also had an influence on CCL11 
transcription under inflammatory conditions, where Va transcribed significantly 
more CCL11 than BM and UC MSCs, as did Ad MSCs (P≤0.05 in all cases) (Figure 
4-7 H). 
In summary, MSCs from all sources expressed a variety of CCL chemokines, 
suggesting that they could attract immune cells such as monocytes, 
macrophages, NK cells, eosinophils and B cells. During homeostatic conditions, 
MSCs transcribed very low levels of CCLs, with the exception of CCL2. 
Conversely, inflammatory stimulation resulted in a marked upregulation of CCL 
transcription by all tissue sources of MSCs. Importantly, the level of CCL2 
transcript production varied with source.  
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 Transcriptional analysis of CXC chemokines under 4.3.2
homeostatic and inflammatory conditions.  
During homeostatic conditions, CXCL transcripts in all MSC sources were low with 
the exception of UC MSCs which transcribed CXCL1 (Figure 4-8 A), CXCL2 
(Figure 4-8 B), and CXCL6 (Figure 4-8 E) at slightly higher levels than other MSC 
sources. UC MSCs also transcribed significantly higher quantities of CXCL5 in 
homeostatic conditions when compared to BM MSCs (P≤0.05) and Is MSCs 
(P≤0.05) (Figure 4-8 D). 
Under inflammatory stimulation, CXCLs 1, 2, 3, 5, 6, 8, 9, 10 and 11 transcripts 
were substantially upregulated by all MSC sources. CXCL1 transcripts were 
significantly upregulated by Ad MSCs (P=0.0262) and BM MSCs (P=0.0043) when 
compared to homeostatic conditions. CXCL1 transcript levels varied slightly 
between MSC tissue sources under inflammatory conditions, where Va MSCs 
transcribed 2.7 fold more than Ad MSCs (Figure 4-8 A). Similarly, CXCL2 was also 
significantly upregulated by Ad (P=0.0130) and BM MSCs (P=0.0204) after 24 
hours of inflammatory stimulation. Transcriptional levels of CXCL2 differed very 
slightly between MSC tissue sources where Ad MSCs transcribed the least and Is, 
Va, UC and BM MSCs transcribed comparable levels (Figure 4-8 B). BM MSCs 
significantly upregulated CXCL3 transcripts (P=0.0240) under inflammatory 
stimulation, however, despite not reaching significance Is, Va, Ad and UC MSCs 
also markedly upregulated CXCL3 transcripts, therefore resulting in no 
differences in CXCL3 transcription between MSC sources (Figure 4-8 C). CXCL5 
transcripts were significantly upregulated by Va (P=0.0172) and UC (P=0.0435) 
MSCs as well as being substantially upregulated by all other MSC sources under 
inflammatory stimulation. Despite differences in CXCL5 transcript levels 
between MSC sources maintained under homeostatic conditions, upon 
inflammatory stimulation, MSCs from all tissue sources transcriptionally 
upregulated CXCL5 to similar levels (Figure 4-8 D). Likewise, CXCL6 was 
transcriptionally expressed at equivalent levels across all MSC tissue sources 
under inflammatory conditions. Slight differences were observed between Is 
MSCs and Va MSCs, where Va MSCs expressed a 2(-ΔCT) 2 fold higher than that of 
Is MSCs (Figure 4-8 E).  
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During homeostatic conditions, CXCL8 was transcribed at moderate levels by Is 
MSCs only. When comparing homeostatic to inflammatory conditions, fold 
changes of up to 21 were seen in Is MSCs CXCL8 2(-ΔCT), along with significant 
upregulation of CXCL8 transcripts by Va MSCs (P=0.0124). Additionally, transcript 
levels of CXCL8 differed depending on MSC tissue source under inflammatory 
stimulation, where Is MSCs exhibited a 2(-ΔCT) 2 fold higher than Va, Ad, UC and 
BM MSCs. Moreover, CXCL8 was the highest transcribed gene by Is and UC MSCs 
on the RT2 array (Figure 4-8 F). Conversely, CXCL9 was the highest transcribed 
gene by Ad and Va MSCs on the RT2 array. MSCs from all sources did not 
transcribe CXCL9 under homeostatic conditions, however fold changes of up to 
120660 by Ad MSC CXCL9 2(-ΔCT) were observed going from homeostatic to 
inflammatory conditions (Figure 4-8 G). Similar to CXCL9, CXCL10 was not 
transcribed under homeostatic conditions by any tissue source of MSC. 
Inflammatory stimulation resulted in a substantial upregulation of CXCL10 
transcripts by Is, Va and UC MSCs, whereas Ad and BM MSCs significantly 
upregulated CXCL10 transcripts (Ad: P=0.0286. BM: P=0.0055). CXCL10 was the 
highest transcribed gene by stimulated BM MSCs on the profiling array (Figure 
4-8 H). CXCL11 was not transcribed by any tissue source of MSC during 
homeostatic conditions. Inflammatory stimulation resulted in a substantial 
upregulation of CXCL11 transcription by Is and UC MSCs and a significant 
upregulation by Va (P=0.0373), Ad (P=0.0220) and BM (P=0.0321) MSCs. CXCL11 
transcription did not significantly vary between MSC tissue source (Figure 4-8 I).  
CXCL12 was transcribed at moderate levels by Va and Ad MSCs, whereas Is, BM 
and UC MSCs transcribed 3 fold less than Va and Ad MSCs in homeostatic 
conditions. Inflammatory stimulation resulted in downregulation of CXCL12 
transcripts by all tissue sources of MSCs, where Va, Ad and BM MSCs transcribed 
similar levels and Is and UC MSCs transcribed more than 9 fold less than Va, Ad 
and BM MSCs (Figure 4-8 J).  
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Figure 4-8 Inflammation and MSC tissue origin impacts CXC chemokine transcript levels in 
MSCs. 
Experimental set up was identical as described previously (Figure 4-3). MSCs from all sources 
were grown to passage 3. MSCs from each donor (n of 3 for each MSC tissue source) were split 
into two T75 flasks. Once MSCs reached 80% confluency, MSCs were either left in homeostatic 
conditions or treated with 10ng/mL IFN-gamma, TNF-alpha and IL-1beta for 24 hours. Quantitative 
reverse transcription PCR (qRT-PCR) was performed to evaluate CXCL transcripts in Is, Va, Ad, 
BM and UC MSCs under homeostatic and inflammatory conditions. Bars represent mean± SEM 
(n=3). Appropriate statistical analysis was performed and includes Students T test between one 
MSC tissue source (Homeostatic vs Inflammatory Conditions) and One Way ANOVA with Tukey’s 
multiple comparisons post-test to compare all MSC sources. Significant differences are marked 
with the appropriate number of asterisks and P values are stated throughout the text. 
 
To summarise, the CXC chemokines were transcribed at relatively low levels 
during homeostatic conditions with the exception of UC MSCs which transcribed 
CXCL1, 2 and 6 at slightly higher levels. Notably, under inflammatory stimulation 
the CXC chemokines were the highest transcribed genes on the RT2 arrays by all 
MSCs. MSC tissue origin dictated which CXCL was most highly transcribed, with 
CXCL8 being the greatest transcribed by Is and UC MSCs, CXCL9 by Va and Ad 
MSCs and CXCL10 by BM MSCs. These findings highlight the effect of 
inflammatory stimulation and the difference that MSC tissue origin has on CXC 
chemokine transcription in MSCs. Additionally, these findings suggest that MSCs 
might attract different immune cells depending on MSC tissue origin, where Is 
and UC MSCs should preferentially attract neutrophils (CXCL8), and Va, Ad and 
BM MSCs should attract T cells, NK cells and dendritic cells (CXCL9, CXCL10). 
Moreover, the exceedingly high levels of CXC chemokine transcription highlights 
target genes for protein analysis.  
 Transcriptional analysis of CC chemokine receptors under 4.3.3
homeostatic and inflammatory conditions. 
In comparison to CCL and CXCL chemokines, CC chemokine receptors are 
transcribed at extremely low levels. Despite low levels of transcription, CCR1 
(Figure 4-9 A.i), CCR2 (A.ii), CCR8 (A.vii), CCR9 (A.ix) and CCR10 (A.xi) follow a 
trend of downregulation by all MSC tissue sources after inflammatory 
stimulation. Due to low transcript levels, differences between MSC sources are 
not measurable. Transcriptional expression of CCR3 (Figure 4-9 A.ii), CCR4 
(A.iv), CCR5 (A.v), CCR6 (A.vi) and CCR7 (A.vii) were high for 1 sample of Is 
MSCs, accounting for the large error bars observed. Using a Grubbs’ test, this 
sample was deemed an outlier and was excluded from the appropriate analysis 
and results are graphed in Figure 4-9 B. Exclusion of this sample allows for 
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better visualisation of CCR4, 5, 6 and 7 transcript levels by all MSC tissue 
sources.   
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Figure 4-9 CC receptor transcript levels in MSCs under homeostatic and inflammatory 
conditions. 
Experimental set up was identical as described previously (Figure 4-3). MSCs from all sources 
were grown to passage 3. MSCs from each donor (n of 3 for each MSC tissue source) were split 
into two T75 flasks. Once MSCs reached 80% confluency, MSCs were either left in homeostatic 
conditions or treated with 10ng/mL IFN-gamma, TNF-alpha and IL-1beta for 24 hours. Quantitative 
reverse transcription PCR (qRT-PCR) was performed to evaluate CCR transcripts in Is, Va, Ad, BM 
and UC MSCs under homeostatic and inflammatory conditions. Graphs above the dotted line 
represent all data collected (A), graphs below the dotted line represent the data, removing the one 
Is MSC outlier (assessed with Grubbs’ test) (B). Bars represent mean± SEM (n=3). Appropriate 
statistical analysis was performed and includes Students T test between one MSC tissue source 
(Homeostatic vs Inflammatory Conditions) and One Way ANOVA with Tukey’s multiple 
comparisons post-test to compare all MSC sources. Where relevant, significant differences are 
marked with the appropriate number of asterisks and P values are stated throughout the text. 
 
To summarise, CCRs were expressed at very low levels. Inflammatory stimulation 
resulted in a transcriptional downregulation in CCRs 1, 2, 8, 9 and 10. No 
differential expression of CCRs was observed between MSC tissue sources with 
the exception of one Is MSC sample for CCRs3, 4, 5, 6 and 7, which was deemed 
to be an outlier. The highest transcribed receptors for all MSC sources were 
CCR7 and CCR10. 
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 Transcriptional analysis of CXC chemokine receptors under 4.3.4
homeostatic and inflammatory conditions.  
Similar to the CCRs, CXCRs were transcribed at very low levels. However, one Is 
MSC sample transcribed CXCR2 (Figure 4-10 A.ii), CXCR3 (A.iii), CXCR4 (A.iv), 
CXCR5 (A.v) and CXCR6 (A.vi) at substantially higher levels than other Is MSC 
samples (accounting for the large error bars) and other MSC tissue sources. This 
was the same Is MSC sample removed from the CCR analysis (Figure 4-9 A+B), 
possibly suggesting that receptor expression is highly variable depending on MSC 
donor. As before, a Grubbs’ test deemed this sample an outlier and therefore it 
was removed from the appropriate graphs. Removing this sample allowed the 
visualisation of CXCR transcription by other tissue sources of MSCs where 
inflammatory stimulation resulted in a downregulation of all CXC chemokine 
receptors with the exception of CXCR4 (Figure 4-10 B).  
As a result of low transcript levels, differences between MSC tissue sources are 
not measurable and all CXCRs are transcribed at comparable levels by all MSC 
tissue sources, with the exception of CXCR1 which was transcribed at slightly 
lower levels than other CXCRs.  
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Figure 4-10 CXC receptor transcript levels in MSCs under homeostatic and inflammatory 
conditions 
Experimental set up was identical as previously described (Figure 4-3). MSCs from all sources 
were grown to passage 3. MSCs from each donor (n of 3 for each MSC tissue source) were split 
into two T75 flasks. Once MSCs reached 80% confluency, MSCs were either left under 
homeostatic conditions or treated with 10ng/mL IFN-gamma, TNF-alpha and IL-1beta for 24 hours. 
Quantitative reverse transcription PCR (QRT PCR) was performed to evaluate CXCR transcripts in 
Is, Va, Ad, BM and UC MSCs in homeostatic and inflammatory conditions. Graphs in (A) represent 
all data collected, graphs in (B) represent the data, removing the one Is MSC ‘outlier’. Bars 
represent mean± SEM (n=3). Appropriate statistical analysis was performed and includes Students 
T test between one MSC tissue source (Homeostatic vs Inflammatory Conditions) and One Way 
ANOVA with Tukey’s multiple comparisons post-test to compare all MSC sources. Where relevant, 
significant differences are marked with the appropriate number of asterisks and P values are stated 
throughout the text 
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 Transcriptional analysis of atypical chemokine receptors 4.3.5
under homeostatic and inflammatory conditions. 
The atypical chemokine receptors were transcribed at higher levels than the CC 
and CXC receptors.  
Under homeostatic conditions, Va and Ad MSCs transcribed moderate levels of 
ACKR2, whereas Is, BM and UC MSCs transcribed substantially less. Ad MSCs – 
which transcribed the highest levels of ACKR2 in homeostatic conditions - 
transcribed 31-fold higher ACKR2 than UC MSCs – which transcribed the lowest 
ACKR2 in homeostatic conditions (Figure 4-11 A.ii). Inflammatory stimulation 
had differential effects on ACKR2 transcription, where Is MSCs marginally 
upregulated ACKR2 expression and Va, Ad, BM and UC downregulated ACKR2 
expression. MSC tissue source also appeared to have an effect on ACKR2 
transcription. Thus during inflammatory conditions, Is MSCs transcribed the 
highest levels of ACKR2.  
ACKR3 (Figure 4-11 A.iii) was the highest transcribed atypical receptor by all 
MSC tissue sources, except Is MSCs which transcribed marginally more ACKR4 
(Figure 4-11 A.iv). During homeostatic conditions, MSC tissue source affected 
the transcript levels of ACKR3, where Va MSCs transcribed significantly more 
than Is MSCs (P≤0.05) and Ad MSCs transcribed significantly more than UC MSCs 
(P≤0.05). Inflammatory stimulation had differential effects on MSC ACKR3 
expression depending on MSC tissue origin. ACKR3 transcripts were upregulated 
by Va, Ad and UC MSCs, downregulated in BM MSCs and remained the same in Is 
MSCs 
MSCs isolated from all sources downregulated ACKR4 transcription under 
inflammatory stimulation. ACKR4 was highest transcribed ACKR by Is MSCs and 
the second highest transcribed ACKR after ACKR3 by Va, Ad, BM and UC MSCs. 
ACKR4 was transcriptionally expressed at similar levels by Is, Va and Ad MSCs, 
whereas UC and BM MSCs show very little ACKR4 transcription (Figure 4-11 
A.iv).  
Excluding the one Is MSC sample which expressed high transcription levels of 
ACKR1 (using Grubb’s test), the remaining Is MSCs and other MSC tissue sources 
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showed very little transcription of ACKR1 (Figure 4-11 B.i), similar to that of 
ACKR5 transcription levels (Figure 4-11 A.v) 
 
Figure 4-11 ACK Receptor transcript levels in MSCs under homeostatic and inflammatory 
conditions 
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Experimental set up was identical as previously described (Figure 4-3) MSCs from all sources were 
grown to passage 3. MSCs isolated from each donor (n of 3 for each MSC tissue source) were split 
into two T75 flasks. Once MSCs reached 80% confluency, MSCs were either left in homeostatic 
conditions or treated with 10ng/mL IFN-gamma, TNF-alpha and IL-1beta for 24 hours. Quantitative 
reverse transcription PCR (qRT-PCR) was performed to evaluate ACKR transcripts in Is, Va, Ad, 
BM and UC MSCs in homeostatic and inflammatory conditions. Graphs above the dotted line 
represent all data collected (A), graphs below the dotted line represent the data, removing the one 
Is MSC ‘outlier’ (B) Bars represent mean± SEM (n=3). Appropriate statistical analysis was 
performed and includes Students T test between one MSC tissue source (Homeostatic vs 
Inflammatory Conditions) and One Way ANOVA with Tukey’s multiple comparisons post-test to 
compare all MSC sources. Where relevant, significant differences are marked with the appropriate 
number of asterisks and P values are stated throughout the text 
 
Overall, atypical chemokine receptors were transcriptionally expressed at higher 
levels that CCRs and CXCRs. Stimulation with inflammatory mediators had 
differential effects on MSC ACKR transcription. Moreover, expression levels of 
AKCR3 are significantly different between MSC tissue sources. Thus inflammatory 
stimulation and MSC tissue source had a profound effect on MSC ACKR 
transcription profiles.  
 Transcriptional analysis of XCL and CX3C chemokines, their 4.3.6
receptors and other cytokines.  
During homeostatic conditions, CX3CL1 (Figure 4-12 A) and its receptor CX3CR1 
(Figure 4-12 B) were transcribed at low levels by all MSCs with the exception of 
one Is MSC sample, accounting for the large error bar observed. XCL1 (Figure 
4-12 C), XCL2 (Figure 4-12 D) and its receptor XCR1 (Figure 4-12 E) were 
transcribed at extremely low levels by all MSC tissue sources.  
Hypoxia-inducible factor 1-alpha (HIF1A) was transcribed at substantial levels by 
Is, Va and Ad MSCs, whereas UC and BM MSCS transcribed considerably lower 
levels under homeostatic conditions. Upon inflammatory stimulation, Is, Va and 
Ad MSCs markedly downregulated HIF1A transcription, and UC and BM 
transcribed HIF1A at similar levels under both conditions (Figure 4.12 F).  
Inflammatory stimulation considerably upregulated IL-1B transcription by MSC 
from all tissue sources and was transcribed at similar levels by all MSCs (Figure 
4-12 G).  
Despite being transcribed at exceedingly low levels, inflammatory stimulation 
resulted in MSCs from all tissue sources downregulating IL-4 transcription (Figure 
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4-12 H). Differences in IL-4 transcript levels between MSC tissue sources are 
hard to interpret due to such low transcript levels. 
Transcription of TNF-alpha was slightly upregulated by MSCs from all tissue 
sources, however variations in TNF-alpha transcription within one MSC 
population was evident, where Ad, UC and BM MSCs exhibited large spreads of 
data, perhaps due to donor variability (Figure 4-12 I).  
TLR4 was transcribed at similar levels by MSCs from all tissue sources under both 
homeostatic and inflammatory conditions with the exception of UC MSCs which 
transcribed significantly less than Ad MSCs (P≤0.05) and substantially less than 
Is, Va and BM MSCs (Figure 4-12 J).  
TLR2 and IL-16 were transcribed at very low levels by all MSCs with the 
exception of one BM MSC donor in TLR2 transcription (Figure 4-12 K) and one Is 
MSC donor in IL-16 transcription (Figure 4-12 L), accounting for the large spread 
of data observed on those graphs for MSCs from those tissue sources.  
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Figure 4-12 Inflammation and MSC tissue origin impacts the transcript levels of other genes 
important in immunity and inflammation 
Experimental set up was identical as previously described (Figure 4-3). MSCs from all sources 
were grown to passage 3. MSCs isolated from each donor (n of 3 for each MSC tissue source) 
were split into two T75 flasks. Once MSCs reached 80% confluence, MSCs were either left in 
homeostatic conditions or treated with 10ng/mL IFN-gamma, TNF-alpha and IL-1beta for 24 hours. 
Quantitative reverse transcription PCR (qRT-PCR) was performed to evaluate transcript levels of 
several genes in Is, Va, Ad, BM and UC MSCs in homeostatic and inflammatory conditions. Bars 
represent mean± SEM (n=3). Appropriate statistical analysis was performed and includes Students 
T test between one MSC tissue source (Homeostatic vs Inflammatory Conditions) and One Way 
ANOVA with Tukey’s multiple comparisons post-test to compare all MSC sources. Where relevant, 
significant differences are marked with the appropriate number of asterisks and P values are stated 
throughout the text 
 
 
To Summarise, CX3CR1, XCR1, XCL1 and XCL2 were all transcribed at very low 
levels. CX3CL1 was transcribed at similar levels by VA, Ad, BM and UC MSCs 
under inflammatory stimulation, suggesting MSCs potential to attract T cells and 
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monocytes during inflammation. Additionally, the pro-inflammatory cytokine IL-
1B was transcriptionally expressed at similar levels by MSCs isolated from all 
tissue sources. TLR4, a molecule important in activating the innate immune 
system was transcribed at similar levels under homeostasic and inflammatory 
conditions in all MSCs with the exception of UC MSCs. HIF-1A was also 
transcribed at different levels depending on where MSCs were isolated from, 
with Is, Va and Ad MSCs transcribing similar levels under homeostasis and all 
MSCs transcribing similar levels after inflammatory stimulation. 
Importantly, these genes are involved in the activation of the immune system. 
Notably, inflammatory stimulation and MSC tissue source had a variable effect 
on the transcript levels of these genes. Therefore MSC tissue source and 
inflammatory stimulation of MSCs may have differential effects on surrounding 
immune cells in vivo.  
 Discussion  4.4
Work presented in this chapter was designed to determine whether the RT2 
arrays were a suitable tool to analyse the transcriptional expression of 
chemokines and their receptors by MSCs isolated from Is, Ad, Va, BM and UC. 
Stringent analysis of the plate’s internal controls, along with an external control 
allowed for the assessment of intra and inter-plate reproducibility and 
established that data generated using this system was accurate and reliable. 
Secondly, after the establishment of a suitable assay, the transcriptional analysis 
of chemokines and chemokine receptors by MSCs from all tissue source 
maintained under homeostatic and inflammatory conditions was assessed and is 
summarised in Figure 4-13. Careful analysis of the transcript data allowed genes 
of interest to be identified and targeted for protein assays. Protein expression of 
chemokines and their receptors are examined in the next chapter to give a more 
thorough examination of the key molecules implicated in MSC phenotype and 
potential in vivo behaviour.  To avoid repetition, a combined, in depth 
discussion on MSC chemokine and chemokine receptor expression at a transcript 
and protein level will follow in the next chapter.  
146 
 
 
147 
 
Figure 4-13 Heat maps of MSC transcriptional expression of chemokines and their receptors  
Data from Figure 4-7 to Figure 4-11 are combined and presented as heat maps to illustrate the 
chemokine and chemokine receptor transcriptional profile of MSCs maintained under homeostatic 
(left) and inflammatory conditions (right). The heat maps summarise each individual tissue source 
of MSC highest and lowest transcribed genes under homeostatic conditions and inflammatory 
stimulation. Genes with low 2(-ΔCT) values are highlighted in blue, genes with intermediate 2(-ΔCT) 
values are highlighted in green and genes with high 2(-ΔCT) values are highlighted in red.  
 
 Conclusions 4.5
To summarise, Is, Va, Ad, BM and UC MSCs differentially expressed chemokines 
and their receptors at a transcriptional level. Inflammatory stimulation resulted 
in a substantial transcriptional upregulation of CC and CXC chemokines, whereas 
it had differential effects on receptor transcripts. Under inflammatory 
conditions, MSCs appeared to have a very specific, distinct chemokine 
transcriptional profile with prominent transcription of the CXC chemokine 
family. Importantly, the tissue source of MSC dictates their chemokine and 
chemokine receptor transcriptional profile. The observation that the original 
MSC tissue source dictates the transcriptional profile of chemokines and their 
receptors could have major effects on MSC in vivo behaviour. Further 
investigation into the expression of these molecules by MSCs at a protein level is 
vital to begin to elucidate if in vivo behavioural differences might exist in MSCs 
isolated from Is, Va, Ad, BM and UC.  
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Chapter 5 Determining the chemokine and 
chemokine receptor expression by MSCs at a 
protein level 
 Introduction and aims 5.1
Work presented in the previous chapter demonstrated that MSCs isolated from 
the islet (Is), visceral adipose (VA), adipose (Ad), bone marrow (BM) and 
umbilical cord (UC) differentially expressed transcripts for chemokines and their 
receptors, depending on their environment (homeostatic or inflammatory) and 
tissue source. Chemokine receptors, in general, displayed low transcript levels, 
however, under both homeostatic conditions and after inflammatory stimulation, 
CCR7, CCR10, CXCR4, CXCR6, ACKR3 and ACKR4 were variously transcribed at 
higher levels. Chemokines were transcribed at much higher levels than 
chemokine receptors under both homeostatic conditions and following 
inflammatory stimulation. Homeostatically maintained MSCs transcribed 
moderate to high levels of CCL2, CCL5, CCL11, CCL13, CXCL1, CXCL2, CXCL5, 
CXCL6, CXCL8, CXCL12 and CXCL14. Upon inflammatory stimulation, the 
aforementioned chemokines were substantially upregulated and moderate to 
high levels of transcription of the following chemokines were induced; CCL1, 
CCL3, CCL7, CCL20, CXCL3, CXCL9, CXCL10 and CXCL11. 
As mentioned previously, chemokine receptor expression by MSCs is reported in 
the literature but the findings are confusing and largely focus on BM MSCs. More 
recently, with the improved ease of access to MSCs isolated from other tissue 
sources, data are emerging reporting chemokine receptor expression profiled for 
MSCs from other sources (242, 243).  Several studies have highlighted the poor 
homing efficiency of MSCs (244), therefore, analysing MSC chemokine receptor 
expression will shed light on the homing potential of MSCs to specific locations 
such as the bone marrow (CXCR4), sites of myocardial infarction (CXCR4) and the 
skin (CCR10). At these sites they can act as anti-inflammatory mediators in  
hematopoietic stem cell transplantation, cardiac regeneration and wound 
healing, respectively (234, 245-247).  Some studies have focussed on attempting 
to upregulate chemokine receptor expression to improve the tissue-specific 
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homing efficiency of MSCs in order to ultimately improve therapeutic efficacy 
(244, 248). Due to the use of alternative isolation methods, different culture 
medium, different passage number and varied tissue culture techniques, the 
literature reporting MSC chemokine receptor expression is inconsistent. Through 
a set of standardised methods, the work presented in this chapter aimed to 
compare chemokine receptor expression of Is, Va, Ad, BM and UC MSCs under 
both homeostatic and inflammatory conditions. Understanding the effect of 
inflammation on chemokine receptor expression could inform our understanding 
of MSC behaviour in inflammatory settings, or provide a rationale for pre-
treating MSCs before infusion into patients. 
MSC secretion of several chemokines is reported in the literature, with some 
studies highlighting differences in chemokine secretion between MSCs isolated 
from different tissue sources. For example, Amable et al. reported that UC MSCs 
secreted higher levels of CXCL8 in comparison to Ad and BM derived MSCs, 
whereas the same group report differential chemokine secretion by MSCs 
cultured in platelet-rich plasma in comparison to fetal bovine serum (249-251). 
Importantly, the majority of studies have focused on human BM MSC chemokine 
secretion, with little clarification of the function of MSC secreted chemokines. 
Some studies suggest that MSC derived chemokines are involved in wound 
healing and others suggest that the secretion of chemokines is key to attracting 
immune cells to areas of tissue regeneration or damage (240). Through a set of 
standardised techniques and reagents, work described in this chapter aimed to i) 
compare chemokine secretion by Is, Va, Ad, BM and UC MSCs under homeostatic 
and inflammatory conditions and ii) to understand if the secretion of these 
chemokines attracts immune cells towards MSCs. Understanding if MSCs 
differentially secrete chemokines and therefore preferentially attract different 
immune cell subtypes, could highlight potential differences in in vivo behaviour 
of MSCs isolated from different sources.  
Therefore, having assessed the transcription of chemokines and their receptors 
by MSCs under both homeostatic and inflammatory conditions, this chapter 
aimed to determine if these differences were also evident at the protein level. 
Additional aims of this chapter included assessing the functionality of MSC 
secreted chemokines. 
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Results 
 Surface chemokine receptor expression by MSCs 5.2
Although the majority of chemokine receptor transcripts were low for all MSC 
populations, a handful that were transcribed at slightly higher levels were 
selected for surface protein analysis – CCR7, CCR10, CXCR6, ACKR3 and ACKR4. 
Although CXCR4 was transcribed at lower levels, it was also included in this 
panel due to the extensive literature reporting its relationship with MSCs (151, 
152).  
To assess whether MSCs expressed chemokine receptors on their surface, and if 
MSC tissue source and/or inflammatory stimulation affected expression levels, 
flow cytometry was used to assess the surface expression of CCR7, CCR10, 
CXCR4, CXCR6 and ACKR3, the mean fluorescence intensity (MFI) was recorded 
and is graphed in Figure 5-1. Positive chemokine receptor expression was 
assessed by the MFI of receptor stained MSCs compared to the respective MFIs of 
isotype controls (black bars). Due to the lack of reliable flow cytometry 
antibodies for ACKR4, IHC was used to identify the presence of ACKR4 on Is, Va 
and Ad MSC (Figure 5-2). 
In agreement with the chemokine receptor transcript data, broadly speaking, 
surface chemokine receptor expression by MSCs was low. CXCR6 - an important 
receptor involved in NK and NKT cell patrolling and retention within the liver 
(252-254) was barely expressed above background levels (isotype controls) by 
MSCs from all sources under homeostatic and inflammatory conditions (Figure 
5-1 B).  Conversely, CXCR4 was expressed at moderate levels above background 
by Va MSCs under homeostatic conditions, whereas Is, Ad, BM and UC MSCs 
minimally expressed CXCR4 above background fluorescence levels (Figure 5-1 
C). Statistically speaking, CXCR4 expression was only affected by inflammatory 
stimulation on BM MSCs, where they were the only tissue source of MSC to 
significantly upregulate CXCR4 expression comparing homeostatic to 
inflammatory conditions (P=0.0453), however both Va and BM MSCs expressed 
CXCR4 at moderate levels above background stained controls. Similarly, CCR7, 
an important receptor for DC trafficking to the lymph node (255), was 
moderately expressed by Va and BM MSCs under both homeostatic and 
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inflammatory conditions. Inflammatory stimulation did not appear to have an 
impact on CCR7 expression (Figure 5-1 D).  
CCR10, a receptor important in immune cell homing to the skin was barely 
expressed by any MSC populations above background levels under homeostatic 
and inflammatory conditions (Figure 5.1 E), suggesting that this receptor is 
likely not expressed on the surface of MSCs.  
The atypical receptor ACKR3, is a scavenging receptor which binds and degrades 
CXCL11 and 12 and is constantly recycling. MSCs isolated from Va and the BM 
were the only MSC populations to stain positively for ACKR3 above background 
levels when maintained under homeostatic conditions and upregulated ACKR3 
expression under inflammatory conditions (Figure 5-1 F). Is and Ad MSCs barely 
expressed ACKR3 above background controls under homeostatic and 
inflammatory conditions, suggesting an absence of this receptor on these MSC 
populations. It is however, important to note that this is an atypical receptor, 
therefore is constantly recycling and is intracellularly stored within endocytic 
vesicles. Despite experiments being carried out at 4oC, which slows receptor 
cycling, it is likely that a large proportion of ACKR3 will be intracellular and 
therefore surface staining might not be an accurate representation of ACKR3 
expression.  
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Figure 5-1 Flow cytometry analysis of surface chemokine receptor expression by MSCs 
(A) A representative histogram showing P3 BM MSCs CXCR4 staining, under homeostatic (yellow) 
or inflammatory (Black) conditions - isotype control in dark blue.  
(B-F) Graphs show mean fluorescence intensity of CXCR6, CXCR4, CCR7, CCR10 and ACKR3. 
Black bar represents isotype controls. 
Each bar represents an n of 3 ± SEM. ONE WAY ANOVA with Tukey’s post test was used to 
statistically analyse receptor expression between MSC sources. Students paired T test was used to 
compare between homeostatic and inflammatory conditions within one MSC tissue source. 
Significance is marked in where applicable.  
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At P3, Is (A), Va (B) and Ad (C) MSCs stained positively for ACKR4 (Orange) 
(Figure 5-2 A-D).                                                                                          
The lack of signal in isotype controls (D) suggests that positive staining was 
specific for ACKR4. Moreover, the punctate staining pattern (highlighted in B 
with a white arrow) is typical staining you would expect to see for an atypical 
chemokine receptor because they reside in vesicles within the cell. This further 
suggests true ACKR4 staining.  
 
Figure 5-2 Immunohistochemistry showing ACKR4 expression by Is, Va and Ad MSCs 
Is (A), Va (B) and Ad (C) MSCs were grown to passage 3 and stained with anti-ACKR4 (Orange 
(A-C)) or isotype control (D) antibodies. Thumbnail inserts show zoomed images of ACKR4 stained 
cells and white arrows point to punctate ACKR4 staining  
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 Chemokine secretion by MSCs 5.3
To assess the chemokines secreted by MSCs, a LUMINEX assay was performed to 
measure the concentration of an array of chemokines present in MSC conditioned 
medium (CM) after 24 hours under homeostatic or inflammatory conditions. Due 
to UC and BM MSCs being tested on separate plates a substantial time apart, it 
was important to establish that the reagents, kits and the machine could still 
perform similarly between experiments. To assess this, a sample (Is MSC CM) 
used on the original plates with Is, Va and Ad MSC samples, was also used on the 
BM and UC MSC plate and the concentrations of each analyte were compared to 
ensure that they matched in both runs. Some analytes displayed very strong 
matches over the plates, suggesting that these analytes were consistent with the 
previous plate and therefore the results for UC and BM samples were accurate. 
Conversely, others showed dissimilar concentrations between runs (CXCL10 and 
CCL20 highlighted in red box) perhaps suggesting that these analytes were not 
performing as successfully as the previous run and therefore the results for BM 
and UC MSCs could not be directly compared to Is, Va and Ad MSCs (Figure 5-3 
A). Thus, to serve as a means of comparison between Is, Va and Ad MSCs 
LUMINEX results vs. BM and UC MSCs LUMINEX results, a dilution value was 
calculated for specific analytes which differed between the two LUMINEX runs 
(Figure 5-3 B). Where appropriate, BM and UC values were divided by the 
calculated dilution factor and graphed. As this is a crude assessment of 
comparison, UC and BM chemokine secretion values have to be interpreted with 
caution. Chemokines where BM and UC values are likely to be accurate, graphs 
are marked with an asterisk (*). Conversely, chemokines where BM and UC 
samples were generated by the division of a dilution factor, graphs are marked 
with a red box. 
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Figure 5-3 Comparison of LUMINEX analytes over two separate runs 
Chemokines in conditioned medium (CM) of Is, Va, Ad, BM and UC MSCs were assessed via 
LUMINEX. BM and UC CM were assessed on the same plates at a substantial time apart from Is, 
Va and Ad CM. Therefore, to assess the reproducibility and comparability of the LUMINEX plates, 
2 Is MSC CM samples used on the previous LUMINEX plates was run along with UC and BM MSC 
CM to assess the reproducibility and sensitivity of the assay. To fully test the range of sensitivity of 
the assay, homeostatically maintained Is MSC CM was used (circles) coupled with an inflamed Is 
CM (triangles). The results from the recent run (red) were compared to results of the previous run 
(grey). The concentration (pg/mL) of reproducible and 2 non-reproducible (red box) analytes are 
graphed in A.   
For analytes where sample 1 and sample 2 values were substantially higher or lower than the 
previous run, a dilution factor was generated to evaluate the spread of results and graphed in B. 
Analytes where symbols are close to 1 (black bar) – CXCL9 and CXCL1 – represent more reliable 
readings for BM and UC MSCs as they did not differ higher than 2 fold. Analytes with a larger 
dilution factor – CXCL10 and CCL2 –are relatively unreliable concentrations for UC and BM MSC 
CM.  
 
 CC Chemokines present in MSC conditioned medium  5.3.1
Concentrations (pg/mL) of the CC chemokines assayed are graphed in Figure 
5-4. As MSCs were cultured in 10% human AB pooled plasma, it was likely that 
this may contain chemokines and skew the results. Therefore MSC culture 
medium alone was run on the plate to serve as a background control.  This 
control is plotted as a black bar for Figure 5-4 and Figure 5-5. When the 
concentrations of chemokine present in MSC conditioned medium was at similar 
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levels to background controls, it was assumed that MSCs did not secrete these 
chemokines. Generally, when CC chemokines were secreted at substantial levels 
by MSCs, there were no significant differences in chemokine secretion between 
different MSC populations. This difficulty in obtaining statistical significance 
between MSC populations is likely due to the extensive donor variability in the 
chemokine concentrations that we observed. However significant differences 
were observed between homeostatic to inflammatory conditions (Figure 5-4). 
CCL2, an inflammatory chemokine important in monocyte chemotaxis, was one 
of the top secreted chemokines out of the CC and CXC families by all MSCs under 
homeostatic and inflammatory conditions (Figure 5-4 A). The levels of CCL2 
secreted by MSCs under homeostatic conditions were surprising as MSCs are 
notoriously anti-inflammatory cells. Although not significant, slight differences 
in the secretion levels of CCL2 under homeostatic conditions between MSC 
populations were observed, where Ad and Is MSCs secreted the most, followed 
by Va, BM and then UC MSCs. Not surprisingly, under inflammatory stimulation, 
Is and Va MSCs substantially upregulated CCL2 secretion, however this did not 
reach significance likely due to donor variability. Ad MSCs however, significantly 
upregulated CCL2 secretion (P=0.0435). BM and UC CCL2 secretion values were 
generated with a dilution factor and therefore are not fully reliable.  
Similar to CCL2, CCL3 is also an inflammatory chemokine. Under homeostatic 
conditions, there were significant differences between the levels of CCL3 in the 
conditioned medium of MSCs, where Va MSCs and Ad MSCs had significantly more 
than Is MSCs (P≤0.001) (Figure 5-4 B). These observations are of note as Va and 
Ad MSC CCL3 secretion were similar to control serum levels of CCL3, whereas Is 
MSC CM had significantly less (P≤0.001) than background serum levels. This could 
suggest that Is MSCs may express high levels of receptors which would bind and 
internalise CCL3 such as ACKR2, however, as discussed, receptor expression by 
MSCs was minimal and therefore it is more likely that Is MSCs are secreting 
significantly more proteases capable of degrading chemokines than other tissue 
sources of MSCs. All populations of MSCs upregulated CCL3 secretion after 
inflammatory stimulation, however no statistical differences were observed 
between MSC populations or above background serum controls.  
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CCL11, a chemokine important in eosinophil chemoattraction, was not secreted 
by any population of MSC at substantial levels above background serum levels 
under homeostatic conditions (Figure 5-4 D). A marked increase in CCL11 
secretion was observed going from homeostatic to inflammatory conditions, 
however this only reached significance in BM (P=0.04) and UC (P=0.01) derived 
MSCs as a result of very low basal level of secretion by these cells. Notably 
however, despite inflamed Is, Va and Ad MSCs secreting substantially more 
CCL11 than BM and UC MSCs (which secreted no more than background controls), 
there were no significant differences in the levels of secretion between these 
populations, again likely due to the donor variability.  
CCL13 was secreted at much lower levels compared to CCL2 and CCL11. Under 
homeostatic conditions, MSCs from all tissue sources had similar levels of CCL13 
in their conditioned medium as background controls, suggesting that this 
chemokine is not secreted (Figure 5-4 E). After inflammatory stimulation, Ad 
MSCs significantly upregulated CCL13 secretion (P=0.0413), whereas Is, Va and 
BM MSCs upregulated CCL13 to similar levels, but the upregulation failed to 
reach significance due to donor variability. UC MSCs did not secrete CCL13 above 
background levels after inflammatory stimulation, suggesting that the secretion 
of CCL13 under inflammatory conditions was dependent on the tissue sources of 
the MSCs. Similarly, the secretion of CCL15 (Figure 5-4 G) also appeared to be 
dependent on MSCs source under inflammatory conditions as BM MSCs secreted 
substantially more than any other population of MSC. 
CCL20, a chemokine involved in Th17 cell recruitment, was not secreted by MSCs 
in large quantities above background serum controls under homeostatic 
conditions (Figure 5-4 I). Strikingly, under inflammatory stimulation, Is, Va, BM 
and UC MSCs substantially upregulated CCL20 and Ad MSCs significantly 
upregulated (P=0.0490) CCL20 secretion. All populations of MSCs secreted similar 
levels of this chemokine. This could suggest that T cell recruitment is a universal 
mechanism of MSC action during inflammatory insult.  
Other CCL chemokines assayed (CCL4 (C), CCL14 (F), CCL18 (H), CCL21 (J), 
CCL24 (K), CCL26 (L) and CCL27 (M)) are graphed in Figure 5-4, however they 
were not secreted at substantial levels above background levels by any of the 
MSCs tested. 
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Although not a part of the chemokine family, vascular endothelial growth factor 
(VEGF) was included as an analyte on the LUMINEX plate. VEGF is an important 
signalling protein involved in angiogenesis and was secreted at moderate levels 
above background controls by Is, Va and BM MSCs under homeostatic conditions 
(Figure 5-4 N). BM MSCs VEGF secretion was particularly enhanced under 
inflammatory stimulation in comparison to all other populations of MSCs, 
perhaps suggesting a tissue specific role of VEGF in the bone marrow in an 
inflammatory environment.  
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Figure 5-4 LUMINEX analysis of CC chemokines 
P3 MSCs at 80% confluence were washed with warmed PBS before the addition of culture medium 
alone or culture medium + inflammatory cytokines (10ng/mL of TNF-α, IL-1β and IFN-ϒ). Cells 
were left for 24 hours before conditioned medium was collected, diluted 1 in 2 and added to the 
LUMINEX plates. Results are graphed as pg/mL. Black bar represents the background volumes 
of chemokine present in human AB pooled plasma within the medium. Each aliquot of AB 
pooled plasma consisted of 7-9 plasma donors, therefore each black bar represents 21-27 donors. 
Red boxes outline analytes where UC and BM values have been generated from a dilution factor 
and therefore are not directly comparable to Is, Va and Ad MSCs.  
Each bar represents an n of 3 ± SEM. ONE WAY ANOVA with Tukey’s post test analysis was 
carried out when comparing Is, Va and Ad MSCs *=P<0.05, **=P<0.001, ***=P<0.0001. Students 
paired T test was used to asses statistical differences between homeostatic and inflammatory 
conditions within one MSC source. Significance is marked on the graphs where applicable and P 
values are stated in the text throughout.  
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Overall, CCL2 was the highest secreted CC chemokine by Is, Va and Ad MSCs and 
the only one to be secreted at levels substantially above background controls 
under homeostatic conditions, suggesting that Is, Va and Ad MSCs could attract 
monocytes prior to any inflammatory insult, however BM and UC MSCs would not 
(BM and UC values for CCL2 secretion have to be interpreted with caution). As 
CCL2 secretion was upregulated, this suggests that monocyte migration towards 
CCL2 secreting MSCs would also be enhanced. In addition to this, CCL20 was 
secreted at very similar levels by all populations of MSCs during inflammatory 
conditions. The combined secretion of CCL2 and CCL20 highlights that regardless 
of the tissue source, MSCs could potentially be programmed to attract both 
monocytes and T cells under homeostatic and inflammatory conditions. 
Conversely, other molecules such as CCL15 and VEGF were secreted specifically 
BM MSCs under inflammatory stimulation, potentially suggesting that not all 
behaviours of MSCs are universal and that tissue origin could impact in vivo MSC 
behaviour.  
 
 CXC Chemokines present in MSC conditioned Medium 5.3.2
CXC chemokines were assayed in the same way as discussed above. Results are 
graphed similarly- BM and UC values have to be interpreted with caution. Due to 
substantial upregulation of CXC chemokines, some graphs have a log 10 Y-axis in 
order to visualise all the data clearly. Due to large donor variation, significant 
findings were minimal. 
The secretion of CXCL1 under homeostatic conditions was specific to UC MSCs 
and up to 16 fold differences were observed in CXCL1 secretion between MSC 
populations (Figure 5-5 A). Under inflammatory stimulation, all MSC populations 
upregulated their secretion of CXCL1, where Ad MSCs significantly upregulated 
CXCL1 305 fold (P=0.0327), resulting in Ad MSCs secreting the most CXCL1, 2 fold 
higher than BM MSCs which secreted the least CXCL1. 
Like CXCL1, CXCL5 is a strong neutrophil chemoattractant. CXCL5 was not 
secreted above background levels by any MSC populations when they were 
homeostatically maintained (Figure 5-5 B). Under inflammatory stimulation, UC 
MSCs upregulated CXCL5 secretion 52 fold, Is MSCs 34 fold, BM MSCs 16 fold, Va 
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10 fold and Ad MSCs 7 fold. Although no significant differences were observed, 
CXCL5 secretion was affected by the tissue origin of MSCs where UC MSCs 
secreted 27 fold higher quantities than Is MSCs under inflammatory conditions. 
This could suggest that UC MSCs might induce the migration of higher quantities 
of neutrophils in comparison to Is MSCs.  
Similar to CXCL1, UC MSCs did not need any prior stimulation to secrete CXCL6, 
this was secreted when they were maintained homeostatically. Ad MSCs also 
secreted CXCL6 under homeostatic conditions, resulting in CXCL6 secretion being 
specific to these tissue sources (Figure 5-5 C). Under inflammatory stimulation, 
MSCs from all sources substantially upregulated CXCL6 secretion, where BM MSCs 
upregulated CXCL6 secretion 181 fold, Va MSCs 34 fold, Is MSCs 20 fold, UC MSCs 
14 fold and Ad MSCs significantly (P=0.0391) upregulated CXCL6 secretion 6 fold. 
Large variations in CXCL6 secretion were observed between Ad and Is MSCs, 
where Ad MSCs secreted 2.7 fold higher volumes of CXCL6 under inflammatory 
conditions than Is MSCs. 
CXCL8 is a strong neutrophil chemoattractant. Strikingly, it was secreted at 
substantial levels by all MSCs above background under homeostatic conditions. 
Ad MSCs secreted the largest amounts of CXCL8, 16 fold higher than Va MSCs 
which secreted the lowest amount of CXCL8 during homeostasis (Figure 5-5 D). 
When MSCs were maintained under inflammatory conditions, CXCL8 secretion 
was markedly enhanced by all MSCs, however, only reaching significance in BM 
(P=0.0062) and UC MSC (P=0.0034) populations. The consistent levels of 
secretion of CXCL8 by all MSC populations, irrespective of tissue origin suggests 
that CXCL8 plays a central and universal role in MSC function perhaps by 
attracting neutrophils.  
CXCL9, 10 and 11 are strong T cell chemoattractants and were not secreted by 
any MSC populations when they were maintained in homeostatic conditions 
(Figure 5-5 E, G and F). Not surprisingly, the secretion of these IFN-ϒ activated 
genes – CXCL9, 10 and 11 – was increased by all populations of MSCs following 
inflammatory stimulation, therefore suggesting that this is a mechanism MSCs 
use in inflammatory environments to perpetuate the inflammatory response, 
perhaps by attracting T cells and/or NK cells which bear the cognate receptor – 
CXCR3- to these chemokines.  
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Other CXC chemokines which were not produced by any MSC in either 
homeostatic or inflammatory conditions are graphed in Figure 5-5 and include 
CXCL12 (H), CXCL14 (I) and CXCL16 (J).  
 
Figure 5-5 Luminex analytes of CXC chemokines 
As before- 
P3 MSCs at 80% confluence were washed with warmed PBS before the addition of culture medium 
alone or culture medium + inflammatory cytokines (10ng/mL of TNF-α, IL-1β and IFN-ϒ). Cells 
were left for 24 hours before conditioned medium was collected, diluted 1 in 2 and added to the 
LUMINEX plates. Results are graphed as pg/mL. Black bar represents the background volumes 
of chemokine present in human AB pooled plasma within the medium. Each aliquot of pooled 
plasma consisted of 7-9 plasma donors, therefore each black bar represents 21-27 donors. Red 
boxes outline analytes where UC and BM values have been generated from a dilution factor and 
therefore are not directly comparable to Is, Va and Ad MSCs.  
Each bar represents an n of 3 ± SEM. ONE WAY ANOVA with Tukey’s post test analysis was 
carried out when comparing Is, Va and Ad MSCs *=P<0.05, **=P<0.001, ***=P<0.0001. Students 
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paired T test was used to asses statistical differences between homeostatic and inflammatory 
conditions within one MSC source, P values are stated in the text throughout. Significance is 
marked on the graphs where applicable and P values are stated in the text throughout. 
 
To summarise, CXC chemokine secretion by MSCs was differentially affected 
depending on MSC tissue source and inflammatory stimulation. During 
homeostatic conditions CXCL8 was the highest secreted CXC chemokine by Is, 
Va, Ad and BM MSCs, whereas UC MSCs secreted more CXCL1 than any other CXC 
chemokine assayed. After inflammatory stimulation, Is, Va and Ad MSCs secreted 
the largest amounts of CXCL1 compared to all other CXC chemokines, whereas 
UC and BM MSCs secreted the largest amounts of CXCL5 and CXCL8, respectively. 
This specific CXC chemokine secretion profile of all MSCs is surprising as this 
would suggest that all MSCs would specifically attract large numbers of 
neutrophils.  
To review, chemokine secretion by all MSC populations, among the CC 
chemokine family, monocyte (CCL2) and T cell (CCL20) chemoattractants were 
secreted with little variability between MSC populations. A specific signature of 
CXC chemokines was differentially secreted by MSCs depending on MSC tissue 
origin, where UC MSCs appeared to secrete the majority of neutrophil 
chemoattractans without prior stimulation, however CXCL8, was secreted by all 
MSC populations when homeostatically maintained. Inflammatory stimulation 
resulted in all neutrophil chemoattractants (CXCL1, 5, 6 and 8) and T and NK cell 
chemoattractants (CXCL9, 10 and 11) being secreted by all MSC populations. This 
specific chemokine secretion profile of MSCs isolated from all sources suggests 
that MSCs would specifically attract monocytes and neutrophils under 
homeostatic conditions. The chemoattraction of NK and T cells would only be 
induced after inflammatory stimulation. Importantly CCL2 and the CXC 
chemokines may also be involved in angiogenesis, which could provide reason for 
the secretion of these molecules by MSCs. Additionally, the chemoattraction of 
monocytes, macrophages and neutrophils (and perhaps T cells and NK cells under 
inflammatory stimulation) appear to be a universal MSC in vivo function. 
Understanding if MSCs attract immune cells and, if there is any differential 
chemoattraction of these immune cells, would provide greater insight into the 
potential in vivo behaviours of MSCs. 
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 Characterising the immune cell attraction profiles of 5.4
MSCs 
 Optimisation of the transwell assays 5.4.1
To assess if the chemokines secreted by MSCs were functional and attracted the 
relevant immune cells, transwell assays were carried out to evaluate the ability 
of MSCs to attract white blood cells through a 5μm pore membrane. Before 
commencing transwell experiments, the assay was optimised to establish the 
ideal experimental procedure, which included ensuring that white blood cell 
separation was satisfactory, ensuring pore size of the transwell allowed 
migration of all immune cells and testing to see if MSC conditioned medium 
could be used as a substitute to MSCs in order to store samples and assay them 
through the same experimental time period.  
To ensure that no major populations of white blood cells (WBCs) were excluded 
after the white blood cell isolation technique (Section 2.5.1), flow cytometry 
was used to assess the cell populations present in 1x106 WBCs via SSC and FSC 
(Figure 5-6 A). Distinct lymphocyte (red box), monocyte (yellow box) and 
granulocyte (orange box) populations were present after the cell separation, 
indicating that this method of cell separation was suitable. Following this, it was 
important to establish an appropriate cell number to place on the top of the 
transwell insert that would include all white blood cell types identified in Figure 
5-6 A and not clog the membrane. 5.5x105 whole white blood cells (input 
population) were assessed via flow cytometry to ensure the presence of 
lymphocyte, granulocyte and monocyte portions and highlighted that the 
reduced number of start WBCs still represented the main WBC populations 
(Figure 5-6 B). Additionally, the ability of WBCs to migrate through the 
membrane towards MSCs was assessed, under homeostatic vs inflammatory 
conditions, to understand if 5.5x105 cells allowed for the free migration of cells 
through the pores without clogging. In homeostatic conditions, all fractions of 
white blood cells migrated through the pores towards MSCs (Figure 5-6 C). 
However, under inflammatory stimulation, the monocyte population failed to 
migrate freely through the pores (Figure 5-6 D- yellow box), likely due to these 
cells becoming activated, resulting in increased adherence to the top of the 
transwell rather than migration through the pores.  
166 
 
Due to inflammatory cytokines remaining in the conditioned medium, 
investigating whether these cytokines (as opposed to the chemokines produced 
by MSCs) were affecting WBCs migration was important. To test this, the 
protocol for inflammatory stimulation was altered and compared. Prior to the 
protocol alteration, MSCs were washed with PBS and then left in 500uL of normal 
medium or 500uL of medium + 10ng/mL IL-1β, TNF-α and IFN-ϒ for 24 hours. 
Protocol alteration required the removal of the inflammatory cytokines from the 
MSC medium. Therefore, MSCs + control wells (no MSCs) were left in normal 
medium or inflammatory medium for 24 hours. After 24 hours, all conditioned 
medium was removed and MSCs + control wells were washed thoroughly with 
warmed PBS. Fresh medium was added and MSCs + controls were left for a 
further 24 hours prior to the addition of WBCs on top of the insert. 5.5x105 WBCs 
were then placed on the insert above and left for 3 hours to migrate through to 
the bottom wells. Lymphocytes, monocytes and granulocytes were able to freely 
migrate under both homeostatic (Figure 5-6 E) and inflammatory conditions 
(Figure 5-6 F). The increased numbers of migrating monocytes observed in the 
new protocol (inflammatory cytokines removed) (Figure 5-6 F) compared to the 
old protocol (inflammatory cytokines present) (Figure 5-6 D) suggests that the 
presence of inflammatory cytokines within the CM was causing monocytes to 
adhere to the upper chamber. Therefore, in all transwell experiments, 
inflammatory cytokines were removed from MSC conditioned medium to allow 
the migration of monocytes towards MSCs.  
To compare the effectiveness of conditioned medium alone to MSCs grown on 
the bottom of the transwells, the total number of WBCs migrating towards MSC 
conditioned medium (without MSCs) under homeostatic and inflammatory 
conditions was compared to the total number of WBCs migrating towards 
conditioned medium + MSCs under homeostatic and inflammatory conditions 
(Figure 5-6 G). These were then compared to background migration of WBCs. 
Background migration of WBCs was measured by recording the number of WBCs 
which migrated (or fell) through the pores towards plastic (graphed as grey 
bars). Additionally, to account for any residual cytokines that might be adhering 
to the plastic wells, an inflammatory background control was set up to measure 
the number of WBCs which had migrated (or fallen) through the plastic  towards 
wells that had been treated the same way as MSCs under inflammatory 
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conditions (10ng/mL of TNF-alpha, IL-1beta and IFN-gamma in MSC medium for 
24 hours, washed with PBS and fresh non-stimulatory MSC medium added for 24 
hours) (Figure 5-6 G). 
In homeostatic conditions, MSCs grown on the bottom of the wells attracted 
WBCs above background migration levels, whereas MSC conditioned medium 
attracted fewer WBCs than background migration. Under inflammatory 
stimulation, MSCs grown on the bottom of the well and stimulated CM attracted 
WBCs above background stimulation controls. Importantly, the presence of MSCs 
appeared to have a stronger chemotactic effect than MSC conditioned medium 
alone as demonstrated through the larger WBC counts. Moreover, the 
stimulatory control well also attracted marginally more WBCs than the medium 
alone control, demonstrating that residual cytokines were adhering to the 
plastic, therefore confirming that this is an appropriate and essential control.  
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Figure 5-6 Optimisation of transwell assays using flow cytometry 
To ensure that the transwell protocol was optimal before commencing all transwells, the white 
blood cell purification step was assessed via flow cytometry. SSC and FSC were used to ensure 
that all white blood cell populations were present – lymphocytes (red box), monocytes (yellow box) 
and granulocytes (orange box) (A). 5.5x105 WBCs were assessed for their WBC composition (B), 
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and their ability to migrate through the 5μm pores under homeostatic (C) and inflammatory (D) 
conditions. To avoid leftover inflammatory cytokines in the conditioned medium of MSCs affecting 
WBC migration, MSCs were either left under homeostatic conditions for 24 hours (E) or stimulated 
with 10ng/mL of IFN-ϒ, TNF-α and IL-1β for 24 hours (F), medium removed and MSCs washed 
with PBS and left for a further 24 hours in normal MSC medium before 5.5x105 WBCs were added 
to the top of the insert. To compare the chemoattraction ability of Is MSCs grown on the bottom of 
the well to Is MSC CM, the total number of WBCs migrated towards Is MSCs (dark blue), Is MSC 
CM (light blue) and background migration under homeostatic (grey bars) or inflammatory (checked 
bars) conditions were counted (G).  
 
To summarise, flow cytometry results from the white blood cell purification 
demonstrated that the isolation process was sufficient to allow assessment of 
the migration of all immune cells towards MSCs. Moreover, slight alteration of 
the stimulation protocol, and the use of 5.5x105 WBCs, allowed for migration of 
lymphocytes, monocytes and granulocytes through the membrane without any 
major evidence of clogging. Lastly, the comparison of the total numbers of WBCs 
migrating through the membranes towards conditioned medium alone or MSCs in 
conditioned medium under homeostatic and inflammatory conditions, 
highlighted that the presence of MSCs had a larger chemotactic effect on WBCs. 
Therefore, for the following transwell experiments, MSCs were grown on the 
bottom of the transwells, stimulated or left in homeostatic conditions for 24 
hours, washed and replenished with medium alone for 24 hours. 5.5x105 WBCs 
were placed on top of the 5μm pores and incubated for 3 hours. A full outline of 
methods is provided in Section 2.5 
 Flow cytometry gating strategies for transwell assays 5.4.2
To assess the immune cell attraction profile of MSCs, WBCs which had migrated 
through the membrane towards MSCs or plastic (controls) were collected and 
assessed via flow cytometry with the following markers; CD4, CD8, CD19, CD1c, 
CD56, Siglec 8, CD14, CD16, HLA-DR and CD66b. Additionally, due to the 
observation of WBCs sticking to MSCs (Figure 5-7 A-D), the adherent WBCs and 
MSCs were removed using TryplE and stained with a different panel of 
antibodies; CD4, CD8, CD14, CD16 and CD45. A simpler panel was used here as 
adherent cell numbers were minimal and it was important to generate a clear 
phenotype of immune cells interacting with MSCs whilst avoiding cell loss in 
assay set-up.  
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Figure 5-7 WBCs adhering to MSCs post-transwell 
MSCs were grown in a monolayer at the bottom of the transwell. 5.5x105 WBCs were added and 
allowed to migrate for 3 hours. Migrated WBCs were pipetted off and MSCs were washed with 
warmed PBS. WBCs adhering to MSCs in unstimulated (A-B) and stimulated (C-D) conditions were 
observed using a phase-light microscope. Black arrows point to adherent WBCs.  
 
Several gating strategies were used to identify T cells, B cells, NK cells, 
neutrophils, eosinophils, monocytes and dendritic cells present in the 
supernatant in the bottom well (Figure 5-8 A-G). To ensure all cells analysed 
were live with doublets excluded, all leukocytes were positively gated and 
doublets excluded using a tight gate around the cells present in the FSC-H, FSC-A 
channels. From here, cells negative for live/dead stain were gated (Figure 5-8 
A). This population of cells was then further analysed for its immune cell 
composition. To identify T cells (CD4+ and CD8+), a gate was drawn around 
CD4/8+ cells, being careful to exclude debris (FSC<50K). From here, FSC-A and 
SSC-A were used to ensure that T cells were of correct size and granularity 
(Figure 5-8 B). To identify B cells, live CD19 + cells were gated on, debris 
excluded (FSC<50K) and FSC-A and SSC-A were used to ensure cells were of 
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correct size and granularity (Figure 5-8 C). To identify NK cells, CD56+ cells 
were gated on and FSC-A, SSC-A were used to ensure cells were of correct size 
and granularity (Figure 5-8 D). To identify neutrophils and eosinophils, CD66b+ 
granulocytes were gated on, siglec 8+ cells were considered eosinophils and 
siglec 8 –ve cells were considered neutrophils (Figure 5-8 E). To identify DCs, 
CD19-ve cells were gated upon to exclude any potential CD1c+ B cells. CD1c+ 
cells were selected and CD16+ CD14-ve to intermediate cells were gated on 
(Figure 5-8 F). These cells were considered DCs. To assess the monocyte 
composition within the supernatant, CD66b-ve cells were gated upon to exclude 
granulocytes, CD19 –ve cells were selected to exclude any CD16+ B cells. Cells of 
correct size and granularity were gated on and classical (CD16lowCD14++), 
intermediate (CD16+CD14++) or non-classical (CD16++CD14+) (Figure 5-8 G) 
populations of monocytes were defined.  
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Figure 5-8 Gating strategies of migrated WBCs using flow cytometry 
Flow cytometry was used to analyse the cells migrating through the transwells (A-G). Initial steps 
included gating on all leukocytes, with doublets excluded and live cells selected (A). From there, a 
specific gating strategy was used (detailed throughout the text) to isolate T cells (B), B cells (C), 
CD 56+ NK cells (D), eosinophils and neutrophils (E), DCs (F) and classical, intermediate and non-
classical monocytes (G).  
 
For the analysis of immune cells stuck to MSCs or plastic (controls) on the 
bottom of the wells, slightly different gating strategies were used to identify 
CD4 T cells, C8 T cells and monocytes.   
The same gating strategy as above was used to isolate live cells (Figure 5-9 A-
C). From here, CD45+ cells were selected to ensure the exclusion of MSCs 
(Figure 5-9 D).  To assess monocytes, CD14 and CD16 were used to identify 
Classical (CD16low CD14++), intermediate (CD16+CD14++) or non-classical 
(CD16++CD14+) monocytes (Figure 5-9 E). CD4 was used to assess CD4 T cells 
and CD8 was used to assess CD8 T cells (Figure 5-9 F).  
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Figure 5-9 Gating strategy of migrated WBCs adhered to MSCs using flow cytometry 
Using flow cytometry, cells of correct size and granularity were selected (A), doublets were 
excluded (B) and live cells were gated on (C). To ensure that MSCs were excluded from the 
analysis, CD45+ve cells were gated on (D). From here, monocytes were assessed by their 
expression of CD16 and CD14 – non-classical CD16++CD14+) in the green box, intermediates 
(CD16+CD14++) in the pink box and classical (CD16low CD14++) in the orange box (E). T cells 
were assessed via their expression of CD4 and CD8 (F).  
 
To ensure that the gating strategies described above were accurate, the immune 
cell composition of the “input population” (5.5x10^5) was assessed (Figure 
5-10). The composition of the leukocytes is graphed as percentages, with T cells 
making up 42.39% (± 4.81%) of the population, B cells making up 4.65% (± 1.50%), 
neutrophils making up 39.51% (± 6.55%), eosinophils making up 5.87% (±5.46%), 
NK cells making up 3.27% (± 0.72%), DCs making up 1.13% (± 0.38%) and 
monocytes making up 3.19% (± 0.63%) (Classical monocytes CD16low CD14++ = 
2.04% (± 0.63%), Intermediate monocytes CD16+ CD14++ = 0.36% (±0.16%), Non-
Classical monocytes = 0.78% (±0.16%)) of the WBC input population.  
177 
 
 
Figure 5-10 Assessment of the composition of the transwell input population 
To ensure that the aforementioned gating strategies (Figure 5-8) were correct, the input 
populations (5.5x105) were assessed for their composition of WBCs and graphed as percentage. 
Graph ordering from the bottom; T cells (~ 42.39%-Blue), B cells (~ 4.65% -Red), Neutrophils (~ 
39.51%-yellow), Eosinophils (~5.87% - orange), NK cells (~3.26%- green), DCs (~ 1.13% - purple), 
monocytes (~3.19% - light blue). N=6.  
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 Analysis of leukocytes migrating towards MSCs in the 5.4.3
transwell assays  
Having established suitable gating strategies, analysis of migrated leukocytes 
towards MSCs was carried out using the same approaches. UC MSCs were not 
tested.  
The total cell number of WBCs migrating towards MSCs and control wells are 
graphed in Figure 5-11 A. Details on how the total cell numbers were 
enumerated are outlined in Section 2.4.3.5. Is MSCs attracted the most white 
blood cells out of Va, Ad and BM MSCs under homeostatic and inflammatory 
conditions. During homeostatic conditions, interestingly only Is MSCs attracted 
significantly more WBCs (P=0.00366) above background controls, whereas Va 
MSCs attracted substantially more. In contrast, Ad and BM MSCs attracted fewer 
white blood cells than homeostatic background migration controls. Under 
inflammatory stimulation, all MSC populations induced the migration of immune 
cells above background inflammatory controls, where Is MSCs and Va MSCs 
attracted significantly more (Is P=0.00138, Va P=0.0285) WBCs, and Ad and BM 
MSCs attracted substantially more WBCs than inflammatory background controls.  
Perhaps not surprisingly due to the extensive secretion of neutrophil 
chemoattractants by MSCs, the predominant WBC present in the migrated 
immune cell population was the neutrophil (CD 66b+, Siglec 8 –ve cells) (Figure 
5-11 B). Although not significant, Is MSCs attracted the most neutrophils out of 
all MSC populations under homeostatic and inflammatory conditions, highlighting 
that MSCs isolated from different tissues display differential behaviour in vitro. 
Under homeostatic conditions, Is and (arguably) Va MSCs were the only MSC 
populations to attract neutrophils at substantial levels above background, 
whereas Ad and BM MSCs attracted slightly less than background controls. Under 
inflammatory stimulation, neutrophil migration towards all MSCs was enhanced 
compared to homeostatic conditions, with all MSCs attracting more neutrophils 
than inflammatory background controls.  
Similarly, fitting with the observation that Is MSCs were one of the top CCL2 
secretors, they also attracted the largest numbers of monocytes (Figure 5-11 H, 
I and J). Classical monocytes (CD16low CD14++) play important roles in 
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scavenging dead cells and debris during inflammation. Under homeostatic 
conditions, classical monocytes specifically migrated towards Is MSCs only 
(Figure 5-11 H). Is MSCs attracted significantly more classical monocytes than 
Va MSCs (P<0.05), Ad MSCs (P<0.05) and BM MSCs (P<0.05). This specific classical 
monocyte chemoattraction by Is MSCs was maintained under inflammatory 
conditions where Is MSCs attracted significantly more MSCs than Va (P<0.05) and 
Ad MSCs (P<0.05). BM MSCs also attracted a large proportion of classical 
monocytes under inflammatory conditions. Conversely, all MSCs tested did not 
induce substantial levels of intermediate (CD16+ CD14++) or non-classical 
(CD16++ CD14+) monocyte chemotaxis above background migration controls 
(Figure 5-11 I & J). Arguably, it could be suggested that Va MSCs showed a 
preferential attraction of intermediate and non-classical monocytes in 
comparison to other MSC populations. This preferential attraction of cells 
towards Va MSCs remained true for eosinophils when MSCs were homeostatically 
maintained, however all other populations of MSCs did not attract eosinophils 
under homeostatic or inflammatory conditions (Figure 5-11 G). Consistently, 
small numbers of NK cells (Figure 5-11 C), T cells (Figure 5-11 D), DCs (Figure 
5-11 E), and B cells (Figure 5-11 F) specifically migrated towards Va MSCs only 
under both homeostatic and inflammatory conditions, whereas all other MSC 
populations did not induce migration of these cells above background control 
levels. 
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Figure 5-11 Flow cytometry analysis of the number of immune cells migrating towards Is, 
Va, Ad, BM or plastic under homeostatic or inflammatory conditions. 
WBCs were allowed to migrate in a transwell assay, through 5μm pores, for 3 hours towards Is 
MSCs (blue), Va MSCs (Green), Ad MSCs (red), BM MSCs (yellow) and plastic (Grey - 
background). MSCs and background controls had either been left under homeostatic conditions 
(coloured bars) or pre-inflamed with 10ng/mL of IFN-ϒ, TNF-α and IL-1β (Coloured, checked bars). 
Using the gating strategies in Figure 5-8, the total number of CD45+ (A), neutrophils (B), NK cells 
(C), T cells (D), DCs(E), B cells (F), eosinophils (G), classical monocytes (H), intermediate 
monosytes (I) non-classical monocytes (J) migrating towards MSCs or plastic were counted and 
graphed as above. Is MSCs: n=3, Va MSCs: n=3, Ad MSCs: n=3, BM MSCs: n=3. Background 
controls show the background migration of all transwell assays combined - total number of blood 
donors: n=6. Statistical analysis: Students T test was used when comparing MSCs from one 
source (unstim vs stim) and when comparing one source of MSC to background migration in 
unstimulated or stimulated conditions (P values stated throughout text). ONE WAY ANOVA with 
Tukey’s post-test was used to assess statistical differences in immune cell migration towards 
MSCs from different sources (*=P<0.05, **=P<0.001, ***=P<0.0001). 
 
Due to the adherence of WBCs to MSCs after transwell migration (Figure 5-7), 
cells were lifted from the plastic using TrypLE and analysed for the presence of 
monocytes and T cells. To account for background adherence to the plastic, cells 
that had adhered to the plastic in background controls were also included in the 
dataset (Figure 5-12).  
During homeostatic conditions, the number of CD45+ve cells adhering to all 
populations of MSCs did not exceed the number of CD45+ve cells adhering to 
plastic in control wells (Figure 5-12 A). Inflammatory stimulation resulted in an 
upregulation of CD45+ cells adhering to MSCs from all tissue sources, which was 
above inflammatory background adherence controls in all MSC samples. This 
could suggest that under inflammatory conditions, MSCs were maintaining a 
specific interaction with immune cells. Through an unknown mechanism, it 
appears that Va MSCs are more efficient at mediating interactions with CD45+ve 
immune cells than other MSC populations as they showed substantially higher 
CD45+ve adherence than other MSC populations (4 fold higher than Is MSCs, 11 
fold higher than Ad MSCs, 14 fold higher than BM MSCs and 33 fold higher than 
background controls) (Figure 5-12 A).  
Under homeostatic conditions, classical monocytes (CD16low CD14++), specifically 
adhered to BM MSCs which was 40 fold higher than classical monocyte adherence 
to background controls (Figure 5-12 B). Inflammatory stimulation resulted in an 
increase of classical monocytes sticking to MSCs from all sources above 
background controls, with the exception of Ad MSCs. Similar to homeostatic 
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conditions, BM MSCs had the highest number of classical monocytes adhered to 
them compared to Is, Va and Ad MSCs. 
Intermediate monocytes did not consistently adhere to any population of MSC 
above background levels under either homeostatic or inflammatory conditions 
(Figure 5-12 C). Similarly, under homeostatic conditions, non-classical MSCs did 
not adhere to any MSC populations above background controls (Figure 5-12 D). 
Inflammatory stimulation resulted in a significant upregulation of non-classical 
monocytes adhering to Is (P=0.0342) and Ad MSCs (P=0.0117), however, Is 
derived MSCs were the only tissue source to consistently facilitate significantly 
more adhesion of non-classical monocytes to their surface above background 
controls (P=0.0288). 
CD8 T cells (Figure 5-12 E) and CD 4 T cells (Figure 5-12 F) did not adhere to 
MSC populations in great numbers above background controls, suggesting that 
MSCs might not specifically interact with these cells.  
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Figure 5-12 Flow cytometry analysis of the number of immune cells migrating towards, and 
adhering to, Is, Va, Ad, and BM MSCs or plastic under homeostatic or inflammatory 
conditions. 
WBCs were allowed to migrate in a transwell assay, through 5μm pores, for 3 hours towards Is 
MSCs (blue), Va MSCs (Green), Ad MSCs (red), BM MSCs (yellow) and plastic (Grey - 
background). MSCs and background controls had either been left in homeostatic conditions 
(coloured bars) or pre-inflamed with 10ng/mL of IFN-ϒ, TNF-α and IL-1β (coloured, checked bars). 
MSCs were washed and leftover adherent WBCs and MSCs were detached and analysed via flow 
cytometry (A-F) 
 Using the gating strategies in Figure 5-9, the total number of CD45+ (A), Classical monocytes (B), 
intermediate monocytes (C), non-Classical monocytes (D), CD8 (E) and CD4 (F) adhering to MSCs 
or plastic were counted and graphed as above. Is MSCs: n=3, Va MSCs: n=3, Ad MSCs: n=3, BM 
MSCs: n=2. Background controls show the background adherence to plastic of all transwell assays 
combined - total number of blood donors: n=6. Students T test was used when comparing MSCs 
from one source (unstim vs stim) and when comparing one source of MSC to background migration 
in unstimulated or stimulated conditions (P values stated throughout text). ONE WAY ANOVA with 
Tukey’s post-test was used to assess statistical differences in immune cell migration towards 
MSCs from different sources (*=P<0.05, **=P<0.001, ***=P<0.0001). 
 
To summarise, Is MSCs attracted the most WBCs cells under both homeostatic 
and inflammatory conditions. The majority of cells migrating towards MSCs and 
plastic (background controls) were neutrophils. The total number of each WBC 
attracted to each MSC population and background is plotted in ‘stack bars’ to 
visualise if a particular tissue source of MSC preferentially attracted a specific 
immune cell Figure 5-13. The graph illustrates preferential attraction of 
classical monocytes by Is MSCs under homeostatic and inflammatory conditions, 
and eosinophils by Va MSCs under homeostatic conditions. Ad and BM MSCs show 
a similar composition of migrated WBCs to background controls.  
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Figure 5-13 Summary of transwell Data 
The same data graphed in Figure 5-11 is represented in a stack bar graph to summarise transwell 
assays and allow for easier visualisation of the immune cell attraction profile of Is, Va, Ad and BM 
MSCs.  
 Discussion 5.5
The aim of this chapter was to examine if genes of interest identified in the 
previous chapter were transcribed into protein. Additionally, through the use of 
standardised isolation procedures and experiments, this chapter aimed to 
objectively compare the chemokine and chemokine receptor expression at a 
protein level by MSCs isolated from the Is, Va, Ad, BM and UC under homeostatic 
and inflammatory conditions. Lastly, this chapter aimed to assess and compare 
the functionality of Is, Va, Ad and BM MSC secreted chemokines under 
homeostatic and inflammatory conditions. This discussion will combine the 
findings in the previous chapter (transcript expression of chemokines and their 
receptors by Is, Va, Ad, BM and UC under homeostatic and inflammatory 
conditions), and the current chapter. The discussion will focus predominantly on 
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the differences of chemokine and chemokine receptor expression between MSC 
sources and what this might mean in a clinical setting.  To keep this discussion 
focussed, differences observed between MSC chemokine and receptor 
transcriptional expression vs. protein expression will not be addressed as the 
reasons for these variabilities could be manifold. 
 Chemokine receptor expression by MSCs 5.5.1
The use of MSCs for cell therapy somewhat relies on these cells homing and 
engrafting/persisting within the target tissue(s). Despite the exact mechanisms 
behind MSC homing and engraftment being poorly understood, they are 
presumed to involve chemokine receptors, along with other molecules such as 
integrins (244, 256, 257). 
No significant differences were observed in the transcription of CC and CXC 
receptors by MSCs isolated from Is, Va, Ad, BM and UC MSCs under homeostatic 
or inflammatory conditions Section 4.3.1 and Section 4.3.2). This could be due 
to low transcription levels of the receptors by all populations of MSCs, therefore 
resulting in higher variability of the results. This observation fits with the 
literature as low chemokine receptor transcripts have been reported for MSCs 
(258), however , it has been shown that this does not impact surface chemokine 
receptor expression (259). Here we found low to moderate transcription of 
CCR7, CCR10, CXCR2, CXCR3, CXCR4, CXCR6, ACKR3 and ACKR4 on MSCs isolated 
from all sources under homeostatic and inflammatory conditions, and tested 
CCR7, CCR10, CXCR4, CXCR6, ACKR3 and ACKR4 at a protein level. Surface 
expression of these molecules on MSCs could result in MSCs migrating towards 
the lymph node (CCR7), skin (CCR10), bone marrow / lung (CXCR4) and 
potentially the liver (CXCR6). ACKR3 and ACKR4 are atypical chemokine 
receptors which play a regulatory role by scavenging the chemokines CXCL11, 
CXCL12 (ACKR3) and CCL19, CCL21 and CCL25 (ACKR4) from the surrounding 
environment. The current study found very little to no surface expression of 
CCR10 and CXCR6 on the surface of all tested MSCs which largely contradicts a 
large body of literature describing the presence of CCR10 and CXCR6 on Ad and 
BM MSCs (151, 242, 247, 260, 261) (262). The discrepancies between these 
observations and the current study could range from different culture 
conditions, to varied methods of chemokine receptor detection and importantly, 
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the notoriously poor quality of chemokine receptor antibody staining. It is also 
worth noting that, although little to no surface staining was observed for 
chemokine receptors, this is a common phenomenon reported in the MSC 
literature, however chemokine receptors still appear to be present and 
functional when tested in migration assays (263).  
Due to the way this study was conducted, what can be concluded is that when Is, 
Va, Ad, BM and UC MSCS are objectively compared using standardised 
techniques, CCR7, CXCR4 and ACKR3 expression was specific to Va and BM 
derived MSCs. This suggests that chemokine receptor expression by MSCs relates 
to MSC tissue origin. To add another layer of complexity, inflammatory 
stimulation only appeared to significantly affect CXCR4 expression on BM MSCs, 
again suggesting a tissue specific response to inflammatory stimulation, which 
affects chemokine receptor expression. This has implications when one considers 
using MSCs in the clinic, where high levels of MSC CXCR4 expression would be 
desirable for hematopoietic stem cell transplantation for the enhancement of 
hematopoietic engraftment or treatment/prevention of graft versus host disease 
and therefore Va and BM MSCs might prove to be the preferential tissue for MSC 
isolation for use within this setting (264-266). Moreover, the highest levels of 
CXCR4 were observed on BM MSCs under inflammatory stimulation, perhaps 
providing a premise to pre-treat MSCs before infusion into patients to improve 
BM MSC homing with hope of ultimately improving clinical outcome. Similarly, 
enhanced expression of CCR7 by BM and Va MSCs could increase the lymph node 
homing of these MSCs in comparison with other tissue sources of MSCs which 
would intensify their in vivo immunomodulatory effects through their superior 
migration to SLO and interaction with T cells (267, 268), potentially having a 
beneficial impact on the prevention of GVHD.  
In contrast to conventional signalling receptors, literature on MSC ACKR3 and 
ACKR4 expression are minimal, making it hard to evaluate the clinical relevance 
of MSC expression of these molecules, however it suggests that MSCs play a role 
in regulating the availability of CXCL11, CXCL12 (ACKR3) and CCL19, CCL21 and 
CCL25 (ACKR4).  
Overall, chemokine receptor transcripts in all MSC populations were low and no 
significant differences between MSC populations were observed. No surface 
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expression of CCR10 and CXCR6 by any population of MSC tested were observed, 
implying that these populations of MSCs maintained in the specified conditions 
would not be desirable in clinical situations where skin (CCR10) and (potentially) 
liver (CXCR6) MSC homing/engraftment were important for clinical outcome. 
Importantly, moderate CCR7, CXCR4 and ACKR3 expression were specific to Va 
and BM MSCs, indicating that the tissue origin of MSCs affects the chemokine 
receptor expression and therefore potentially their in vivo migratory capacity. 
These data provide evidence to support further study into the expression and 
function of chemokine receptors by MSCs – in a standardised manner – as the 
tissue source of MSCs could impact MSC in vivo migratory capacity and thereby 
influence clinical outcome.   
  Chemokine secretion by MSCs 5.5.2
In vitro, constitutive secretion of a multitude of chemokines in the CC and CXC 
families by MSCs has been reported, including; CCL2, CCL3, CCL4, CCL5, CCL7, 
CCL20, CCL26, CXCL1, CXCL2, CXCL5, CXCL8, CXCL10, CXCL11, CXCL12 and 
CX3CL1, along with other non-chemokine related factors such as VEGF (269, 
270). However, there is a lack of data surrounding the comparison of chemokines 
secreted by MSCs isolated from different tissues and what this might mean in a 
clinical setting- the majority of studies focus on chemokine secretion by BM 
MSCs. From the chemokines cited above, target immune cells that could be 
attracted towards MSCs include; neutrophils, monocytes, eosinophils, basophils, 
T Cells, B cells, DCs and NK cells (271-273). Chemokine secretion could be 
considered a vital immunomodulatory effect of MSCs in vivo, as chemokines 
mediate interactions between MSCs and surrounding immune cells, however, it is 
important to add that the chemoattraction of immune cells might not always 
lead to MSC immunomodulation of these cells. Moreover, the types, combination 
and the effects of chemokines secreted by MSCs may vary depending on the 
specific microenvironment and surrounding immune cells.  
In the current study, chemokines that were transcribed and secreted at the 
highest levels by MSCs maintained under homeostatic conditions included; CCL2, 
CXCL1, CXCL5, CXCL6 and CXCL8. These chemokines are strong 
chemoattractants for monocytes and neutrophils, which were the predominant 
cell types to undergo chemotaxis towards MSCs in the transwell assays (68, 271, 
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274). Under inflammatory stimulation, MSCs from all tissue sources tested, 
upregulated the transcription and secretion the aforementioned chemokines, 
whilst also inducing the transcription and secretion of CCL20, CXCL9, CXCL10 
and CXCL11. Although these data present many interesting findings, for the 
purpose of this discussion, I will focus on the chemokines that were secreted at 
high levels (CCL2, CCL20, CXCL1, CXCL5, CXCL6, CXCL8, CXCL9, CXCL10 & 
CXCL11) by MSCs and the specific immune cells they attracted.  
CCL2 is produced by a variety of cell types including endothelial cells, 
fibroblasts, epithelial cells, smooth muscle cells, monocytes and macrophages 
(275-277).  It regulates the migration and infiltration of monocytes, memory T 
cells, NK cells (278, 279) and is implicated in multiple excessive inflammatory 
disorders including atherosclerosis and multiple sclerosis whilst also being a 
mediator of angiogenesis and neovascularisation (274, 280). Several reports 
document the homeostatic secretion of CCL2 by BM and Ad derived MSCs and 
discuss MSC secreted CCL2 effects (281, 282). However, to my knowledge, 
differential CCL2 transcription, secretion or subsequent monocyte 
chemoattraction by MSC isolated from various tissues has not been documented. 
Here I show that Is, Va and Ad MSCs transcribed (Section 4.3.1 Figure 4-9 A) and 
secreted (Figure 5-4 A) substantial levels of CCL2 when maintained under 
homeostatic conditions. Transcription and secretion of CCL2 was markedly 
upregulated after inflammatory stimulation by MSCs isolated from all tissue 
sources. Is MSCs secreted the most CCL2 under inflammatory stimulation, which 
is consistent with the observation that Is MSCs attracted the most monocytes 
under inflammatory conditions, whereas Va, Ad and BM MSCs secreted less CCL2 
and attracted fewer monocytes. Evidence suggests that MSCs secrete CCL2 to 
induce the migration of CCR2 positive inflammatory monocytes and drive 
monocyte differentiation towards a tumour associated macrophage phenotype, 
confirmed through inhibition of monocyte TNF secretion, and increased IL-10 
secretion (283), driving an ‘M2-like’ phenotype. Differences in the monocyte 
populations (Classical, intermediate or non-classical) are ascribed to their 
surface molecule phenotype, cytokine production, antigen uptake and antigen 
presentation, however, there is little consensus in the literature about these 
attributes. It is largely accepted that classical monocytes are rapidly recruited 
to sites of inflammation and phagocytose microorganisms and dying cells (284). 
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Intermediate monocytes are recruited at a later stage of inflammation and are 
involved in high secretion of pro-inflammatory cytokines and chemokines and 
wound healing (285, 286). Non-classical monocytes display a patrolling behaviour 
and are also involved in inflammation via TNF-alpha production (286). CD16 
expressing monocytes (intermediates and non-classical) have been implemented 
as proinflammatory cells, as they are rapidly expanded during inflammation 
(287). However, several reports contradict these findings and term classical 
monocytes as pro-inflammatory (288) and non-classical monocytes as pro-
angiogenic (289). Phenotyping of the migrated monocytes towards MSCs showed 
that the majority of monocytes attracted to Is, Ad and BM MSCs were classical 
monocytes under homeostatic and inflammatory conditions, whereas the 
majority of monocytes attracted to Va MSCs were non-classical monocytes, 
further suggesting that the tissue origin of MSCs could impact their in vivo 
behaviours.  As a result of the literature describing conflicting roles of the 
monocyte populations, which is likely due to their function being shaped by their 
surrounding environment, it is difficult to conclude whether the attraction of 
specific subsets of monocytes by a particular tissue source of MSC would be 
beneficial or detrimental in a clinical environment. Importantly, the attraction 
of monocytes is probably not only CCL2 dependent. Other chemokines identified 
in this study that could play a role in the differential MSC chemoattraction of 
monocytes include; CCL3 and CCL15 (290-292).  
With the exception of CCL2, the CXC chemokines were secreted at higher levels 
by all MSCs populations than other CC chemokines, this mirrors the transcript 
data, where the CXC chemokines were the highest transcribed chemokines by all 
tissue sources of MSCs (Figure 5-5). MSC secretion of CXCL1, 5, 6 and 8 has been 
reported for mouse and human MSCs (293) and differential secretion of CXCL1, 
CXCL2, and CXCL5 has been observed between human Ad and BM MSCs.  Here I 
report differential transcription and secretion of the neutrophil 
chemoattractants CXCL1, CXCL5, CXCL6 and CXCL8 by Is, Va, Ad, BM and UC 
MSCs. Under homeostatic conditions, CXCL1- involved in angiogenesis, 
arteriogenesis, tumorigenesis, wound healing and inflammation (7, 294)- was 
secreted in large amounts by UC MSCs only. Conversely, CXCL8 was secreted by 
all tissue sources of MSCs under homeostatic conditions, namely Is and Ad 
derived MSCs (295, 296). Interestingly the high levels of CXCL1, 5, 6 and 8 
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secretion by Is MSCs was mirrored by the specific chemoattraction of large 
numbers of neutrophils towards Is MSCs. Moreover, the MSC secretion of the 
aforementioned chemokines was upregulated following inflammatory 
stimulation, which was also associated with an influx in migrating neutrophils 
towards MSCs isolated from all tissue sources assayed – Is, Va, Ad and BM MSCs. 
The differences observed in MSC neutrophil chemoattraction abilities, where Is 
MSCs attracted substantially more than any other tissue source of MSC under 
homeostatic and inflammatory conditions, are difficult to interpret. Firstly, the 
chaotic redundancy within the chemokine family makes it impossible to easily 
understand the favoured/key neutrophil chemoattractancts involved in this 
process. Put simply, neutrophils bear CXCR1 and CXCR2 which together, bind a 
combination of all of the neutrophil chemoattractants listed above, ultimately 
resulting in neutrophil migration, thus making it nearly impossible to identify a 
single chemokine that is specific for the induction of neutrophil migration 
towards Is MSCs specifically. Secondly, given that Ad and BM MSCs secreted high 
levels of CXCL5 and CXCL8 under homeostatic conditions, which was not 
mirrored by neutrophil migration towards these populations of MSCs, it is also 
likely that, Is MSCs could specifically be secreting other un-assayed factors that 
enhance neutrophil migration. Alternatively, Ad and BM MSCs could secrete 
mediators such as Tumor necrosis factor inducible gene 6 (TGS-6) which has 
been shown to inhibit neutrophil migration in a similar transwell system by 
binding to CXCL8 and inhibiting its interaction with CXCR2 (297). 
CXCL9, 10 and 11 are structurally related chemokines that bind to CXCR3 and 
promote chemotaxis of T cells and NK cells. Generally, they are not secreted 
under physiological conditions but are strongly induced during injury or infection 
(298). CXCL9, 10 and 11 secretion by human and mouse BM MSCs has been 
documented (299, 300) where mouse BM MSCs CXCL9, 10 and 11 secretion was 
important in the attraction, and subsequent immunomodulation of T cells (301). 
Data surrounding CXCL9, 10 and 11 secretion by MSCs isolated from alternative 
tissue sources are minimal. In the current study, the results show differential 
transcription and secretion of CXCL9, 10 and 11. In accordance with the 
literature, these chemokines were not transcribed or secreted by MSCs under 
homeostatic conditions, however upon inflammatory stimulation, transcription 
and secretion of CXCL9, 10 and 11 were upregulated by all MSCs, where Va MSCs 
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secreted substantially more CXCL9 and 11 than Is, Ad, BM and UC MSCs. These 
data are somewhat confirmed by the enhanced chemoattraction of small 
numbers of NK, CD4 and CD8 T cells towards Va MSCs only. However it does not 
explain the absence of T cell migration towards Is, Ad and BM MSCs despite their 
secretion of CXCL9, 10 and 11. The low number of T cells migrating towards 
MSCs could be explained by the absence of activated T cells in the peripheral 
blood. In the transwell system, the majority of T cells would have been naïve T 
cells which bear the receptor CCR7 and not CXCR3 (302). These T cells would 
respond to CCL19 and CCL21. CCL19 was transcribed at very low levels and likely 
not secreted by MSCs (Section 4.3.1). Similarly, CCL21 was transcribed at very 
low levels by MSCs and was not secreted in large amounts (Figure 5-4). In fact, it 
appeared that Is MSCs were degrading CCL21, perhaps accounting for the lower 
number of T cells migrating towards Is MSCs than background controls. 
 Conclusions 5.6
To summarise and conclude, this chapter aimed to determine if MSCs expressed 
genes –identified in the previous chapter- that were differentially/highly 
expressed at a protein level. More specifically, MSCs were assessed for their 
surface expression of CCR7, CCR10, CXCR4, CXCR6, ACKR3 and ACKR4 under 
homeostatic and inflammatory conditions. Low surface expression of all 
receptors assessed by flow cytometry was observed -this could be due to poor 
antibody staining of receptors. Low surface expression of chemokine receptors 
could mean that MSCs are unlikely to migrate away from a graft site if they are 
directly delivered there. Importantly, stimulation with cytokines resulted in an 
upregulation of CXCR4 which could give reason to pre-treat MSCs with cytokines 
to upregulate receptors and improve MSC homing to target tissues. To truly 
understand differential receptor expression and functionality of receptors 
expressed by Is, Va, Ad, BM and UC MSCs, migration assays towards chemokines 
would have to be performed.  
Additionally this chapter aimed to assay chemokine secretion by Is, Va, Ad, BM 
and UC MSCs and to understand if tissue source of MSC resulted in differential 
chemokine secretion under homeostatic and inflammatory conditions. Similar to 
transcript data, MSCs were observed to produce large quantities of CCL2, CCL11, 
CCL20 and CXCL1, CXCL5, CXCL6, CXCL8, CXCL9, CXCL10 and CXCL11 at 
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differential levels depending on MSC tissue origin. Importantly, the secretion of 
these chemokines appeared to induce migration of target immune cells such as 
monocytes (CCL2) and neutrophils (CXCLs1,5,6 & 8) towards all MSCs, whereas 
migration of T cells and NK cells (CCL20, CXCL9,10 &11) was observed to a lesser 
extent. Interestingly, the substantial attraction of immune cells by Is MSCs under 
homeostatic and inflammatory conditions compared to Va, Ad and BM MSCs 
highlighted them as MSCs with potent and differential chemoattraction ability. 
This chapter clearly highlighted differential chamoattraction abilities of MSCs 
depending on their tissue origin and suggests that MSCs isolated from various 
tissues would act differentially in vivo. The chemoattraction of immune cells 
could be beneficial or detrimental in a clinical setting depending on the 
phenotype of the migrated immune cells and the interactions that MSCs have 
with them. Determining if MSCs exhibit the same immune cell attraction in vivo 
would be an important next step in understanding the potential behaviour of 
MSCs in vivo.  
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Chapter 6 Defining the immune cell attraction 
profile of islet derived MSCs in vivo 
 Introduction and aims 6.1
Results presented in the previous chapter showed that MSCs isolated from the 
islet (Is), visceral adipose (Va), adipose (Ad), bone marrow (BM) and umbilical 
cord (UC) expressed low levels of chemokine receptors on their surface. 
Additionally, Is, Va, Ad, BM and UC MSCs secreted CCL2, CCL20, CXCL1, CXCL5, 
CXCL6 and CXCL8 during homeostasis which induced chemotaxis of target cells 
(monocytes and neutrophils) in an in vitro transwell system (with the exception 
of UC MSCs which were not assessed in the transwell system). Inflammatory 
stimulation resulted in a substantial upregulation in the secretion of the 
aforementioned chemokines with additional secretion of CCL11, CXCL9, CXCL10 
and CXCL11 by Is, Va, Ad, BM and UC MSCs. This upregulation of chemokine 
secretion under inflammatory conditions was mirrored by an increase in 
monocyte (classical) and neutrophil migration towards all MSCs. Migration of NK 
cells, DCs, eosinophils, T cells and B cells towards MSCs was barely above 
background controls, despite MSC secretion of CCL11 (eosinophils), CXCL9, 10 
and 11 (NK cells, T cells). As inflammatory stimulation is considered a 
mechanism of MSC licensing whereby MSCs have to be stimulated with IFN-ϒ, 
TNF-α and IL-β to exert their anti-inflammatory effects (133, 303-305), the 
current study’s findings of mass immune cell migration towards MSCs post-
inflammatory stimulation, seem contradictory to the belief that MSCs are anti-
inflammatory after licensing. Thus, this has wider implications when one 
considers the infusion of MSCs into a patient with an existing inflammatory 
condition, where immune cells, recruited by MSC derived products could 
ultimately exacerbate and prolong inflammation. Conversely, the relatively new 
body of literature surrounding the concept of pro-inflammatory and anti-
inflammatory/pro-angiogenic neutrophils in mice and humans could suggest that 
MSCs might attract a particular type of neutrophil, or immunomodulatory 
neutrophils (306). Moreover, the attraction of specific subsets of monocytes has 
also been reported to have inflammatory (307, 308) or pro-regenerative and 
anti-viral effects in mice and humans (309, 310). Thus, as Is and Va MSCs 
attracted immune cells without inflammatory stimulation, they have the 
potential to exaggerate inflammation or, promote an anti-inflammatory/pro-
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regenerative outcome without being pre-licensed. Therefore, it is possible that 
these MSCs could be beneficial or detrimental to tissue regeneration in a clinical 
setting, depending on the phenotype of the immune cells they attract.  
The overall aim of this thesis was to gain insight into the in vivo behaviour of 
MSCs by assessing which immune cells MSCs attract and therefore potentially 
interact with. Having observed the immune cell attraction profile of MSCs in 
vitro, understanding if MSC chemokine secretion resulted in a similar immune 
cell attraction profile in vivo was the next logical step in this study. To assess 
this, a murine air pouch model was used. The air pouch model is well-
established to study immune cell infiltration - often promoted by the injection 
of an inflammatory agent (LPS/Carrageenan) - into an artificially created air 
pouch on the back of mice/rats (model discussed further in Section 6.2.1) (311, 
312). Thus, the air pouch served as an ideal, relevant in vivo environment to 
assess immune cell infiltration in response to pre-inflamed Is MSC introduction 
into the air pouch of mice. Pre-inflamed Is MSCs were used in the in vivo system 
as they attracted the largest number of immune cells in vitro. Similar to the in 
vitro system, MSCs were stimulated with 10ng/mL of IFN-ϒ, IL-1β and TNF-α for 
24 hours and thoroughly washed prior to infusion into the air pouch to ensure 
immune cell attraction was MSC specific and not a result of the inflammatory 
cytokines used.  
Therefore, this chapter aimed to assess; i) the in vivo immune cell attraction 
profile of pre-inflamed Is MSCs, ii) the phenotype of infiltrated immune cells and 
iii) the potential anti-inflammatory and immunomodulatory mechanisms of MSCs 
on chemoattracted immune cells by measuring the transcription of several genes 
including Tumour necrosis factor inducible gene 6 (TSG6), indoleamine 2,3-
dioxygenase (IDO), complement factor H (CFH), CD 274, hepatocyte growth 
factor (HGF), TGF-beta (TGF-β) and Granulocyte macrophage colony stimulating 
factor (GMCSF) under homeostatic and inflammatory conditions. 
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Results 
 Assessing the in vivo immune cell attraction profile 6.2
of stimulated Is MSCs by using a murine air pouch 
model 
 Overview of air pouch model, timeline and set up 6.2.1
To prevent human MSC rejection, the air pouch model studies were initially 
performed in immunocompromised NOD/SCID-GAMMA (NSG) mice (Details of 
genotype in Section 2.6.2.1). NSGs are considered immunocompromised due to 
multiple defects in the innate and adaptive immune systems including lack of; 
complement, T cells, B cells and NK cells coupled with defective macrophages 
and DCs (313, 314). To assess the immune cell attraction profile of stimulated Is 
MSCs in vivo, an air pouch was created under the dorsal skin of NSG mice.   
After concluding that NSG mice could tolerate the air pouch procedure and 
injection of human MSCs, OT-1 mice were used to assess the effect of human 
MSCs in mice with a fully-functional immune system. OT-1 mice became 
available to use throughout the experimental timeline and therefore served as a 
comparison to the NSG mouse strain. OT-1 are transgenic mice, where the CD8+ 
T cells express a TCR specific for the SIINFEKEL peptide of ovalbumin, however 
all other immune cells are present and fully functional (315). 
The comparison of results between NSG and OT-1 mice assessed the validity of 
the NSG results. In other words, using OT-1 mice made it possible to determine 
if the results from NSG mice may relate to their incomplete immune system, or 
not. Additionally, OT-1 mice allowed an assessment of the infiltration of 
adaptive immune cells into the air pouch. Therefore, the following sections 
include air pouch data from both NSG and OT-1 mice.  
The timeline of how the air pouch was created and maintained is shown in 
Figure 6-1 A. Due to the availability of mice, 10 female NSG mice between 14 
and 16 weeks and 5, 14 week old OT-1 males were used. On Day 7 post pouch 
creation, mice were injected with 1 mL of sterile PBS (control mice) or 5.5x105 
pre-stimulated Is MSCs (10ng/mL of TNF-α, IL-1β and IFN-ϒ for 24 hours) in 1mL 
of PBS (treated mice) and left for 24 hours. Mice were then sacrificed and the air 
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pouch was dissected and assessed (For full detail, see Section 2.6).  The immune 
cell infiltration into the air pouch fluid, upper and lower membranes of each 
mouse (Figure 6-1 B) was assessed using flow cytometry and histology.  
 
Figure 6-1 Diagrammatic illustration of the time course and anatomy of the air pouch model 
on NSG and OT-1 mice. 
The timeline of the air pouch model is illustrated in A. On day 0, the dorsal skins of mice were 
shaved. Day1, 3 mL of sterile air was injected subcutaneously into the dorsal of each mouse. Mice 
were left for two days prior to a 3mL sterile air top up into the air pouch (Day 4). Mice were left for 
one day before topping up the air pouch again with 1mL of sterile air (Day 6). 24 hours post air 
injection, mice were injected with 1mL of sterile PBS (control mice) or 5.5x105 pre-inflamed Is 
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MSCs in 1mL of sterile PBS (Day7) and left for 24 hours before mice were sacrificed (Day 8). The 
air pouches of all mice were dissected by injecting 1mL of PBS into the air pouch and carefully 
removing all liquid from the air pouch – all cells within this sample were termed “air pouch” samples 
(B). The upper membrane of the pouch was dissected and digested – all cells within this sample 
were termed “upper membrane”. The lower membrane was dissected and digested in a similar 
manner to the upper membrane – all cells isolated from the lower membrane were termed “lower 
membrane”.  
 
 Flow cytometry gating strategies for the NSG and OT-1 air 6.2.2
pouch models 
Flow cytometry was used to assess the immune cell infiltration into the air 
pouch fluid, upper and lower membranes of NSG and OT-1 mice after 24 hours. 
An array of mouse cell markers including; CD11c, F480, CD11b, Ly6c, Ly6g, 
CD45, Siglec F and human CD105, coupled with a specific gating strategy (details 
in Figure 6-2) was used to identify neutrophils (Figure 6-2 B), macrophages 
(Figure 6-2 C), eosinophils (Figure 6-2 D)  monocytes (Figure 6-2 E), DCs 
(Figure 6-2 F), and human Is MSCs. 
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Figure 6-2 Flow cytometry gating strategy to identify various mouse innate immune cells in 
the NSG and OT-1 air pouch Model 
Flow cytometry was used to assess and identify the immune cell infiltration into the air pouches of 
NSG and OT-1 mice. Doublets were excluded and live cells were selected as described in previous 
chapters (plots not shown). Black arrows highlight the gating pathway and red arrows highlight 
gated cell populations. CD45 +ve cells were selected (A) and CD11b +ve, Ly6g +ve cells were 
considered neutrophils (B). The remaining population were assessed for their expression of F480. 
F480 +ve, CD11b +ve cells were considered macrophages (C). The remaining population of cells 
were assessed for expression of Siglec F. Siglec F +ve cells were considered eosinophils (D). 
CD11b +ve, Ly6c +ve cells were considered monocytes (E). The remaining cells were assessed for 
the expression of CD11c. Any cells expressing CD11c were classified as dendritic cells (F). 
Positive staining was measured through the use of ‘Fluorescence minus one’ controls.  
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As OT-1 mice have an adaptive immune system, an additional flow cytometry 
panel (details in Figure 6-3) was used in conjunction with the aforementioned 
panel (Figure 6-2), to assess the infiltration of adaptive immune cells including 
NK cells (Figure 6-3 B), CD4 and CD 8 T cells (Figure 6-3 C) and B cells (Figure 
6-3 D).   
 
Figure 6-3 Flow cytometry gating strategy to identify cells of the adaptive immune system in 
the OT-1 air pouch model. 
Flow cytometry was used to assess the presence of adaptive immune cells in the OT-1 air pouch 
model. Doublets were excluded and live cells were selected as described in previous chapters 
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(plots not shown). Black arrows highlight the gating pathway. Red arrows highlight the gated cell 
population. CD45 +ve cells were selected (A) and assessed for their expression of NK1.1, 
CD8alpha, CD4 and B220. NK1.1 positive cells were considered NK cells (B) and NK1.1 –ve cells 
were assessed for the expression of CD4 and CD8 (C) and considered CD4 T cells or CD 8 T cells, 
respectively. Cells negative for CD4 and CD8 were assessed for their expression of B220 and 
positive cells were considered B cells (D). Positive staining was measured through the use of 
fluorescence minus one controls.   
 
Although the fine details of specific marker expression by immune cell subsets is 
beyond the scope of this chapter, immune cells broadly characterized using the 
gating strategies mentioned above will be referred to as neutrophils, 
macrophages, monocytes, eosinophils, DCs, NK cells, T cells and B cells.  
 Analysis of the cellular infiltration into the air pouches of 6.2.3
NSG and OT-1 Mice.  
 Immune cell infiltration into the air pouches of NSG mice  6.2.3.1
Using flow cytometry, the total numbers of CD45+ cells that had infiltrated into 
the air pouches of NSG and OT-1 mice were analysed and are graphed in Figure 
6-4 (details on how the total numbers were calculated are described in Section 
2.4.3.5). Minimal migration of CD45 +ve cells into control NSG air pouches was 
observed. This demonstrated that the creation of the air pouch or PBS injection 
itself, does not result in substantial immune cell infiltration/inflammation at the 
24 hour time point. Macrophages were the predominant immune cell present in 
the air pouches of control mice, followed by smaller numbers of neutrophils, 
DCs, monocytes and eosinophils (Figure 6-4 A). Pre-stimulated Is MSCs in the 
NSG mice air pouches (treated) resulted in a 30 fold increase in CD45 +ve cells 
compared to control mice. In contrast to control animals which predominantly 
attracted macrophages into the air pouch, neutrophils were the predominant 
infiltrating cell type in treated animals, attracting of 91 fold more neutrophils 
compared to control mice. This highlights that Is MSCs preferentially attracted 
neutrophils in NSG mice and that the immune cell attraction was not just an 
amplification of the inflammatory reaction/immune cell infiltrate, observed in 
control mice. Macrophage infiltration increased by 14 fold compared to control 
mice and made up the second largest population of cells within the air pouch. 
DCs, monocytes and eosinophils made up smaller proportions of the infiltrating 
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CD45 +ve immune cells in treated NSG air pouches and their infiltration 
increased 5, 18 and 8 fold, respectively, when compared to control mice.  
 Immune Cell Infiltration into the Air Pouches of OT-1 mice  6.2.3.2
Similar to NSG control mice, OT-1 control mice did not recruit large numbers of 
CD45 +ve cells into the air pouch and macrophages were the predominant CD45 
+ve cell (Figure 6-4 B). Pre-stimulated Is MSCs in OT-1 air pouches upregulated 
CD45 +ve cell infiltration 153 fold compared to control mice. Again, the 
predominant infiltrating cell type was neutrophils in treated OT-1 mice, which 
infiltrated 1610 fold higher than in control OT-1 mice. The switch in the 
predominant cell type in the air pouches of control vs treated mice, again, 
suggested a selective attraction of neutrophils towards Is MSCs in OT-1 mice. An 
increase in macrophage infiltration by 53 fold was observed when comparing 
control to treated mice and a significant upregulation of DC infiltration by 30 
fold (P=0.0090), monocyte infiltration by 71 fold and eosinophil infiltration by 46 
fold was also seen.  
The presence of adaptive immune cells in the air pouch of OT-1 mice was low in 
control mice (Figure 6-4 C). The presence of pre-stimulated MSCs resulted in a 
substantial increase in NK cells and a small increase in CD8 and CD 4 T cells and 
B cells. However, adaptive immune cell infiltration into MSC containing pouches 
remained relatively low. This complements the in vitro data observed in the 
previous chapter. 
 Comparing the immune cell Infiltration into NSG and OT-1 air 6.2.3.3
pouches.  
To assess if the immune cell infiltration in treated NSG and OT-1 mice was 
specific to the presence of Is MSCs and not a result of the mouse genotype used, 
a direct comparison between control NSG vs. OT 1 mice and treated NSG vs. OT-
1 mice was made. No significant differences were observed in the presence of 
immune cells in the air pouches of control NSG and OT-1 mice, suggesting that 
similar numbers of immune cells infiltrating into the air pouches of control mice 
are equally capable of migrating in both mouse strains (Figure 6-4 D).   
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Eosinophil migration into the air pouches of treated mice was significantly 
reduced in NSG mice, compared to OT-1 mice (P=0.0053). This could be due to a 
defect in NSG eosinophils which is not widely reported within the literature, 
and/or, a result of defects in NSG cytokine secretion capabilities. All other 
immune cells were fully capable of migrating in similar numbers towards Is MSCs. 
This suggests that the majority of immune cells observed infiltrating into the air 
pouches of NSG and OT-1 mice were as a result of Is MSCs and not due to the 
mouse genotype (Figure 6-4 E).  
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Figure 6-4 Immune cell infiltration into the air pouches of NSG and OT-1 mice. 
An air pouch was created on the dorsal of 10 female mice between 14-16 weeks old (NSG) and 5, 
14 week old male mice (OT-1). After 6 days, mice received either 1 mL of PBS (control mice n=4 
NSG, n=2 OT-1) or 5.5x10^5 pre-stimulated Is MSCs in 1mL of PBS (treated mice n=6 NSG, n=3 
OT 1) for 24 hours before they were sacrificed. Flow cytometry was used to assess the immune 
cell infiltration into the air pouches of NSG and OT-1 mice. The total number of CD45 +ve, F480 
+ve macrophages, Ly6g +ve neutrophils, CD11c +ve DCs, Ly6c +ve monocytes and Siglec  F+ve 
eosinophils that had infiltrated into air pouches of control and treated NSG and OT 1 mice are 
graphed in A and B, respectively. The total number of NK1.1 +ve (NK cells), CD8α +ve (CD8 T 
cells), CD4 +ve (CD4 T cells) and B220 +ve (B cells) that had infiltrated into the air pouches of OT-
1 mice are graphed in C. To assess if mouse strain had any effect on the immune cell infiltrate into 
the air pouches of NSG and OT-1 mice, a direct comparison between control NSG vs OT-1 (D) and 
treated NSG vs. OT-1 mice was made (E). 2 Is MSC donors were used for the NSG air pouch 
experiment (3 mice per MSC donor) and 1 Is MSC donor was used for the OT-1 air pouch 
experiment.  
Students T test (unpaired) was used to assess control vs. treated immune cell infiltration. 
Significance is marked where appropriate and P values are stated throughout the text.  
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 CD45 –ve cell infiltration into the air pouches of NSG and OT-1 mice  6.2.3.4
To assess if CD45 –ve cells infiltrated into the air pouches of NSG and OT-1 mice, 
CD45 –ve cells were gated (Figure 6-5 A) and results are graphed in Figure 6-5 B 
& C. In NSG control mice, small numbers of CD45-ve cells were present in the air 
pouches compared to treated animals which had significantly more (P=0.0491) 
CD45-ve cells (Figure 6-5 B). 
Similarly, CD45-ve cells were present in significantly higher (P=0.0008) numbers 
in treated OT-1 mice air pouches compared to OT-1 controls (Figure 6-5 C). 
To ensure that the significant increase in CD45-ve cells observed in treated NSG 
and OT-1 mice was not a result of the presence of CD45-ve human Is MSCs, and 
to assess if human MSCs resided within the air pouch, NSG and OT-1 air pouches 
were analysed for the presence of CD105+ve Is MSCs. Previous data (Section 3.3, 
Figure 3-3) showed that human Is MSCs highly expressed CD105 (Figure 6-5 D).  
Moreover, the human CD105 antibody was not cross reactive with mouse cells 
(Figure 6-5 E), therefore, human CD105 was included in the panel to identify Is 
MSCs.  
As expected, CD105+ve Is MSCs were not observed in the air pouches of NSG and 
OT-1 control mice (Figure 6-5 F.i, F.ii). Surprisingly, Human CD105+ve Is MSCs 
were also not observed in the air pouches of NSG and OT-1 treated mice (Figure 
6-5 G.i, G.ii). To rule out that human Is MSCs might be dead and residing in the 
air pouches of NSG and OT-1 mice, the dead cell gate was removed and the air 
pouches were assessed for the presence of human CD105+ve Is MSCs (Figure 6-5 
H.i, H.ii). Live or dead human CD105+ve cells were not detected in the air 
pouches of NSG or OT-1 mice.  
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Figure 6-5 Assessment of the CD45-ve cell infiltration into the air pouches of NSG and OT-1 
mice 
To assess the infiltration of CD45-ve cells into the air pouches of NSG and OT-1 mice, CD45 cells 
were gated on (A) and the total numbers of CD45-ve cells that had infiltrated into the air pouches of 
NSG and OT-1 mice were counted and graphed in B and C respectively. To ensure that the 
increased number of CD45-ve cells observed in the air pouches of treated mice was not a result of 
the presence of Is MSCs, NSG and OT-1 air pouches were assessed for positive staining of human 
CD105. Previous data highlighted strong positive staining of human CD105 on Is MSCs (D) and 
this marker did not cross react with mouse cells (E). CD105 expression was assessed in control 
NSG (F.i) and OT-1 (F.ii) air pouches.  CD105 expression was also assessed in treated NSG (G.i) 
and OT-1 (G.ii) air pouches. To ensure the MSCs were not dead within the air pouches, the dead 
cell gate was removed and CD45–ve cells were assessed for their expression of CD105 in NSG 
(H.i) and OT-1 (H.ii) mice.  
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To summarise, Is MSCs specifically attracted significantly more CD45-ve cells into 
the air pouches of NSG and OT-1 mice compared to control mice, which could 
consist of an array of mouse cells including; fibroblasts, pericytes and MSCs, 
along with others. Moreover, live or dead CD105+ve Is MSCs were not detected in 
the air pouches of NSG and OT-1 mice, suggesting that MSCs might have 
migrated out of the air pouch into the upper and/or lower membranes of the 
pouch. 
 Morphology of immune cells within the air pouch of NSG and OT-1 6.2.3.5
mice 
To analyse the morphology of immune cells within the air pouch, a cell sample 
from each mouse was examined using Giemsa stained cytospin (Figure 6-6).  The 
immune composition of NSG (Figure 6-6 A-F), OT-1 (Figure 6-6 G-J) and control 
(Figure 6-6 K-N) mouse cytospins complimented the flow cytometry data, where 
the predominant cell type in NSG and OT-1 cytospins were mature neutrophils 
(black arrow). Mature neutrophils were characterised by segmented nuclei, 
whereas, immature neutrophils were characterised by band shaped nuclei (blue 
arrow). Macrophages (red arrow) were also present in NSG and OT-1 air pouch 
cytospins. Macrophages were characterised by their light purple stained 
cytoplasm and ruffled edges, and can be seen phagocytosing (red arrow with an 
asterisk) neutrophils and other cellular debris. Fewer monocytes (green arrow) 
and dendritic cells (yellow arrow) were observed in NSG and OT-1 air pouches. 
Consistent with the flow cytometry data, small numbers of eosinophils were 
observed. Eosinophils can be characterised by their ‘S’ shaped nuclei and, in 
some cases, appeared to be degranulating – highlighted by dark pink granules 
emerging from the cell (blue arrow with asterisk (Figure 6-6 F)). Lymphocytes 
(pink arrow) were present in the cytospins of OT-1 mice and are identified by 
their small round appearance with a large nucleus (Figure 6-6 G&H).  
No immune cells were observed on the cytospins from the air pouches of control 
mice (Figure 6-6 K-N).  
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Figure 6-6 Histology of the cellular infiltration into the air pouches of control and treated 
NSG and OT-1 mice. 
2x104 cells isolated from the air pouches of treated NSG (A-F) and OT-1 (G-J) and control (K-N) 
mice were prepared for cytospins. All slides were stained with Giemsa and imaged using an 
epifluorescent microscope - brightfield channel. Light blue arrows point to immature neutrophils 
(band/ringed shaped nuclei), black arrows point to mature neutrophils (segmented/hyper-
segmented nuclei), red arrows point to macrophages, red arrows with an asterisk (*) point to 
phagocytosing macrophages, green arrows point to monocytes, dark green arrows point to 
eosinophils, dark blue arrows with an asterisk (*) point to degranulating eosinophils (F), pink arrows 
point to lymphocytes, yellow arrows point to DCs. Magnified inserts on  B,E,G,H,I and J allow for 
clearer visualisation of nuclear morphology. Control slides had a noticeable reduction of cells from 
cytospin analysis (K-N). 
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 Summary of the cells present in the air pouch of control vs 6.2.4
treated mice 
To summarise, the presence of pre-inflamed Is MSCs in the air pouches of NSG 
and OT-1 mice substantially increased the number of CD45+ve and CD45 -ve cells 
recruited into the air pouches compared to control pouches. The composition of 
immune cells in the air pouch of NSG and OT-1 control mice (predominantly 
macrophages) differed from treated NSG and OT-1 mice (predominantly 
neutrophils), suggesting that Is MSCs preferentially attracted neutrophils and 
that they did not just exaggerate the immune cell infiltration caused by the 
generation of the air pouch -observed in control animals. Neutrophils in treated 
NSG and OT-1 air pouches had segmented/hyper-segmented nuclei, indicative of 
mature neutrophils. Macrophages were also common in the air pouches of NSG 
and OT-1 mice and were often phagocytosing neutrophils and cellular debris. An 
increase in DCs, monocytes and eosinophils was observed in the air pouches of 
treated NSG and OT-1 mice compared to control mice. However they appeared 
in substantially lower numbers than macrophages and neutrophils. Extremely low 
numbers of T cells and B cells were observed in the air pouches of control and 
treated OT-1 mice, this could be due to the 24 hour time point used, which 
might not be long enough to trigger an adaptive response.  
With the exception of eosinophils, no significant differences were observed in 
immune cell infiltration between mouse strains in control or treated mice. This 
highlights that the observed results were specific to the presence of Is MSCs and 
not an artefact of the mouse genotype used.  
 Analysis of CD45 +ve and CD45 -ve cells present in the 6.2.5
upper membrane of the air pouch 
 Assessment of CD 45+ve cells present in the upper membrane of 6.2.5.1
NSG mice 
As the results of the air pouch fluid were consistent between the two mouse 
strains, assessment of the CD45 +ve and CD45 -ve cells present in the upper and 
lower membranes of the air pouch was only carried out on NSG mice.  
The presence and composition of immune cells in the upper membrane of the air 
pouch were assessed using the same gating strategies as previously performed in 
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NSG mice. The numbers of macrophages, neutrophils, DCs, monocytes and 
eosinophils are expressed as a percentage of the total CD45 +ve cells in the 
upper membrane and are graphed in Figure 6-7. Total numbers of immune cells 
in the membrane were not graphed as the amount of membrane dissected from 
each mouse varied. Due to the thin membrane, standardising the amount of 
membrane extracted was extremely difficult and therefore not carried out. 
In control NSG mice, macrophages were the predominant CD45 +ve immune cells 
in the upper membrane. DCs, monocytes and neutrophils made up a small 
portion of the upper membrane in NSG control mice. The remaining portion of 
cells which could not be identified with the flow cytometry panel used could 
consist of basophils and mast cells and are represented as ‘remaining cells’.  
Macrophages made up the largest proportion of immune cells in the upper 
membrane of the air pouch in control mice, followed by the undefined 
proportion of CD45+ve ‘remaining cells’. Substantially smaller percentages of 
DCs, neutrophils, monocytes and eosinophils were present. 
The presence of pre-inflamed Is MSCs resulted in a slight decrease in the 
percentage of macrophages and “remaining cells” present in the upper 
membrane, whereas the percentage of eosinophils significantly decreased 
(P=0.0267). The reduction in the percentages of these cells in the upper 
membrane of treated could be a result of them migrating out of the membrane, 
into the air pouches in treated mice. A small increase in the percentage of DCs, 
monocytes and neutrophils in the upper membranes of treated NSG mice 
compared to control mice was observed.  
Cytospins from the upper membrane of NSG mice, further confirmed that the 
majority of immune cells present were macrophages (red arrow) (Figure 6-7 B). 
Moreover, the immune cell composition of the cytospins from control and 
treated mice looked very similar, therefore complementing the observations 
from the flow cytometry data, where no major differences were observed 
between control and treated mice.   
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Figure 6-7 Assessing the immune cell composition of the upper membrane in NSG air 
pouches using flow cytometry and histology 
Flow cytometry was used to identify the immune cell composition of the upper membrane of NSG 
control and treated mice (A). Each bar in the control group represents 4 mice ± SEM. Each bar in 
the treated group represents 6 mice and 2 Is MSC donors ± SEM. Students (unpaired T test was 
used to assess statistical differences between control and treated mice. Significance is marked 
where appropriate and P value(s) are stated throughout the text. Histology (cytospins and Giemsa 
staining) was used to further assess the phenotype of cells in the upper membrane of treated (B) 
and control (C) NSG mice. As before, red arrows point to macrophages, yellow arrows point to 
DCs, black arrows point to mature neutrophils, blue arrows point to immature neutrophils and green 
arrows point to monocytes.  
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 Assessment of the upper membrane of the air pouch in NSG mice for 6.2.5.2
CD105+ve human Is MSCs  
To assess whether human MSCs resided in the upper membrane of the air pouch 
in NSG mice, the CD45 -ve portion of the upper membrane was analysed for 
positive expression of human CD105 (Figure 6-8). No live or dead human CD105 
+ve Is MSCs were observed in the upper membrane of treated NSG air pouches.  
 
Figure 6-8 Assessment of the upper membrane for live and dead CD105 +ve Is MSCs in NSG 
mice 
Using flow cytometry, the upper membrane of treated NSG air pouches were assessed for 
CD105+ve Is MSCs. As in Figure 6-5, CD45–ve cells were gated on and assessed for positive 
CD105 staining. Neither live (green) nor dead (red) CD105+ve Is MSCs were present in the upper 
membrane of NSG mice air pouches.  
To summarise, with the exception of eosinophils, no significant differences were 
observed in the immune cell composition of the upper membrane between 
control and treated mice. The significant decrease in eosinophils and slight 
decrease in macrophages observed in the upper membrane of treated animals 
might be due to eosinophil and macrophage egress into the air pouch from the 
upper membrane. Equally, the substantial increase in DC and neutrophil 
percentages could have altered the immune cell composition of the upper 
membrane in such a way that it appears as if macrophages and eosinophils have 
decreased in percentage. Neither live, nor dead, Is MSCs resided in the upper 
membrane of NSG air pouches.  
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 Analysis of CD45 +ve and CD45  –ve cells present in the 6.2.6
lower membrane of the air pouch 
 Assessment of the CD45 +ve cells present in the lower membrane of 6.2.6.1
NSG mice 
The number of macrophages, neutrophils, DCs, monocytes and “remaining cells” 
as a percentage of the total CD45 +ve cells in the lower membrane of control 
NSG mice were similar to the percentages observed in the upper membrane of 
control NSG mice. Macrophages were the predominant immune cell type and the 
remaining CD45 +ve cells were made up of small fractions of neutrophils, DCs, 
monocytes and “remaining cells” (Figure 6-9 A). 
Is MSCs in the NSG air pouch resulted in a change in the lower membrane 
immune cell composition.  Similar to the upper membrane, the percentage of 
macrophages decreased along with a very marginal degrease in eosinophil 
percentages when comparing control to treated mice. A slight increase in DCs, 
monocytes and “remaining cells” was observed, coupled with a significant 
increase in the percentage of neutrophils (P=0.0314) (Figure 6-9 A).  
Cytospins from the lower membrane of treated NSG mice (Figure 6-9 B) showed 
that the majority of immune cells were macrophages and that neutrophils (black 
arrows = mature, blue arrows = immature) are present throughout the lower 
membrane of treated mice. Conversely, in control mice (Figure 6-9 C), the 
lower membrane lacks neutrophil infiltration, whilst maintaining high numbers 
of macrophages.  
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Figure 6-9 Assessing the immune cell composition of the lower membrane in NSG Air 
pouches using flow cytometry and histology 
Flow cytometry was used to identify the immune cell composition of the lower membrane in NSG 
control and treated mice (A). Each bar in the control group represents 4 mice ± SEM. Each bar in 
the treated group represents 6 mice and 2 Is MSC donors ± SEM. Students unpaired T test was 
used to assess statistical differences between control and treated mice. Significance is marked 
where appropriate and P value(s) are stated throughout the text. Histology (cytospins and Giemsa 
staining) were used to further assess the phenotype of cells in the upper membrane of treated (B) 
and control (C) NSG mice. As before, red arrows point to macrophages, yellow arrows point to 
DCs, black arrows point to mature neutrophils, blue arrows point to immature neutrophils and green 
arrows point to monocytes.  
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 Assessment of the lower membrane of the air pouch in NSG mice for 6.2.6.2
CD105+ve human Is MSCs in  
The presence of CD105 +ve Is MSCs in the lower membrane of the air pouch in 
NSG mice was assessed in the same way as for the upper membrane. Similar to 
the upper membrane of the air pouch, no live or dead (Figure 6-10) human 
CD105+ve MSCs were detected in the lower membrane of the air pouch in NSG 
mice.  
 
Figure 6-10 Assessment of the lower membrane for the presence of live or dead CD105 +ve 
Is MSCs in NSG mice. 
Using flow cytometry, the lower membrane of treated NSG air pouches were assessed for their 
presence of CD105 +ve Is MSCs. As in Figure 6-5, CD45 –ve cells were gated on and assessed 
for positive CD105 staining. Neither live (green) nor dead (red) CD105 +ve Is MSCs were present 
in the lower membrane of NSG mice air pouches.  
 
In summary, the lower membrane of control and treated NSG mice showed 
similar immune cell composition with the exception of neutrophils which made 
up a significantly higher percentage of the immune cells in treated animals 
compared to control animals, likely due to a large influx of neutrophils migrating 
through the membrane into the air pouch. A mixture of mature (segmented 
nuclei) and immature neutrophils (band neutrophils) was observed in the lower 
membrane of treated mice. Live or dead MSCs were not detected in the lower 
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membrane of the air pouch, suggesting that they might have migrated through 
the membrane and away from the air pouch. 
 Transcriptional analysis of immunomodulatory and 6.3
anti-inflammatory genes in Is, Va, Ad, BM and UC 
MSCs.   
To assess if MSCs isolated from various sources could have differential 
immunomodulatory and anti-inflammatory capacity on immune cells in close 
proximity under homeostatic and inflammatory conditions, Is, Va, Ad, BM and UC 
MSCs were assessed for their transcriptional expression of several non-chemokine 
related genes including; Tumour necrosis factor inducible gene 6 (TSG-6), 
indoleamine 2,3-dioxygenase (IDO), complement factor H (CFH), CD274, 
hepatocyte growth factor (HGF), TGF-beta (TGF-β) and Granulocyte macrophage 
colony stimulating factor (GMCSF).  
 TSG-6 is known as a multi-functional protein which mediates anti-inflammatory 
and protective effects in disease models by reducing neutrophil infiltration and 
inhibiting the presentation of chemokines on the surface of glycosaminoglycans 
(316). Under homeostatic conditions, Is, Va, Ad, BM and UC MSCs 
transcriptionally expressed TSG-6 at similar, moderate levels. Inflammatory 
stimulation resulted in Is, Va, Ad and UC MSCs substantially upregulating 
transcription of TSG-6 and BM MSCs significantly upregulating TSG-6 transcription 
(P=0.0176). BM MSCs transcribed the highest levels of TSG-6, significantly more 
than Is (P=<0.05), Va (P=<0.05) and Ad (P=<0.05) MSCs and 2 fold higher than UC 
MSCs (Figure 6-11 A). 
As previously discussed in this thesis, MSC secretion of IDO, is a well-documented 
mechanism of MSC immunomodulation within the literature and causes a 
downregulation of T cell proliferation (317). Under homeostatic conditions, IDO 
was not transcribed by Is, Va, Ad, BM and UC MSCs. Inflammatory stimulation 
resulted in an upregulation of IDO transcription by Is, Va, Ad and UC MSCs and a 
significant upregulation by BM MSCs (P=0.0360). BM MSCs transcribed the most 
IDO, exhibiting a 2(-ΔCT) 6.3 fold higher than Is MSCs IDO expression (Figure 6-11 
B).  
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CFH is an anti-inflammatory factor that inhibits the formation of complement 
and its secretion by MSCs is considered a mechanism of immunosuppression 
(109). CFH was transcribed at moderate and similar levels during homeostatic 
conditions by all MSC tissue sources. Inflammatory stimulation resulted in a 
moderate upregulation in CFH transcription by Is, Va and Ad MSCs to similar 
levels. Conversely, BM (P=0.0020) and UC (P=0.0243) MSCs significantly 
upregulated CFH transcription to similar levels. BM and UC MSCs transcribed 
significantly more CFH than Is MSCs which transcribed the least CFH under 
inflammatory conditions (BM: P=<0.01, UC: P=<0.05) (Figure 6-11 C). 
CD274, otherwise known as programmed death-ligand 1 (PD-L1), is a 
transmembrane protein which plays an important role in the suppression of the 
immune system during autoimmune disease and tissue allografts via binding to 
its receptor PD-1 on the surface of T cells and ultimately inhibiting their 
proliferation (318). Its expression on MSCs has been documented and is 
considered another method of immunosuppression by MSCs (319). Under 
homeostatic conditions, Is, Va, Ad, BM and UC MSCs transcribed CD274 at very 
low levels. Inflammatory stimulation however, resulted in Is, Va and Ad MSCs 
substantially upregulating CD274 transcription and BM (P=0.0205) and UC 
(P=0.0349) MSCs significantly upregulating CD274 transcription. Inflammatory 
stimulation resulted in BM MSCs transcribing significantly more CD274 than Is 
(P=<0.001), Va (P=<0.05) and Ad (P=<0.05) MSCs. Similarly, UC MSCs also 
transcribed significantly more CD274 than Is (P=<0.01), Va (P=<0.05) and Ad 
MSCs (P=<0.01) (Figure 6-11 D).  
HGF is a cellular growth and motility factor secreted by MSCs. It has been shown 
to have potent anti-inflammatory effects in multiple animal models of disease 
via NF-kappaB inhibition (320). Under homeostatic conditions, Is, Va and Ad MSCs 
HGF transcript levels were very low and transcribed at similar levels between 
these MSC tissue sources. Conversely, UC MSCs expressed moderately higher HGF 
transcripts than Is, Va and Ad MSCs and slightly less than BM MSCs.  BM MSCs 
transcribed significantly higher levels of HGF than Is (P=<0.05), Va (P=<0.05) and 
Ad MSCs (P=<0.05) under homeostatic conditions. Inflammatory stimulation 
resulted in a slight upregulation in HGF transcript levels in Is, Va, Ad and UCs, 
whereas BM MSCs substantially upregulated HGF transcripts. BM MSCs had 
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significantly higher HGF transcript levels than Is (P=<0.001), Va (P=<0.001), Ad 
(P=<0.001) and UC MSCs (P=<0.001) (Figure 6-11 E). 
TGF-β is a secreted protein that performs many functions in regulation of 
inflammation. The multi-faceted effects of TGF-β are cellular and environmental 
context dependent (321). MSCs from all tissue sources transcribed TGF-β at 
similar levels during homeostatic conditions. Inflammatory stimulation resulted 
in a slight upregulation or downregulation of TGF-β transcript depending on MSC 
tissue origin where Is MSCs, Ad MSCs and UC MSCs downregulated TGF-beta 
transcription and Va and BM MSCs upregulated TGF-β transcription (Figure 6-11 
F).  
GMCSF is a secreted protein that promotes neutrophil, monocyte and 
macrophage proliferation and maturation. Additionally, it can alter neutrophil 
receptor expression and inhibit their degranulation and migration (322). During 
homeostatic conditions, Is, Va, Ad, BM and UC MSCs expressed very low levels of 
GMCSF transcripts. Inflammatory stimulation resulted in a substantial 
upregulation of GMCSF transcription by Is MSCs only, with a slight upregulation 
by BM and UC MSCs and minimal upregulation by Ad MSCs (Figure 6-11 G). 
226 
 
 
Figure 6-11 Assessing the transcriptional expression of anti-inflammatory and 
immunomodulatory genes under homeostatic and inflammatory conditions by Is, Va, Ad, 
BM and UC MSCs. 
Is, Va, Ad, BM and UC MSCs were grown until 80% confluent at P3. MSCs were either stimulated 
or left in homeostatic conditions for 24 hours. After 24 hours, MSCs were detached, RNA was 
extracted and cDNA was synthesised prior to the assessment of the transcriptional expression of 
TSG-6 (A), IDO (B), CFH (C), CD274 (D), HGF (E), TGF-β (F) and GMCSF (G) using RT PCR. 
Each bar represents an n of 3 ± SEM. A students (paired) T test was used when measuring 
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statistical differences within one MSC tissue source (homeostatic vs. Inflammatory). A ONE WAY 
ANOVA with Tukey’s multiple comparisons test was used to assess statistical differences between 
all MSC tissue sources. Significance is marked where appropriate and P values are stated 
throughout the text.  
To summarise, the aforementioned anti-inflammatory and immunomodulatory 
genes were transcriptionally upregulated by MSCs isolated from all tissue sources 
after inflammatory stimulation, with the exception of TGF-β. Interestingly, the 
tissue origin of MSC had an effect on the transcriptional level of anti-
inflammatory and immunomodulatory genes where BM and UC MSCs expressed 
significantly more CD274 and CFH than Is, Va and Ad MSCs. Moreover BM MSCs 
consistently expressed higher transcripts than other MSCs for several genes 
including TSG-6, IDO, CFH, CD271, HGF and TGF-β when maintained under 
inflammatory conditions, whereas Is MSCs expressed higher transcript levels of 
GMCSF than any other tissue source of MSC.  
 Discussion 6.4
Using the air pouch model on NSG and OT-1 mice, this chapter aimed to identify 
and examine the in vivo immune cell attraction profile of pre-stimulated Is MSCs 
via flow cytometry and histology. 
Moreover, data from the previous chapter demonstrated that Is, Va, Ad, BM and 
UC MSCs secreted chemokines and attracted target immune cells in vitro, 
therefore, this chapter aimed to understand the potential immunomodulatory 
effects of Is, Va, Ad, BM and UC MSCs might have on immune cells within close 
proximity. Thus, the expression of several immunomodulatory and anti-
inflammatory genes were assessed at a transcriptional level. These included; 
TSG-6, IDO, CFH, CD274, HGF, TGF-β and GMCSF. 
 The in vivo immune cell attraction profile of pre-stimulated 6.4.1
Is MSCs 
As discussed throughout this thesis, it is established that MSCs are anti-
inflammatory and immunomodulatory cells as demonstrated in a variety of 
disease models (323, 324). Importantly, it is accepted that MSCs attract immune 
cells in close proximity in order to immunomodulate them and exert their anti-
inflammatory properties on surrounding immune cells (325). The mechanisms by 
which MSCs apply their anti-inflammatory and immunomodulatory effects have 
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been thoroughly explored in vitro (133). However, the exact mechanisms of how 
this occurs in vivo are largely not understood.  
The current study found that licensed Is MSCs (pre-stimulated with 10ng/mL of 
IFN-ϒ, TNF-α and IL-β for 24 hours), recruited large numbers of leukocytes into 
the air pouches of NSG and OT-1 mice. The predominant recruited cell type in 
both mouse strains was neutrophils, followed by macrophages and smaller 
numbers of DCs, monocytes and eosinophils. Additionally, OT-1 mice also 
recruited NK cells. This is in contrast to control NSG and OT-1 mice which had 
markedly less CD45 +ve cells within the air pouch and the predominant 
infiltrating cell type was macrophages. This highlights that the creation of the 
air pouch does not result in a substantial immune cell reaction and that the 
immune cells recruited by Is MSCs was not influenced by the mouse genotype 
used, suggesting that Is MSCs specifically recruited neutrophils. Specific 
neutrophil chemoattraction by Is MSCs was further emphasised by the significant 
increase in the percentage of neutrophils in the lower membrane of treated NSG 
mice, compared to control. Literature surrounding MSC immune cell attraction in 
various disease models exists, however are somewhat contradictory to the 
current study. Georgiev-Hristov et al documented an Ad MSC dependant block in 
neutrophil recruitment and enhanced macrophage recruitment at the 24 hour 
time point within a tracheal anastomosis murine model (326). Moreover, 
Carceller et al showed that Ad MSCs alone in an air pouch model did not induce 
migration of neutrophils at a time point of 18 hours (327). The discrepancies 
between the studies is likely due to the different populations of MSCs used as 
the current study observed that unstimulated Ad MSCs did not attract 
neutrophils in vitro  (Figure 5-11 Flow cytometry analysis of the number of 
immune cells migrating towards Is, Va, Ad, BM or plastic under homeostatic or 
inflammatory conditions.). Collectively, this suggests that the attraction of 
neutrophils is Is MSC specific and highlights that MSCs attract/block recruitment 
of specific, differential immune cells, depending on what tissue they are 
isolated from. Therefore, Is MSCs chemoattraction of neutrophils and the 
potential clinical implications is the focus of this discussion.  
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 Is MSCs and their in vivo attraction of neutrophils  6.4.2
Neutrophils express high levels of CXCR1 and CXCR2 which bind to CXCL1, 
CXCL2, CXCL3, CXCL5, CXCL6, CXCL7 and CXCL8 and result in neutrophil 
recruitment and migration into target tissues (328, 329). Out of these 
chemokines, Is MSCs were tested for their secretion of CXCL1, CXCL5, CXCL6 and 
CXCL8, which they secreted at high levels when maintained under homeostatic 
and inflammatory conditions. Therefore, although an array of molecules are 
involved in neutrophil migration (329), it is likely that Is MSC specific neutrophil 
attraction profile is due to the predominant secretion of CXC chemokines. In the 
first instance, the attraction of neutrophils towards Is MSCs could be regarded as 
detrimental within the clinic as large numbers of neutrophils are associated with 
inflammatory diseases such as rheumatoid arthritis (330) and transplant 
rejection, where neutrophil accumulation in the lungs after transplantation 
leads to acute graft failure (331).  
Conversely, accumulating evidence proposes that the presence of neutrophils is 
not always related to inflammation and suggests that this view is a rather 
limited interpretation of neutrophil function.  
Firstly, the engulfment of neutrophils by macrophages is an anti-inflammatory 
process in itself, which prevents the uncontrolled release of damaging 
proteolytic and oxidative mediators from neutrophils and also results in the 
production of anti-inflammatory cytokines such as IL-10 and TGF-β from 
phagocytosing phagocytes (332). Macrophages phagocytosing neutrophils and 
cellular debris was a common phenomenon visualised in the air pouches of NSG 
and OT-1 mice within this study (Figure 6-6 (red arrow with asterisk)).  
Secondly, neutrophils may inhibit graft inflammation via promoting wound and 
tissue repair coupled with graft revascularisation. Lammermann et al described 
how neutrophils swarmed around sites of necrotic tissue in vivo, isolating it from 
surrounding viable tissue and limiting further damage (333). Additionally, 
Christoffersson et al discussed the importance of VEGF-A in attracting 
CD11b+/GR-1+CXCR4hi neutrophils to the site of islet engraftment in mice. VEGF-
A recruited neutrophils, expressed high levels of MMP9 and MMP9 deficient mice 
were unable to revascularise transplanted islets. Thus they found that a subset 
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of CD11b+/GR-1+CXCR4hi, MMP9 secreting neutrophils were vital in islet graft 
revascularisation, likely due to increased vascular density and blood flow caused 
by MMP9 (334, 335). Similarly, the same group found that revascularisation of 
islets transplanted into striated muscles within mice was indispensably 
dependant on the presence of neutrophils (336).  
The contradictory roles of neutrophils in inflammation and transplantation 
models could be cellular and environmental context dependent. However, 
recent observations suggest that different subsets of neutrophils exist in mice 
and humans – inflammatory and anti-inflammatory/pro-angiogenic. It is unclear 
whether these are truly distinct subsets of neutrophils or if they are a continuum 
of maturation -changing phenotype in response to extracellular queues.   
Using mice infected with methicillin-resistant Staphylococcus aureus (MRSA), 
Tsuda et al observed different populations of neutrophils. Neutrophils isolated 
from mice resistant to MRSA and mice susceptible to MRSA showed distinct 
patterns in their cytokine production, TLRs and surface marker expression (337). 
The neutrophils isolated from MRSA resistant mice were considered 
inflammatory neutrophils and secreted IL-13 and CCL3, whereas neutrophils 
isolated from MRSA susceptible mice were considered anti-inflammatory and 
secreted IL-10 and CCL2. Moreover, inflammatory neutrophils were observed to 
have segmented nuclei (indicative of mature neutrophils) and anti-inflammatory 
neutrophils were observed to have ring-shaped nuclei (indicative of immature 
neutrophils). In the current study, the majority of neutrophils which had 
infiltrated into the lower membrane and air pouches of NSG and OT-1 mice had 
segmented/hyper-segmented nuclei, indicating that these might be 
inflammatory neutrophils, whereas small numbers of immature, ringed shaped 
nuclei neutrophils were observed on the cytospins of NSG and OT-1 mice.  
As an added complication to establishing whether or not the attraction of 
neutrophils by Is MSCs in vivo would be detrimental or beneficial in a clinical 
setting, an ongoing debate exists on whether neutrophils and granulocytic 
myeloid derived suppressor cells (GMDSCs) are analogous or distinct cells. 
GMDSCs are well established as anti-inflammatory immune cells largely 
implicated in the negative regulation of immune responses in various cancers, 
ultimately promoting tumour angiogenesis, tumour cell invasion and metastasis 
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(338-340). They share identical surface markers to neutrophils and their nuclear 
morphology is debated within the literature. Greifenberg et al found that 
GMDSCs had ring shaped nuclei, whereas cells with segmented nuclei were not 
suppressive (341). Conversely others have extensively reviewed GMDSCs nuclear 
morphology and associated a segmented nucleus with immune suppression (342-
346).  
Given the current data, drawing conclusions on whether Is MSC in vivo 
chemoattraction of neutrophils would be beneficial or detrimental in a clinical 
setting is not possible. However, it has been proposed that MSCs attract immune 
cells in close proximity to immunomodulate them. Therefore, is it possible that 
MSCs attract inflammatory neutrophils and through undocumented interactions, 
steer them towards an anti-inflammatory neutrophil. Mediators potentially 
involved in this process are discussed below.  
 Immunomodulatory genes transcribed by Is MSCs and their 6.4.3
potential effects on neutrophils  
TSG-6 is a secreted glycoprotein expressed at sites of inflammation and injury. It 
is produced by endothelial cells, monocytes/macrophages and mast cells in 
response to inflammation or injury and interacts with glycosaminoglycans (GAGs) 
such as heparin sulphate as well as inhibiting the binding and presentation of 
CXCL8 on the surface of GAGs (347). TSG-6 is considered an anti-inflammatory 
protein, produced in episodes of inflammation to limit tissue damage during 
acute inflammatory episodes. The secretion of TSG-6 by MSCs is associated with 
the reduction in inflammation in rodent models of myocardial infarction and 
corneal transplantation (228, 348). In both models, this reduction of 
inflammation is associated with a reduction in infiltrating leukocytes – mainly 
neutrophils and macrophages. The anti-inflammatory effects of TSG-6 have been 
loosely associated with the inhibition of neutrophil extravasation into 
inflammatory sites by inhibiting the presentation of CXCL8 on GAGs. CXCL8 
presentation on GAGs is a vital step in the rolling and tethering of immune cells 
prior to extravasation (297, 349). In the current study, high levels of TSG-6 
transcription by inflamed Is MSCs was observed, coupled with high levels of 
neutrophil infiltration. This directly contradicts the findings discussed above 
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where TSG-6 inhibits neutrophil infiltration into sites of inflammation. Several 
proposals discussed below could account for this observation:  
1. Is MSCs do not transcribe TSG-6 into a protein/ produce TSG-6 in low 
quantities. As data suggesting MSC inhibition of neutrophil migration via 
TSG-6 secretion were collected using BM isolated MSCs, it is possible that 
Is MSCs do not secrete functional TSG-6 or that they secrete low levels of 
TSG-6 (348, 350). In the current study, significantly higher TSG-6 
transcription by BM MSCs compared to Is MSCs could suggest that BM MSCs 
secrete significantly more TSG-6 in vivo, therefore impairing neutrophil 
migration more effectively than Is MSCs. This would explain why BM MSCs 
have been demonstrated to inhibit leukocyte migration, whereas Is MSCs 
failed to.  
2. Neutrophils in the air-pouch are anti-inflammatory/pro-angiogenic and 
do not use the CXCL8/CXCR1, CXCR2 axis to gain entry into the air 
pouch, therefore the effects of TSG-6 are overridden. Christoffersson 
et al described that VEGF secreting islets attracted MMP9-secreting 
neutrophils which were vital in islet transplant revascularisation in mice. 
VEGFR-/- mice resulted in a reduction of more than two fold in the 
recruited neutrophils towards the islets and this impaired islet 
revascularisation (334). Therefore, it could be possible that the 
neutrophils observed in the air pouch were recruited via VEGF secretion – 
which Is MSCs have been shown to secrete under homeostatic and 
inflammatory conditions (Figure 5-4). 
3. The neutrophils observed in the air pouch are GMDSCs and therefore 
use alternative methods of extravasation, thus the effects of MSC 
secreted TSG-6 on neutrophil recruitment are irrelevant. As discussed, 
neutrophils and GMDSCs are often indistinguishable (351), however, 
despite the mechanisms of GMDSCs trafficking not being fully understood, 
it is reported that their means of trafficking involve molecules such as 
GMCSF, IL-1β, IL-6, VEGF and IL-10 as well as chemokines (351). Serafini 
et al demonstrated that GMCSF attracted GMDSCs in vitro which resulted 
in substantial immunosuppression of anti-tumour T cell responses (352). 
Interestingly, in the current study, GMCSF transcription was specific to Is 
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MSCs. Importantly, GMCSF transcription was upregulated after 
inflammatory stimulation. This could account for the specific 
neutrophil/GMDSC attraction by Is MSCs observed in vitro Figure 5-11 and 
in vivo, which was upregulated after inflammatory stimulation.  
Other molecules involved in the migration and immunomodulation of 
neutrophils are discussed in the context of cancer, where the existence of 
tumour associated neutrophils are either N1 (inflammatory, anti-tumorigenic 
neutrophils) or N2 (anti-inflammatory, pro-tumour and pro-angiogenic 
neutrophils) (353). As mesenchymal stromal cells are widely implicated in 
cancer progression and its metastasis as a result of their immunosuppression 
of the immune system, it is reasonable to assume that the molecules they 
secrete could play a role in the N1/N2 paradigm (354-356). It is also 
reasonable to assume that MSCs could act similarly in other diseases other 
than cancer.  
Here I report the transcription of TGF-β1 by all MSCs at similar levels during 
homeostatic and inflammatory conditions. TGF-β is a secreted multi-
functional protein involved in many processes including immune suppression, 
inflammation and disease progression (357). It plays a role in neutrophil 
chemoattraction (358) and inhibition of neutrophil degranulation (359). In the 
context of cancer, TBF-β is involved in tumour progression which has been 
associated with neutrophil polarisation (353).  Through the use of a variety of 
injected tumour cell lines, Fridlender et al demonstrated the effects of TGB-
β blockade on an in vivo model of tumour progression. Blocking TGF-β 
resulted in an accumulation of neutrophils with an N1 “inflammatory” 
phenotype, characterised by their expression of TNF-α and CCL3. Moreover, 
they demonstrated that neutrophil depletion in mice bearing tumours with no 
TGF-β blocker (i.e. depletion of N2 neutrophils), increased CD8 T cell 
activation, whereas the depletion of neutrophils in mice bearing tumours 
with a TGF-β blocker (i.e. depletion of mice with N1 neutrophils) resulted in 
decreased activation of intra-tumoral CD8 T cells (353).Thus, it is possible 
that TGF-β secretion by Is MSCs in the air pouch could promote the 
recruitment of anti-inflammatory neutrophils, whilst also inhibiting their 
cytotoxic effects, resulting in downstream effects on other immune cells such 
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as CD8 T cells. As Is MSC TGF-β transcription is not necessarily transcribed 
into a protein, assumptions on the actions of MSC TGF-β secretion are not 
conclusive. It is important to note that the only true means of comparison 
between Fridlender et al and the current study is the nuclear morphology of 
the neutrophils, where Fridlender et al observed hyper-segmented nuclei in 
N1 inflammatory neutrophils, similar to the nuclear morphology of the 
neutrophils within the air pouch of NSG and OT-1 mice.  
 Conclusions 6.5
The initial aim of this work was to better understand the in vivo behaviours 
of MSCs isolated from various tissues through the assessment of MSC 
chemokine and chemokine receptor expression. Having extensively reviewed 
chemokine secretion by MSCs, it was obvious that the chemoattraction of 
specific immune cells towards MSCs - Is and Va MSC in particular - was a 
mechanism employed by MSCs in vitro. Moreover, the specific neutrophil 
chemoattraction observed in vitro was consistent in vivo.  Given the 
evidence, it is appropriate to suggest that neutrophils were recruited into the 
air pouch of NSG and OT-1 mice under the influence of Is MSC secreted 
chemokines such as CXCL1, 5, 6 and 8. Other mediators which were 
transcribed by MSCs and therefore could be secreted such as TGF-β, TSG-6, 
IDO and GMCSF, could play a role in which type of neutrophil is recruited and 
influence overall neutrophil behaviour.  
Overall, due to a newly emerging N1 and N2 field coupled with an inability to 
distinguish neutrophils from GMDSCs, makes it difficult to understand if 
neutrophil attraction by Is MSCs would be detrimental or beneficial in a 
clinical setting. This study highlights the specific in vivo attraction of 
neutrophils by licensed Is MSCs. Additionally it demonstrates that anti-
inflammatory and immunomodulatory genes are upregulated after licensing 
which mirrors the upregulation of chemokine secretion and immune cell 
attraction. Through the secretion of TGF-β, IDO and GMCSF, Is MSCs could be 
attracting a specific type of neutrophil which could be beneficial in a clinical 
setting. However, it is important to address that it is probable that 
neutrophil phenotype is shaped by the surrounding microenvironment and 
therefore they exist in a spectrum of states, rather than the existence of two 
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distinct neutrophil populations. Thus, this work would greatly benefit from an 
investigation into the phenotype of infiltrating neutrophils towards MSCs. 
 
 
 
237 
 
 
Chapter 7 General Discussion  
 Introduction 7.1
Bone Marrow (BM) MSCs are considered to be the “gold-standard” MSC and are 
widely studied as a cellular therapeutic in several clinical settings, including 
transplant and inflammatory diseases to act as anti-inflammatory and 
immunomodulatory mediators. Recently, other more easily accessible, less 
invasive and more cost-efficient tissues such as the ones utilised throughout this 
study – Islet (Is), visceral adipose (Va), adipose (Ad) and umbilical cord (UC) - 
have been identified as an attractive, alternative source of MSCs. This has 
resulted in a plethora of studies, using MSCs isolated from various alternative 
tissues to act as anti-inflammatory and immunomodulatory mediators for 
inflammatory diseases and in transplant settings. However, a full, standardised 
comparison of the phenotype and function of these MSCs does not exist, 
resulting in a lack of understanding of their true potential clinical applications. 
Additionally, more often than not, MSCs are frequently phenotyped when 
maintained under homeostatic conditions, which often disregards the ultimate 
fate of many MSCs - infusion into an inflammatory environment.  Therefore, 
through a stringent set of standardised techniques, the aim of this study was to 
begin to understand and compare the potential in vivo function of Is, Va, Ad, BM 
and UC MSCs under homeostatic or inflammatory conditions. This would help us 
assess and possibly identify a “preferred” tissue source for the isolation of MSCs, 
for use within a broad range of clinical settings, with particular focus on the co-
infusion of MSCs with pancreatic islets to act as anti-inflammatory mediators and 
treat individuals with Diabetes mellitus type 1 (DMT1). To address this aim, 
three key questions were considered: 
1) Do Is, Va, Ad, BM and UC MSCs have the same phenotype? 
2) Where could MSCs potentially migrate to when infused into a patient and 
does the tissue origin of MSCs impact this?   
3) How do MSCs interact with surrounding target (or off-target) tissue(s) and 
does the tissue origin stimulation of MSC impact their behaviour? 
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Chapter 3 of this thesis addressed question number one and ensured that the 
MSCs studied met the minimum criteria outlined by the International Society of 
Cellular Therapy (ISCT) to be defined as a MSC (95). MSCs were assessed for 
basic phenotypical properties through passage by monitoring their spindle-
shaped morphology and ability to adhere to plastic. Through a set of 
standardised techniques, the surface molecule expression, size and granularity 
of MSCs were assessed in homeostatic conditions and after inflammatory 
stimulation. Moreover, basic MSC function was assayed by the assessment of 
MSC differentiation potential into adipocytes, chondrocytes and osteocytes.  
Chapters 4 and 5 addressed question number 2. Chemokine receptor expression 
by MSCs at a transcript (Chapter 4) and protein (Chapter 5) level, were assessed 
in homeostatic conditions and under inflammatory stimulation to understand if 
MSCs possessed migratory capacity and if MSC tissue origin could affect their 
migratory potential. An extensive assessment of all the chemokine receptors 
expressed by MSCs at a transcript level highlighted genes of interest to be 
assessed at a protein level and outlined specific anatomical locations that MSCs 
might be more inclined to migrate to when infused into a patient.  
Chapters 4, 5 and 6 addressed question number 3. Chemokine expression by 
MSCs at a transcript level (Chapter 4) and protein level (Chapter 5) were 
assessed under homeostatic and inflammatory conditions to begin to understand 
how MSCs might behave when they reach target (or off-target) tissue(s). After 
highlighting that MSCs extensively transcribed and secreted a particular set of 
chemokines under homeostatic and inflammatory conditions, chemokine 
function was tested in vitro (Chapter 5) and in vivo (Chapter 6) by assessing the 
immune cell attraction profile of MSCs. Moreover, transcriptional analysis of 
anti-inflammatory and immunomodulatory genes (Chapter 6) provided a better 
insight into how MSCs might be interacting with the immune cells they 
attracted. The following sections will discuss these findings and how they relate 
to specific areas of clinical relevance.  
239 
 
 The tissue origin of MSCs could impact their 7.2
performance within the clinic  
Clinical performance of MSCs is often monitored by the temporary or prolonged 
resolution of symptoms and/or (in the case of transplants) the promotion of 
graft survival (216, 360). Depending on the specific clinical setting, the efficacy 
of MSCs is somewhat dependent upon the successful migration/delivery of MSCs 
to target tissues, their differentiation capacity and how MSCs interact with their 
surrounding allogeneic environment (tissues and immune cells) (226). Thus, as 
MSCs isolated from the Is, Va, Ad, BM and UC differentially express chemokine 
receptors, (which could impact their migratory potential) and chemokines, 
(which was shown to have impact on their immune cell attraction profiles), the 
data generated in this thesis provides evidence to support that MSCs isolated 
from particular tissues might be more beneficial than other tissue sources of 
MSCs in specific clinical settings. For the purpose of this discussion, I will focus 
on two clinical settings – transplantation and cancer- and highlight which tissue 
source of MSC might be more beneficial as a cellular therapy in these settings, 
whilst also discussing which tissue source of MSC might be less beneficial or 
detrimental. 
 The optimal tissue for MSC isolation to co-transplant with 7.2.1
pancreatic islets 
Islet transplantation is an attractive alternative to pancreas solid organ 
transplantation (SOT) to treat diabetes mellitus type 1 (DMT1) as it is minimally 
invasive and reduces the intensity of the immunosuppressive regime post-
transplant because the islets present as a smaller immunogenic tissue mass 
(176). However, islet survival and function after transplantation is known to 
diminish over time due to graft rejection and failure of the islets to re-
vascularise (361-363). Graft rejection is a multifactorial process, consisting of 
multiple immune mediated reactions including activation of complement, 
antibody mediated rejection, alloantigen specific induction of T-cell 
proliferation and the activation of T-cell effector functions (364). Thus, due to 
MSC anti-inflammatory, immunomodulatory and pro-regenerative properties, the 
co-infusion of islets with MSCs could reduce graft rejection, whilst prolonging 
graft survival.  
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Islets are typically infused into the hepatic portal vein and engraft within the 
liver. Infusion of cells into this vein increases the blood pressure, subsequently 
activating the endothelium and ultimately increasing immune cell 
transendothelial migration into the liver, which could promote unwanted 
inflammation (365, 366). Thus, considering the size of MSCs being co-infused 
with islets is important in minimising potential unwarranted immune cell 
trafficking into the liver parenchyma, as the infusion of smaller cells would 
result in decreased pressure (367). In the current study, MSCs isolated from the 
Is, Va, Ad, BM and UC were of identical shape (Figure 3-2) and size (Figure 3-7) 
under homeostatic and inflammatory conditions. Moreover, CXCR6 – a receptor 
thought to be involved in immune cell trafficking and retention within the liver – 
was expressed at slightly higher levels by BM MSCs than any other population of 
MSCs under both homeostatic and inflammatory conditions (Figure 5-1). 
Therefore, based on this observation, it could be proposed that BM MSCs possess 
greater migratory and retention capacity within the liver and thus could deliver 
enhanced therapeutic effects for the islets longer than other tissue sources of 
MSCs.  
Once MSCs and islets are engrafted within the liver, MSCs must function to i) 
deter graft rejection whilst simultaneously ii) promoting graft survival and 
longevity.  
i) To deter graft rejection, MSCs must control the activation and proliferation of 
immune cells, namely allo-specific T cells (176). Firstly, mismatched MSCs 
themselves should not provoke alloreactivity. It is widely accepted that under 
homeostatic or inflammatory conditions, MSCs do not express the key antigens 
involved in immediate rejection - ABO blood group antigens (368). Additionally, 
the expression of HLA-DR (another key molecule involved in graft rejection) on 
MSCs is documented only after inflammatory stimulation, an observation which 
the current study agrees with (Figure 3-6) (369). Conversely, Is, Va and Ad (BM 
and UC not tested) MSCs expressed HLA-ABC when maintained in homeostatic 
conditions which was substantially upregulated after inflammatory stimulation. 
Here we found that Ad derived MSCs expressed significantly more HLA-DR and 
substantially more HLA-ABC on their surface than Is derived MSCs in both 
homeostatic conditions and after inflammatory stimulation. Therefore the Islet 
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might be the more suitable MSC tissue source for use within transplantation 
settings to avoid allogeneic rejection of MSCs.  Notably however, MSCs do not 
express co-stimulatory molecules and therefore they are unlikely to provoke 
extensive activation of T cells based on mismatched HLA-ABC expression and 
thus the expression levels of these molecules might not play a huge role in their 
rejection.  
Secondly, MSCs must also induce tolerance and immunomodulate the surrounding 
cells to prevent the primary cause of early islet damage – inflammation (370). 
Infusion of islets into the hepatic portal vein can trigger complement activation 
which leads to the lysis of islets (364, 371). Complement factor H (CFH) is a 
complement regulatory protein which binds to GAGs and protects cells from 
complement-mediated destruction via the cleavage of C3b and accelerating the 
decay of C3-convertases. CFH deficiency promotes graft rejection and therefore 
CFH secretion by MSCs could serve as a mechanism of protection for 
transplanted islets (372, 373). MSC constitutive secretion of CFH has been 
documented which is upregulated after inflammatory stimulation. Similarly, the 
current study showed constitutive, moderate levels of transcription of CFH by all 
tissue sources of MSCs in homeostatic conditions, which was significantly 
upregulated by BM and UC MSCs and substantially upregulated by Is, Va and Ad 
MSCs after inflammatory stimulation (Figure 6-11). BM MSCs transcribed the most 
CFH, significantly more than Is MSCs. Assuming that the MSC transcription levels 
of CFH are proportionately transcribed into protein and that higher levels of CFH 
are optimal in controlling aberrant complement activation, the BM would be the 
desired tissue source for MSCs to avoid islet rejection via complement 
activation, whereas the islet would be the least desired tissue source due to low 
CFH transcription.  
Akin to complement activation, allogeneic T cell proliferation and activation are 
prerequisites for islet allograft rejection, along with the concurrent activation of 
existing autoimmune T cells (374). A large body of literature shows that MSCs 
can inhibit T cell proliferation whilst also promoting a T regulatory cell 
phenotype through the secretion of several mediators including IDO, TGF-β and 
expression of CD 274 (133, 375, 376). Induction of tolerance is often associated 
with T regulatory cells and secretion of these mediators by MSCs has been 
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associated with islet allograft tolerance, function and regeneration (376-380). In 
chapter 6, substantial transcription of the above mediators was observed by all 
tissue sources of MSCs after inflammatory stimulation, where BM MSCs 
transcribed the most IDO, CD274 and marginally more TGF-β than Is, Va, Ad and 
UC MSCs (Figure 6-11). Collectively, based on the transcription of CFH, IDO, 
CD274 and TGF- β, BM MSCs might possess more potent immunosuppressive 
capabilities than other tissue sources of MSCs, which would promote islet 
survival, whilst also supporting graft tolerance. Importantly however, Chapter 5 
and Chapter 6 demonstrated that despite MSC secretion of T cell 
chemoattractants (CCL20, CXCL9, 10 and 11) under inflammatory stimulation, 
MSCs do not attract any T cells in vitro or in vivo. This could suggest that MSCs 
do not need to be in close proximity to T cells to elicit their anti-inflammatory 
effects, or indeed that MSC and T cell interactions do not play a major role in in 
vivo MSC immunomodulatory/anti-inflammatory actions.  
ii) In addition to immune cell modulation, MSCs must promote islet survival. As 
well as inflammation causing a significant amount of islet loss, a lack of blood 
supply also plays an important role. The process of isolating islets destroys the 
external vasculature whilst potentially damaging the internal islet vascular 
network (381). Ito et al demonstrated that the co-infusion of rat BM MSCs and 
rat islets into the liver of streptozotocin-diabeted synergetic recipients or 
transplanted under the renal capsule of NOD SCID mice resulted in an 
improvement of islet graph morphology and function, which was in part due to 
the revascularisation of the graft, mediated by MSCs (381). Factors such as 
vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) 
are widely recognised as pro-angiogenic mediators which are involved in the 
revascularisation of islets (382, 383). Importantly, in the current study MSCs 
were observed to secrete VEGF (Figure 5-4) and transcribe HGF (Figure 6-2). In 
homeostatic conditions MSCs secreted ~ 300pg/mL of VEGF, however, UC MSCs 
did not secrete VEGF above background levels. Is, Va, Ad, BM and UC MSCs 
upregulated VEGF secretion under inflammatory stimulation and BM MSCs 
secreted double the amount of VEGF than any other tissue source of MSC. 
Importantly, Walker et al. demonstrated that a dose response blockade of VEGF 
using the monoclonal antibody bevacizumab showed decreased vascular density 
in mouse brains with increased concentrations of bevacizumab (384). This 
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suggests that increased concentrations of VEGF could increase the vascular 
density of islet grafts and therefore higher volumes of VEGF may be optimal over 
lower volumes and thus BM MSCs would be the preferential tissue source of MSC 
to promote angiogenesis and islet re-vascularisation, whereas Ad derived MSCs 
would promote little angiogenesis. Conversely however, Carlsson et al. described 
that the amount of VEGF available to the islets does not correlate to the degree 
of re-vasularization of islets (385). This could be due to the presence of other 
angiogenic mediators secreted by MSCs such as HGF which is known to play a 
role in angiogenesis and islet survival. HGF is secreted by hepatocytes in the 
liver which support islet graft function and longevity. In Chapter 6, HGF was 
shown to be transcribed by all tissue sources of MSCs, with BM MSCs transcribing 
significantly more than Is, Va and Ad in homeostatic conditions, and significantly 
more than Is, Va, Ad and UC MSCs under inflammatory conditions, again 
suggesting that BM MSCs might possess greater angiogenic potential than other 
tissue sources of MSCs. Despite BM MSCs secreting and transcribing the most 
VEGF and HGF, respectively, it is important to recognise that these are not the 
only angiogenic mediators that Is, Va, Ad, BM and UC MSCs were found to 
secrete in this study. In Chapter 4 and 5, MSCs were shown to transcribe (Figure 
4-10) and secrete (Figure 5-5) substantial levels of the pro-angiogenic 
chemokines CXCL1, 5, 6 and 8 (386-389). CXC chemokine secretion by MSCs was 
differentially affected depending on MSC tissue source and inflammatory 
stimulation. During homeostatic conditions CXCL8 was the highest secreted CXC 
chemokine by Is, Va, Ad and BM MSCs, whereas UC MSCs secreted more CXCL1 
than any other CXC chemokine assayed. The pro-angiogenic role of CXCL8 has 
been described in various models and in some cases, is associated with aberrant 
blood vessel formation (390). The angiogeneic contribution of CXC chemokines in 
islet transplantation is – to my knowledge not documented. However, their 
detrimental role in islet graft survival has been reported, where CXCR1/2 
(receptors for CXCL1, 5, 6 and 8) blockade with an allosteric inhibitor - reparixin 
- enhanced islet survival after transplantation.  This could be due to a decrease 
in neutrophil infiltration towards the graft site as neutrophils are considered to 
have detrimental effects on lung and cardiac allografts, due to their 
inflammatory secretory profiles and interaction with surrounding immune cells 
(391-394). Challenging the observation that neutrophils are detrimental in a 
transplant setting is work carried out by Christoffersson et al, which describes 
244 
 
that MMP9 secreting neutrophils were pivotal in the revascularisation of islets 
that had been transplanted into the striated muscle of mice (334). In the current 
study, neutrophils were the predominant CD45 +ve cell attracted towards MSCs 
in vitro (Chapter 5) and in vivo (Chapter 6). Is and Va MSCs were the only tissue 
sources of MSCs to attract substantial numbers of neutrophils above background 
levels in homeostatic conditions, whereas Ad and BM MSCs did not. Under 
inflammatory stimulation, neutrophil attraction towards all MSCs was 
upregulated above background levels in vitro, mirroring the upregulation in 
neutrophil chemoattractant chemokine secretion by all tissue sources of MSCs. Is 
derived MSCs attracted the most neutrophils under homeostatic and 
inflammatory conditions, whereas BM MSCs attracted the least. The immune cell 
attraction profile of Is MSCs was mirrored exactly when moving from in vitro 
analysis into the in vivo air pouch models in two individual mouse strains, where 
neutrophils were the predominant CD45 +ve cell in the air pouch. Additionally, Is 
MSCs attracted significantly more CD45 -ve cells than in control mice. It 
therefore could be proposed that MSCs enhance graft revascularisation not only 
through substantial VEGF and HGF secretion but by the extensive secretion of 
pro-angiogenic chemokines that chemoattract neutrophils, ultimately resulting 
in prolonged graft survival. Moreover, the observation that Is MSCs attracted 
CD45 –ve cells in vivo suggests that MSCs could attract endogenous MSCs to the 
graft site and perpetuate MSC anti-inflammatory and immunomodulatory effects. 
Transplanted MSCs attracting endogenous MSCs has been documented (395). 
The limitations of this hypothesis are that MSC neutrophil chemoattraction was 
observed in an air pouch model and not in an islet transplant model. Moreover, 
Christoffersson et al. described that the neutrophils required for islet 
revascularisation were attracted via VEGF and that these were of a pro-
angiogenic phenotype. Despite nuclear morphology analysis of the neutrophils – 
which were hypersegmented – a conclusive phenotype of the infiltrating 
neutrophils could not be made.  
To summarise, MSCs isolated from various tissues express different levels of 
CXCR6 which could impact MSC migration and retention within the liver. 
Additionally, BM MSCs secreted the largest quantities of VEGF and transcribed 
HGF at the highest levels in homeostatic conditions and after inflammatory. 
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MSCs isolated from all sources secreted substantial amounts of pro-angiogenic 
chemokines under homeostatic and inflammatory conditions, which could impact 
the vascularisation of islets via the angiogenic nature of chemokines themselves 
or through the attraction of pro-angiogenic neutrophils. The current study 
highlights that MSCs differentially transcribed and secreted pro-angiogenic 
mediators, depending on their tissue origin. This could have profound impact, 
not only in islet transplantation, but in any transplant setting. Additionally, the 
tissue source of MSCs also dictates their immune cell attraction profile, which 
could be detrimental or beneficial in an islet transplant setting, depending on 
the phenotype of the immune cells attracted. The differential immune cell 
attraction profile of MSCs could also be harboured in other transplant settings. 
For example, the presence of macrophages positively impacts the regenerative 
potential of hepatocytes in the liver (396, 397). Thus infusing MSCs that attract 
monocytes and macrophages (Is MSCs) with hepatocytes could promote the 
attraction of endogenous MSCs to the liver and aid in liver regeneration.  
 The optimal tissue for MSC isolation for potential 7.2.2
therapeutic use in Cancer 
MSCs have been described as a double edged sword in cancer, providing pro-and 
anti-tumorigenic signals. Despite florid documentation on MSCs role in promoting 
tumour growth and metastasis (398), they are an attractive candidate for 
delivery of anti-tumour agents due to their ability to home to tumour sites and 
secrete cytokines/chemokines (399).   
It has been suggested that BM and Ad derived MSCs can migrate to sites of 
tumour development via the expression of several different receptors such as 
VEGFR, CCR2 and CXCR4. Additionally, MSC localisation to the inflammatory 
tumour environment might also involve other receptors (CXCR6 and ACKR3) that 
respond to the chemokines that the tumour environment produces (400-402). 
Thus, the expression levels of these receptors by MSCs might influence their 
migratory potential to the tumour. The current study highlighted that BM MSCs 
expressed the highest surface expression of CXCR4, CXCR6 and ACKR3, whereas 
Is and Ad MSCs expressed low surface levels of these receptors. Moreover, BM 
MSCs markedly upregulated their expression of ACKR3 and CXCR4 under 
inflammatory stimulation, suggesting that pre-treating MSCs with inflammatory 
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mediators prior to infusion into cancer patients could improve BM MSC homing 
capabilities to the tumour site. 
Once within the tumour site, MSCs can work in two ways i) promoting tumour 
growth and metastasis or ii) inhibiting tumour growth.  Their dual role within 
several clinical settings has prompted investigations into the possibility of two 
MSC phenotypes – anti-inflammatory and pro-inflammatory. It is not assumed 
that these phenotypes are distinct subsets of MSCs, but rather thought to be a 
result of MSCs being able to sense their environment (403). It is possible that 
MSCs isolated from different tissues might be more inflammatory than others 
due to the environment they were isolated from. Thus MSCs isolated from 
different tissue sources could promote tumour growth or inhibit it.  
i) Through the secretion of immunomodulatory and pro-angiogenic mediators 
(along with an array of other cytokines and chemokines), it is believed that MSCs 
are involved in the regulation of immune surveillance, apoptosis and 
angiogenesis during tumour development (404-407). The expression of IDO by BM 
MSCs has been reported to inhibit T-cell-mediated immune responses against 
tumours (404). Moreover, BM MSC secretion of TGF beta was found to stimulate 
the proliferation, migration and invasion of a prostate cancer cell line in vitro 
and VEGF secretion by BM MSCs was observed to contribute to blood vessel 
density and tumour angiogenesis in pancreatic carcinoma (408, 409). As 
mentioned earlier, BM MSCs secreted twice as much VEGF in an inflammatory 
environment than other tissue sources of MSCs. Similarly, BM MSCs transcribed 
IDO and TGF-beta at higher levels than any other tissue source, suggesting that 
despite BM MSCs high surface expression of chemokine receptors that would 
promote delivery of BM MSCs to the tumour environment, the BM would not be 
the desired tissue origin of MSCs to use when MSCs reach the tumour 
environment, as they appear to be relatively anti-inflammatory cells. 
Conversely, Is and Ad derived MSCs would be preferential due to their low 
transcription of TGF-beta and IDO (Is MSCs) and low secretion of VEGF (Ad MSCS) 
under both homeostatic and inflammatory conditions. Their low expression of 
receptors however could result in poor migration towards the tumour. 
ii) Despite the current study finding that BM MSCs appear to be largely anti-
inflammatory, they have been described to have anti-tumour capabilities, where 
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BM MSCs inhibited the survival of non-Hodgkin’s Lymphoma cells in a mouse 
xenograft model (410). Additionally, Ad and UC MSCs have also been described 
as anti-tumorigenic cells where Ad MSCs were documented to inhibit the 
proliferation of breast cancer cells (411) and UC MSCs significantly inhibited the 
proliferation of glioblastomas in a co-culture system, whilst simultaneously 
increasing apoptosis of glioma cells (412). As this is a relatively new emerging 
field, detailed mechanisms of how MSCs contribute to the prevention of tumour 
progression are somewhat unexplored. CCL2 is involved in the attraction of 
monocytes and macrophages to the tumour site and stimulates macrophage 
cytolic activity against tumour cells. Moreover, CCL2 injection into the tumour 
site results in mononuclear cell infiltration, leading to rapid tumour rejection 
(413, 414). CCL2 was transcribed and secreted by all tissue sources of MSCs when 
maintained in homeostatic and inflammatory conditions. During homeostatic 
conditions, Is and Ad MSCs secreted the largest volumes of CCL2 (~5000 pg/mL), 
whereas under inflammatory stimulation only Is MSCs, secreted the largest 
volumes of CCL2 (24410pg/mL) (Figure 5-4). Despite high levels of CCL2 
secretion by all MSCs, Is MSCs were the only tissue source to attract large 
numbers of classical monocytes in vitro. The attraction of monocytes and 
macrophages towards pre-inflamed Is MSCs was also observed in the in vivo air 
pouch models. The in vitro immune cell attraction profile data in this study 
suggests that Is derived MSCs have a greater capacity to attract monocytes and 
macrophages than other tissue sources of MSCs, which could be very beneficial 
in a tumour environment. In addition to CCL2 secretion, MSC CXCL8 secretion 
could also prevent tumour metastasis, through the attraction of neutrophils 
(415). Large neutrophil chemoattraction towards Is and Va MSCs was observed in 
homeostatic conditions, whereas Ad and BM MSCs did not attract any neutrophils 
above background levels. Inflammatory stimulation resulted in the upregulation 
of neutrophil migration towards all tissue sources of MSCs, with Is MSCs inducing 
the largest neutrophil chemoattraction despite similar secretion of CXCL 
chemokines compared to other MSCs, this could be a result of Is MSC GM-CSF 
secretion as Is MSCs were the only tissue source of MSC to transcribe this 
neutrophil chemottractant. Neutrophils were also the predominant cell type 
attracted towards pre-stimulated Is MSCs in vivo. Based on these observations, 
the islet could serve as a very promising tissue source for MSC isolation to inhibit 
the progression of tumours.  
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As well as immune cell attraction, chemokines themselves play an important role 
in the tumour microenvironment, where the ELR +ve chemokines (CXCL1, 2, 3, 
5, 6, 7 and 8) promote tumour angiogenesis and the ELR-ve chemokines  (CXCL 
9, 10 and 11) play an angiostatic role in the tumour microenvironment (416).  
Through the interaction with CXCR3, the ELR –ve chemokines have been 
observed to inhibit the angiogenic effects of ELR +ve chemokines (417).  As Is, 
Va, Ad, BM and UC MSCs secreted high volumes of both ELR +ve and ELR –ve 
chemokines  in the current study under inflammatory stimulation, it could be 
proposed that only in inflammatory environments (such as cancer) MSCs employ 
a safety mechanism to avoid aberrant angiogenesis via the secretion of ELR –ve 
angiostatic chemokines (416). It is therefore of no surprise that MSCs are termed 
‘the double-edged sword’ in cancer. Their chemokine secretion leads to immune 
cell attraction which could either result in further immune cell 
immunomodulation to support the tumour microenvironment, or it could result 
in tumour destruction. Equally, the pro-angiogenic chemokines that MSCs secrete 
in an inflammatory environment could enhance tumour angiogenesis, whereas 
the simultaneous secretion of ELR –ve chemokines could inhibit this.  
In summary, it is clear that MSCs isolated from various tissues have the potential 
to function differentially with respect to the mediators they secrete and immune 
cells they attract. BM MSCs could potentially home to tumour sites more 
efficiently than other MSC tissue sources due to their high receptor expression, 
however their large secretion of pro-angiogenic mediators and substantial 
transcription of immunomodulatory factors suggests that they might act as an 
anti-inflammatory MSC in the context of cancer. On the other hand, MSCs 
isolated from the Is and Va might home less efficiently in comparison to BM 
MSCs, but through the attraction of higher numbers of immune cells and lower 
transcription of immunomodulatory mediators than BM MSCs, Is and Va MSCs 
might function as a more pro-inflammatory MSC in the cancer setting. A 
schematic in Figure 7-1 highlights the differences observed between Is MSCs and 
BM MSCs throughout this study and summarises how these differences might 
influence the tumour microenvironment.
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Figure 7-1  Simplified schematic highlighting the potential actions of Is MSCs (left) vs. BM MSCs (right) in a tumour microenvironment 
BM MSCs (right) are potentially capable of migrating to tumour microenvironments due to their higher surface expression of chemokine receptors which is depicted by 
the increased number of BM MSCs surrounding the cancer cells compared to Is MSCs (left). Once within the tumour microenvironment, Is MSCs secrete substantially 
more CCL2, which results in a large influx of CCR2 +ve monocytes and macrophages to the tumour, whereas BM MSCs reduced secretion of CCL2 attracts 
substantially less monocytes and macrophages. Is and BM MSCs secrete similar levels of ELR +ve neutrophil chemoattractants (CXCL1, 5, 6 and 8), however Is 
MSCs attract substantially more neutrophils, perhaps due to the secretion of GM-CSF (Chapter 6). Is and BM MSC secreted CXCL1, 5, 6 and 8 have pro-angiogenic 
effects with potential to promote tumour angiogenesis which are inhibited by the MSC secretion of ELR –ve angiostatic chemokines – CXCL9, 10 and 11. BM MSCs 
potentially secrete substantially more immunomodulatory factors than Is MSCs and therefore surrounding immune cells could be immunomodulated and unable to kill 
cancer cells, whereas Is MSCs low secretion of immunomodulators results in the apoptosis of cancer cells due to the large number of infiltrating immune cells having 
cytotoxic effects on cancer cells.  Notably, it is also important to appreciate that the large attraction of immune cells towards Is MSCs could be detrimental if they are of 
an anti-inflammatory phenotype.  
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 Overview  7.3
It is widely appreciated that MSCs are anti-inflammatory cells capable of 
immunomodulating surrounding immune cells and repairing damaged tissue and 
for that reason they are routinely used in clinical trials to act as anti-
inflammatory mediators. As mentioned, BM MSCs are considered the gold 
standard MSC due to their routine use within the clinic, however their frequency 
within the bone marrow is low and therefore other tissues are being widely 
exploited for MSC isolation. The wide use of MSCs isolated from alternative 
tissue sources, cultured in different conditions and used throughout experiments 
at varied passage makes comparing MSC literature near impossible. The 
standardised experiments throughout this study comparatively explored the 
potential in vivo differences of MSCs isolated from the islet, visceral adipose, 
adipose, bone marrow and umbilical cord. Through the assessment of chemokine 
receptors at a transcript and protein level, this study highlighted that MSCs 
isolated from various tissue sources could harbour greater migratory potential.  
Moreover, pre-treating MSCs with inflammatory mediators could increase MSC 
migratory potential due to an upregulation in chemokine receptor expression.  
This finding has clinical implications when considering which tissue source of 
MSC to utilise when MSCs are being infused systemically, where high chemokine 
receptor surface expression could provide more efficient homing to target 
tissues. Based solely on chemokine receptor expression, the ideal tissue to 
isolate MSCs from in order to direct migration towards specific anatomical 
locations is outlined in Figure 7-2 Overview of chemokine receptor expression by 
MSCs at a transcript and protein level under homeostatic and inflammatory 
stimulation.
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Figure 7-2 Overview of chemokine receptor expression by MSCs at a transcript and protein 
level under homeostatic and inflammatory stimulation.   
Chemokine receptor expression by MSCs isolated from the Is Va, Ad, BM and UC were compared 
to each other in homeostatic (top) and inflammatory (bottom) conditions to understand which tissue 
source of MSC expressed the highest levels of CCR7, CCR10, CXCR4 and CXCR6 at a transcript 
(left) and protein (right) level. Colour coding highlights tissue sources that express receptors at the 
highest (red) intermediate (green) and lowest (blue) levels (blank boxes depict receptors that were 
not tested). In homeostatic conditions, Va MSCs expressed the highest protein levels (red boxes) 
of CCR7 and CXCR4, suggesting that visceral adipose might be the preferred tissue to isolate 
MSCs to enhance migration towards the lymph node (CCR7) and bone marrow, heart and lungs 
(CXCR4) (highlighted by green lines). Conversely, BM MSCs expressed the highest surface levels 
of CXCR6 and CCR10 (red boxes), suggesting that the BM might be the desired source of MSCs 
to enhance trafficking to the liver and skin, respectively. After inflammatory stimulation, the BM 
would be the optimal tissue for MSC isolation for enhanced migration to the listed tissues. ACKR3 
is not involved in migration and therefore is not listed. Importantly, this summary diagram highlights 
that transcriptional expression of receptors by MSCs does not correspond to protein expression 
and highlights a need for rigorous testing of receptors at a protein level. Transcript data shown here 
is summarised from Chapter 4, Figure 4-7 and Figure 4-8 . Protein data shown here is summarised 
from Chapter 5, Figure 5-1.
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The in vitro experiments in this study also highlighted the influence of MSC 
tissue origin in dictating how they might interact with their surrounding 
environment when infused into a patient. In homeostatic conditions, all MSCs 
had a similar chemokine secretion profile, where CCL2 was the top chemokine 
secreted by all MSC populations. However, the immune cell attraction profile of 
MSCs differed drastically where Is and Va MSCs attracted substantially more 
immune cells than BM and Ad, which did not attract any above background 
levels. Inflammatory stimulation resulted in an upregulation of CCL2 secretion as 
well as a huge shift towards the secretion of ELR +ve and ELR –ve CXC 
chemokines. The secretion of these CXC chemokines was met with the specific 
chemoattraction of neutrophils towards all tissue sources of MSCs, however, the 
number of cells attracted towards MSCs varied considerably depending on MSC 
tissue origin, where Is MSCs attracted substantially more than BM MSCs, which 
attracted the least. This has huge clinical implications as inflammatory 
chemokine secretion and monocyte, macrophage and neutrophil attraction are 
largely viewed as detrimental mediators in a number of clinical settings. An 
overview of the chemokines MSCs expressed at a transcript and protein level and 
subsequent immune cell attraction by MSCs under homeostatic and inflammatory 
conditions is outlined in Figure 7-3.
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Figure 7-3 Summary of the CC and CXC chemokines MSCs transcribed, secreted and subsequent immune cell attraction under homeostatic and 
inflammatory conditions.  
A colour coding system was generated to highlight the top transcribed (left hand box) and secreted (right hand box) chemokines by each tissue source of MSC in 
homeostatic (top) and inflammatory (bottom) conditions. Generally, where low transcription was observed (blue), no chemokine was secreted (blue) under both 
homeostatic and inflammatory conditions. Equally, if the gene was transcribed at high levels (red) it was often secreted as a protein in high quantities (red/brown). The 
immune cells that each chemokine could potentially attract have been highlighted by colour coded lines that match specific immune cells. For example, CCL3 &15, 
CXCL1, 5, 6 & 8 are involved in neutrophil chemoattraction, highlighted by the blue line joining the chemokines to the target cell – neutrophils.  
The same colour coding system was implemented (blue-red) based on the number of immune cells MSCs attracted as a percent of the input population, highlighting 
which immune cells MSCs preferentially attracted in vitro. As a worked example: in homeostatic conditions (top box), Is MSCs transcribed and secreted high levels of 
CCL2 and CXCL8, which in turn attracted high numbers of monocytes and neutrophils, respectively. Under inflammatory stimulation, Is MSCs transcribed high levels of 
CXCL8 and 9 and moderate levels of CXCL1 and CCL2. Is MSCs secreted the highest levels of CCL2, followed by CXCL1 and CXCL8, whereas CXCL9 was secreted 
at lower levels. Mirroring the chemokine secretion profile, Is MSCs also attracted large numbers of monocytes and neutrophils, however, T cell and NK cell attraction 
was not observed. Additionally, pre-inflamed Is MSCs attracted substantial numbers of neutrophils and lower numbers of monocytes in vivo in both NSG and OT-1 
mouse models. However, it is likely that the monocytes had differentiated into macrophages which were attracted towards Is MSCs at moderate levels in vivo.
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 Hypothesis 7.4
I therefore hypothesise that the tissue origin of MSCs would highly influence MSC 
in vivo behaviour via the differential expression of chemokine receptors and the 
differential secretion of chemokines and immunomodulatory mediators, which 
has a direct impact on how MSCs interact with surrounding immune cells. Based 
on these observations, I believe that it is highly likely that MSC tissue origin 
predisposes MSCs as being more anti- or pro- inflammatory.  Moreover, the 
current study focussed on the differences in MSC migratory capacity and how 
they interact with their surrounding environment, however I believe that there 
will be other undiscovered profound differences between MSCs isolated from 
different tissue sources that will have a direct impact on their clinical abilities.  
 Conclusions 7.5
This study provides novel, clinically relevant insights into the phenotypical and 
functional behaviours of MSCs isolated from the islet, visceral adipose, adipose, 
bone marrow and umbilical cord. The findings described in this thesis also 
highlight the extensive difference in MSC behaviour which is dependent upon the 
tissue origin of MSC and the surrounding environment – homeostatic or 
inflammatory. To conclude, I will answer the questions outlined in the 
introduction of this chapter: 
1) Do Is, Va, Ad, BM and UC MSCs have the same phenotype? With the 
exception of HLA surface molecule expression, tissue origin does not appear 
to affect MSC surface molecule phenotype, where, Is, Va, Ad, BM and UC 
express similar levels of MSC surface markers and present as identically-
sized and spindle-shaped adherent cells.  
2) Where could MSCs potentially migrate to and does the tissue origin of 
MSCs impact this?  Based on the transcript and protein expression of 
chemokine receptors, MSCs could migrate to the bone marrow, lung, heart, 
kidneys and lymph nodes and the tissue origin of MSC affects the surface 
expression of chemokine receptors suggesting that particular tissue sources 
might be more beneficial to improve homing to specific anatomical sites.  
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3) How do MSCs interact with surrounding target (or off-target) tissue(s) and 
does the tissue origin of MSC impact their behaviour? MSCs appear to have 
a chemokine secretion phenotype, where all tissue sources of MSCs secrete 
CCL2 at moderate levels in homeostatic conditions. This could act as an 
angiogenic mediator and depending on the tissue source of MSC, could 
attract monocytes (Is MSCs). After inflammatory stimulation, all tissue 
sources of MSCs upregulate neutrophil chemoattractants, which was 
mirrored by an upregulation in neutrophil migration towards all MSCs, 
however, the tissue origin of MSC dictates the quantities of neutrophils 
attracted. The immune cell attraction profile of Is MSCs was mirrored 
exactly in vivo in two different mouse strains suggesting that Is MSCs 
specifically attract neutrophils. Moreover, immunomodulatory mediators are 
transcribed in homeostatic conditions and upregulated under inflammatory 
stimulation. The levels of transcription of these mediators are dependent on 
the tissue origin of MSCs, suggesting that specific tissue sources might 
possess greater immunomodulatory capacity on the differential numbers of 
immune cells they attract and therefore highlights that the tissue origin of 
MSCs predisposes them to have an anti- or pro-inflammatory phenotype.  
These data highlight both similarities and differences in MSCs isolated from the 
Islet, visceral adipose, adipose, bone marrow and umbilical cord.  Despite MSCs 
isolated from various tissues phenotypically presenting as identical cells- based 
on surface CD molecule phenotype - their in vivo function could potentially be 
very different and this could have huge impact in a number of clinical settings.  
 Future Direction 7.6
Despite the studies in this thesis revealing some novel and interesting data, the 
experiments described throughout are not without their limitations and would 
benefit from more rigorous testing of the systems involved.  
To confidently address MSC migratory potential, experiments on the chemokine 
receptors expressed by MSCs and their function must be thoroughly tested. To 
assess this, receptor functionality should be tested by intracellular calcium flux 
assays which would assess if receptors are able to signal upon ligand binding. 
Moreover, MSC migration assays would test the migratory potential of MSCs in 
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vitro. For example, MSC migratory capacity towards CXCL16 would have to be 
assayed and compared against other sources of MSCs in order to confidently 
conclude which tissue source of MSCs possessed greater migratory capacity. 
Specific migration could be tested via a dose response of MSCs towards 
increasing concentrations of CXCL16 or via a CXCR6 blocker in a transwell 
system. Additionally, in vivo trafficking and retention of MSCs within specific 
sites should be address to confidently conclude that these systems are functional 
in vivo. Fluorescent labelling of MSCs, coupled with targeted knock out of a 
specific MSC chemokine receptor would thoroughly evaluate the chemokine 
receptors involvement of MSC trafficking to specific sites.   
Additionally, despite the chemokines that MSCs secreted matching the immune 
cells that MSCs attracted in vitro and in vivo, with an upregulation in the 
magnitude of response after inflammatory stimulation, it is important to regard 
the shortcomings of these experiments. Although different tissue sources of MSCs 
secreted varied levels of chemokines, the levels of chemokine secreted did not 
mirror the number of immune cells MSCs attracted. For example, CXCL5, 6 and 8 
were secreted by Ad MSCs in homeostatic conditions, however, neutrophil 
chemoattraction here was not observed. This could be evidence to support that 
Is MSCs attract neutrophils via alternative mechanisms such as VEGF – VEGFR or 
GM-CSF- GMCSFR. Moreover, Ad MSCs secreted high volumes of CCL2, however, 
monocyte chemoattraction in vitro was not observed. Thus to ensure that 
monocyte attraction towards MSCs was mediated through CCR2 and that 
neutrophil attraction was mediated via CXCR1/2 or VEGFR, transwells should be 
repeated with the appropriate receptor blockers to fully confirm that the 
chemokines MSCs secrete are fully involved in the immune cell attraction profile 
we observe.   
Although the in vivo air pouch model in two individual strains of mice mirrored 
the exact immune cell attraction profile of MSCs in vitro, due to availability of 
mice, the air pouch model did not have fully adequate controls and therefore 
the data generated are limited. Assessing the immune cell infiltration towards 
another cell type with a different chemokine secretion profile such as fibroblasts 
or keratinocytes in the air pouch model would serve as an appropriate control to 
confidently conclude that the immune cell attraction into the air pouch was 
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specific to Is MSCs secreted mediators. To strengthen the air pouch data, the 
experiment could benefit from the addition of extra time points. In spite of the 
absence of adaptive immune cell attraction towards MSCs in vitro, it is likely 
that the time point of 24 hours did not allow the full assessment of adaptive 
immune cell infiltration in vivo, as T and B cells would likely infiltrate at a later 
stage. It would therefore be advantageous to have 2 time points at 24 and 72 
hours to assess the infiltration of the innate and adaptive immune systems.  
This thesis would also benefit from a full in vivo comparison of the immune cell 
attraction profile of homeostatically vs. inflammatory maintained Is, Va, Ad, BM 
and UC MSCs into the air pouch, to further confirm and clarify the substantial 
differences observed in the in vitro system. Subsequently, a full phenotypical 
analysis of the immune cells MSCs attract would strengthen the hypothesis that 
MSCs isolated from various tissues are pre-disposed to being more pro- or anti-
inflammatory.  
Lastly, and perhaps beyond the scope of this thesis, this study would greatly 
benefit from the assessment and comparison of MSCs isolated from various 
tissues in different clinical models such as mouse islet transplantation and 
tumour models. This work would clarify if MSCs isolated from different tissues 
perform differently in clinical settings and would also highlight if the immune 
cell attraction profile of MSCs remains consistent in varied environments. This 
could underpin a vital role of MSC immune cell attraction in different clinical 
settings and further clarify the differences in MSCs isolated from various tissu
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